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Molecular interactions and their
impact on life sciences
Tom Scheidt
The behaviour and function of biomolecules represent a fundamental aspect in modu-
lating the activity of micro and macro-scale complexes evolved in cells and tissues. The
network of interactions of such biomolecules allow for the formation and regulation of
the basic machinery of life, yet is commonly studied under non-physiological conditions.
In order to characterise the behaviour and function of such biomolecules, they have to be
analysed under relevant conditions, ideally in biofluids, cells or artificial systems which
mainly imitate these properties. Recent microfluidic applications present an orthogonal
approach for determining the interactions between a wide range of biomolecules, thus
allow the study of molecular binding in the condensed phase with no need for extensive
dilution, sample immobilisation or changes to the molecular environment from the liquid
to the gas phase.
As part of my PhD, I capitalised on microfluidic diffusion approaches, developed in
the Knowles lab to systematically study the binding and thermodynamics of small heat
shock proteins, such as clusterin, αB-crystallin and the Brichos chaperone domain, to
aggregated forms of amyloid-beta and α-synuclein, protein aggregates that are associ-
ated with a wide range of neurodegenerative diseases. The three chaperones are cru-
cial components of the cellular proteostasis network and characteristically overexpressed
during cell stress. Each chaperone type shows distinct binding behaviour to protein
aggregates, which can be related to its inhibitory function. While αB-crystallin binding
to α-synuclein is entropically driven by conformational rearrangement, the binding of
Brichos to amyloid-beta fibrils is shown to be enthalpically driven as it inhibits specif-
ically secondary nucleation processes. In contrast to the specific secondary nucleation
inhibition by Brichos, clusterin inhibits specifically fibril elongation of amyloid-beta.
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I could show that these two specific aggregation processes are affected by the two chap-
erones, Brichos and clusterin, in a non-cooperative manner.
These molecular details are particularly relevant in the context of the rational design
of drug molecules that could, potentially in combination, target multiple specific aggre-
gation steps in a selective manner. Therefore, I further screened the binding of a wide
range of monoclonal antibodies to either amyloid-beta monomers or fibrils, which are
currently at different stages of clinical phase trials for Alzheimer’s therapy. I thus show
that the obtained stoichiometry and affinity information of the drug correlates with the
distinct inhibition mechanisms and consequently provides mechanistic and structural
information.
In contrast to studying disease related model systems in vitro under homogeneous con-
ditions, measurements in complex body fluids are key in medical applied science, e.g.
cancer treatment or immunological characterisation. In my research, I have undertaken
the challenge of extending the platform developed above to characterise the binding of a
wide range of molecules under complex solution conditions. Preliminary data obtained
during my PhD underlines the extraordinary capability of the diffusion-based microflu-
idics to being applicable for investigating the binding parameters of molecules involved
in alloimmunisation in human serum.
Along with my main focus on measuring protein interactions with diffusion-based mi-
crofluidics, I further developed a technique using selective separation properties, such as
particle charge, hydrophobicity, size or immunoaffinity and coupled it with a series of
microfluidic devices for an instantaneous and full biophysical characterisation of hetero-
geneous solutions. This new technique can be used to explore the formation of protein
oligomers or protein complexation, characterisation and identification of complex mix-
tures in the context of amyloid formation and protein homeostasis.
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An introduction to protein interactions
1.1 Protein interactions
Proteins, the major structural material of animal tissues, are condensed polymers com-
posed of amino acids and can adapt a wide range of morphologies, ranging from very
extended fibrous structures to highly condensed spheres[205]. In order to shape a di-
verse set of structural elements and execute a multitude of functionalities, the structural
flexibility and static/dynamic interactions are crucial attributes of living organisms.
Therefore, it is not surprising that over 80% of proteins do not appear on their own
but as part of complexes[22]. The assembly of proteins into macromolecules is a highly
regulated process in organisms and often lethal if malfunctioning[62, 139]. The majority
of protein interactions are transient, so called non-covalent interactions. In contrast,
covalent bonds between molecules evolve from interactions involving electron sharing
and lead to the formation of stable and discrete molecules or complexes. This is often
found in protein modifications, such as ubiquitination, phosphorylation or glycosylation.
Transient ”non-covalent” interactions, on the other hand, with variations classified by
their physical basis can be characterised as electrostatic forces involving point charges,
dipole and induced dipole interactions, ion pairs and salt bridges, van der Waals and
hydrophobic interactions or hydrogen bonds, resulting in a wide range of structurally
discrete assemblies which in turn lead to different chemical and physical properties of
1
2 Chapter 1 Introduction
the formed complex. This interplay is not limit to intermolecular protein interactions,
but also to intramolecular interactions where they enable correct protein folding.
1.1.1 Intramolecular interactions - the driving force of protein folding
and misfolding
Following decades of research, the mechanism of protein folding is only partially un-
derstood. It is commonly accepted that protein folding is the stochastic search for
accessible conformations which leads to the structure that is most thermodynamically
or kinetically favoured[60, 64, 250]. The thermodynamic stability of a protein depends
on the intrinsic properties of the amino acid sequence[3]. Usually, the most thermo-
dynamically stable conformation under physiological conditions is the native state of
proteins[64]. The stochastic search is often described as a trial and error process with
Figure 1.1: Funnel shaped free-energy landscape showing how intra- and inter-
molecular interactions lead to stable protein conformations which can be either
the native protein structure or a wide range of aggregates. In vivo the pro-
cess of protein folding, assembly and aggregation are controlled by chaperones,
which can recover or prevent kinetically trapped conformations or deleterious
intermolecular interactions. Reproduced with permission from ref. 92.
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a downhill path through only a small number of possible conformations in a funnel-
shaped potential energy surface (Fig. 1.1). Based on experimental results, a nucleation
model of protein folding was proposed in which few amino acids form a nucleus fol-
lowed by a step-wise restriction of the accessible conformations[75]. However, besides
this postulated molten globule model different other folding mechanisms are possible in
vivo. On the one hand, the co-translational protein folding exists with partial folding
of the nascent-chain, whereas the complete protein is not yet fully synthesised by the
ribosome[88]. On the other hand, many proteins are mainly folded after being released
from the ribosome or even translocated into cellular compartments, such as the mito-
chondria or the endoplasmic reticulum[34, 93]. However, in the crowded cellular milieu,
harsh conditions preventing efficient protein folding are represented. Despite the low
concentration of proteins (6% plasma, 2% interstitial fluid, 30% cytosol) in the extra-
cellular milieu, the conditions are even worse, where fluids are continuously subjected
to shear stress and a more oxidising environment[212]. These harsh conditions can in-
terfere with the formation of stabilising intramolecular interactions, such as disulfide
bond or electrostatic bond formation, crucial for native secondary and ternary struc-
tures. Incompletely folded proteins are prone to inappropriate interaction with other
biomolecules. These interactions or the failure to fold correctly can lead to protein
aggregation, amyloid synthesis or malfunction.
1.1.2 Intermolecular protein interactions
Intermolecular interactions all possess an electromagnetic nature. Nevertheless, they
can be classified by the distance between the interacting moieties, according to the three
ranges of interatomic separation[124]. The short range interactions are dominated by
repulsion and electronic exchange, due to overlap of electron shells. In the intermediate
range with the van der Waals minimum, those repulsive forces are in balance with at-
tractive forces. Whereas, for the large distance interactions, essentially only attractive
forces can be observed[124]. ”Biological intermolecular interactions” are different from
simple chemical reactions or physical changes of a system, as these include a complex
set of different molecules in terms of type, size and properties under continuous non-
equilibrated conditions[113]. The intermolecular interactions found in living organisms,
thus, are dynamic yet tend to lead toward the equilibrium state or some local metastable
low energy state[113]. More precisely, the cellular milieu represents a densely packed
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body, filled with a diverse set of molecules, leading to constant collision of individual
proteins, ions, membranes, nucleic acids and other biomolecules. Those interactions can
vary in frequency, specificity and duration[152]. The variation of such intermolecular in-
teractions is responsible on the one hand for the appearance of stable assemblies and on
the other hand for short-lived interactions with no or little biological relevance promoted
by intracellular crowding[152]. However, even interactions of very short duration can be
of crucial functional importance, such as those found in cell signalling[181, 204]. There-
fore, intermolecular interactions play a major role in all enzymatic processes, protein
assembly and molecule recognition. Thus, formation of tertiary and quaternary protein
structures is driven by intermolecular interactions. Those interactions lead usually to a
stabilisation of the complex and increase the rigidity of the individual molecules[152].
1.1.2.1 Functional protein assembly
Functional protein assembly and even protein polymerisation are crucial, highly regu-
lated processes in living organisms, ranging from the formation of ribosomes, composed
of 79-80 proteins and four RNAs in eukaryotes or the ∼120 MDa nuclear pore complex
containing about 1000 protein subunits to continuously polymerising and depolymeris-
ing cytoskeleton protein complexes of actin and tubulin[55, 144]. The advantages of
extended quaternary protein structures are the accumulation of different functions in
close proximity and therefore being able to increase the efficiency and speed of bio-
logical processes. In this manner, a substrate can be bound/detected and get directly
facilitated to an active site to initiate a wide range of enzymatic reactions. Further-
more, functional protein aggregation can be found e.g. in bacteria where it leads to the
formation of extracellular biofilms. However, functional protein aggregation is highly
regulated and fibril self-replication is prevented by several mechanisms such as control-
ling local monomer concentration and low elongation rates[2]. An increasing number
of aggregated or even amyloid forms of proteins have been found in living organisms
where they fulfil functional purposes[174]. Those functional amyloids work as struc-
tural components as seen for bacterial biofilms, storage units as found for peptide hor-
mones in eukaryotes or as ”immunological” barrier and signaling mechanism known for
HET-s/S prion systems in fungi[174]. The crucial difference between functional and
disease-related amyloids or other polymers is, that the macromolecules are not toxic,
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coming from their distinct structure which is diverging from their disease-related coun-
terparts. The aggregation/polymerisation of such biomolecules is highly regulated and
depending on the homeostasis of different proteins together with the control of the phys-
ical–chemical environment and that there is no off-pathway being responsible for toxic
oligomer formation[174]. The advantages of protein assembly is not limited to morpho-
logical and enzymatic purposes only, but are also energetically economical. It is simpler
to assemble a large complex from multiple copies of smaller subunits rather than produc-
ing a much larger protein[51]. The reduction of genetic code and better quality control
of proteins would be one advantage[152]. Another advantage can be a polydisperse dis-
tribution of large complexes or oligomeric proteins inside the cell providing regulatory
abilities and extending the functionality of the subunits, as has been previously shown
for small heat-shock proteins (sHsps)[113, 216].
1.1.2.2 Protein aggregation and related diseases
Currently, ∼36 proteins have been identified in the context of mammalian amyloid dis-
eases, yet in vitro experiments indicate that the ability to form ordered amyloid struc-
tures is not a rare phenomenon associated with a small number of diseases[61, 62, 211].
This has lead to the hypothesis that physiological mechanisms have been evolved in na-
ture as a protection against amyloid formation. The microscopic phenotype of amyloid
related diseases is associated with the deposition of such aggregates in a variety of organs
and tissues, e.g. brain, central nervous system (CNS), heart, liver, spleen, skeletal tis-
sues and joints[244]. All of the disease-related amyloid deposits are found extracellular
and just a few disease-related intracellular inclusions have been found to exhibit par-
tial amyloid-like characteristics[211]. Despite the diversity in the characteristics of the
soluble forms of the proteins and the progression of the related diseases, the structural,
physical and chemical properties of the aggregates are similar. The amyloid external
morphology (long, unbranched formation, typically 6-12 nm in diameter and typically
consists of 2-6 protofilaments that are often twisted around each other to form super-
coiled rope like structures) and internal structure (beta strands running perpendicular
to the protofilament axis) are commonly found, contributing to a characteristic ‘cross-β’
X-ray fibre diffraction pattern and a specific optical behaviour upon bind of certain dyes
e.g. thioflavin T (ThT) or Congo red[217]. Fibril formation is a nucleated polymerisa-
tion reaction presenting a sigmoidal-like growth curve, describing the conversion from
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soluble proteins into ordered amyloid structures[130]. This aggregation phenomena is
divided into several microscopic processes (Fig. 1.2). Primary nucleation describes the
process of spontaneous nucleation of free monomers, whereas fibril elongation is specified
as the addition of monomers to the fibrillar ends. Furthermore, several secondary pro-
cesses are also involved in the aggregation process. One such secondary process is frag-
mentation, which doubles the number of growing fibril ends following each breakage[45].
Another secondary process is secondary nucleation, which is characterised as a monomer
nucleation process with the fibril surface acting as a template for aggregation also known
as prion-like behaviour[33, 130]. Such nucleation processes play a significant role in dis-
ease initiation and progression as they increase the amount of soluble oligomers, shown
to be the primary toxic species in neurodegenerative diseases[90, 135, 147]. Whereas
fibrillar aggregates or their deposits may be inert or even protective[66, 248]. It is
known that the amyloid burden in neurodegenerative diseases, such as Alzheimer’s, the
most common neurodegenerative disease, can be quite low and its existence is poorly
correlated with the local extent of neuronal death and synaptic loss, as well as with
cognitive impairments[36, 84, 147, 232]. Suspected reasons for oligomer toxicity are e.g.
disruption of membrane homeostasis caused by amphipathic oligomer insertion, complex
Figure 1.2: The Aggregation of proteins is divided into several mechanisms.
The Aβ40 and Aβ42-aggregation can be described by primary nucleation, fibril
elongation and secondary nucleation, in which the primary nucleation describes
the spontaneous nucleation of free monomers (orange spheres), elongation the
addition of free monomers to the fibril ends (green stick) and secondary nucle-
ation the nucleation process of free monomers on the fibril surface. The impact
of each single mechanism depends on the Aβ-monomer concentration. Analysed,
measured and simulated data indicate that the second step of secondary nucle-
ation is the rate-determining step (RDS) under high monomer concentration,
whereas under low monomer conditions, effectively only single-step secondary
nucleation can be observed. Both conditions are relevant for Aβ40, but for Aβ42,
only the low monomer behaviour could be observed[158].
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formation with ions, induction of Fenton reactions and disruption of the electron trans-
port chain in the mitochondria or activated apoptosis[198]. Amyloid related diseases
such as Alzheimer’s, Parkinson’s and type 2 diabetes are strongly age-associated disor-
ders that has emerged as the most costly, in terms of health care and social disruption
with an increasing life expectancy in industrial and developed countries[177, 179]. Cur-
rently >26 million people are affected by Alzheimer’s and it is predicted that by 2050
the amount will increase to ∼106 million people[30]. Therefore, there is a high demand
for therapies leading to the development of antibody and small molecule therapeutics
with some being in clinical trial, yet without any success.
1.1.2.3 Molecular chaperones as counterparts to protein aggregation
Increasing evidence indicates that amyloid structures have a smaller free energy level
than the proteins functional ”native” state, which is separated by a high activation
barrier from the metastable states[20]. In vivo mice studies have shown that chaper-
one deficiency or knock-out can lead to lethality[103], which underlines the necessity of
chaperones for accurate folding in the presence of destabilising mutations and harsh en-
vironmental conditions. The aggregation process in vivo occurs in the presence of other
proteins, membranes, metabolites and a wide range of more biomolecules, each of which
may affect both its rate and equilibrium with free protein[52, 81]. Molecular chaperones
are defined as an essential and ubiquitous group of proteins with a wide range of func-
tionalities, which are mainly responsible for the stabilisation of unfolded proteins and
facilitate their native folding, control protein assembly, cellular transport of proteins into
subcellular compartments and guiding proteins to degradation[91]. The term ’molecular
chaperone’ was first used by Ron Laskey in 1978[138] and the concept of its general
function was suggested by Hugh Pelham in 1986[178]. Since these pioneering works,
many different classes of structurally unrelated chaperones have been identified to exist
in the cell. Most of the molecular chaperones have been found to be upregulated under
stress conditions, in which the concentration of aggregation-prone folding intermediates
increases, and are therefore known as heat-shock proteins (Hsps). However, it should be
noted that not all chaperones are Hsps and not all Hsps are chaperones. Chaperones are
usually classified according to their molecular weight or their sequence/structural homol-
ogy. Their interaction partners are typically identified by their hydrophobic amino acid
side chains exposed by non-native proteins[92]. Chaperones are important for protein
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quality control and essential for the maintenance of protein homeostasis. The ability
to buffer mutations which disrupt the stable fold of a protein is crucial for the evolu-
tion of new protein functions and phenotypic traits[92]. Malfunctioning chaperones or
their lack of function (chaperonopathy) has thus been implicated in several diseases such
as the MitCHAP-60 disease[148], interstitial lung diseases, familial British and Danish
dementia[202] and their involvement in others may be underestimated. Whereas many
intracellular chaperones have been identified, only seven molecules are known to popu-
late the extracellular environment: these are clusterin, haptoglobin, α2-macroglobulin,
apolipoprotein E, serum amyloid P component, αE-fibrinogen and casein[114]. Intra-
cellular chaperones such as Hsp70 and Hsp90 have been observed extracellular as well,
but whether their existence is functional or whether they are released by necrosis or
apoptosis is still unclear. The extracellular concentration of these primarily intracellu-
lar chaperones is very low (ng/ml) and the required ATP-concentration is a thousand
times lower than inside the cell[72, 259, 260]. Currently, several other extracellular chap-
erones (EC) or chaperone-domains are being investigated due to their potential diverse
function compared to intracellular chaperones. A better understanding of their basic
functions can give necessary information in the context of disease evolution and provide
starting points for future therapies.
1.2 Microfluidic applications for the investigation of pro-
tein interactions under native conditions
1.2.1 Diffusional sizing of heterogeneous protein solutions
Generally, microfluidics stand for fluid control in channels (often consisting of poly-
dimethylsiloxane, polyimide, polycarbonate, glass or silicon) at the scale of microns.
This leads to the reduction of gravity effects and inertial forces. On the other hand, vis-
cosity forces come to the fore. In the case of a low Reynolds number of the fluid, a laminar
flow behaviour occurs and the mixing between parallel streams of fluids happens only
by translational diffusion. This process can be described by the Einstein-Smoluchowski
equation:
< x2 >= 2Dtt (1.1)
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where the average mean square displacement < x2 > of a molecule in three dimensions
is proportional to the time t and the translational diffusion coefficient Dt, which itself
is inversely proportional to the hydrodynamic radius rH .
In order to characterise the size distribution of a wide range of molecular species un-
der native conditions, I have used a previous designed microfluidic system that allows
molecular diffusion to be monitored directly in solution (Figure 1.3)[9, 164]. Within
this microfluidic device, a beam of analyte is generated through flow focussing in the
centre of a micron-sized channel between two streams of buffer. While advecting along
the longitudinal direction y, the biomolecules diffuse laterally along the perpendicular
directions x and z. At low Reynolds numbers, convective mixing is generated, leading to
highly reproducible mass transport properties. The diffusion profiles, giving the mass-
concentration of analyte molecules as a function of x at different times and at different
positions along the channel, are then recorded directly within the device by fluorescence
microscopy and fitted by model simulations based on advection-diffusion equations to
provide the distribution of diffusivities, and therefore of the sizes, of the analytes[9, 164].
The flow velocity in the channel is set to have a dominance of convective flow along the
longitudinal direction (Péclet number, Pex>>1) and of diffusive motion in the verti-
cal direction (Péclet number, Pez<<1). The sample concentration is therefore uniform
along the height of the channel. By contrast, it exhibits a spatial dependence along
the horizontal direction, where the Pey>1. The diffusional sizing technique applied in
this work monitors this spatial propagation along the horizontal direction at different
diffusion times and different diffusion positions along the channel. The relation of the






where kB is the Boltzmann constant and η the viscosity of the fluid at a given temper-
ature T . This implicates that besides the diffusion profiles measured by the diffusion-
based microfluidic device, the molecular size distribution can be determined based on
accurate numerical calculations and least square fittings of simulated and measured diffu-
sion profiles. For the simulation of the experimental fluorescence profiles, a combination
of basis functions were used[164]
|D − Σni=1ciBi|2 − αΣni=1ciln(ci) (1.3)
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where D is the measured profile and Bi represents a kernel function for different
molecules i at given measurement points. Their coefficients ci regulate the amplitudes
of each kernel and are fixed between 0 and 1 to give the amount of each molecule species
and α can be used as a control of the allowed maximum entropy term. The Kernel
function is based on the Einstein-Smoluchowski and Langevin equation[164]
∇k+1 = ∇k +
√
2Dtdt ·Random{−1,+1}+ v(xk)dt (1.4)
which calculates the position ∇ of a molecule at a given time point k for all three
dimensions in respect to the channel’s velocity profile v(xk)dt, which is taken into account
only in flow direction x. The advantage of using fluorescence-labels, such as the fusion-
protein GFP or chemically attached Alexa or Atto dyes, is the ability to target and
follow only specific proteins and their behaviour in heterogeneous solutions. However,
intrinsic fluorescence generated by the aromatic amino acids tryptophan, tyrosin and
phenylalanin can be exploited but only works for homogeneous samples.
As seen above, bound molecules can be distinguished from their unbound counterparts
by their altered hydrodynamic radius and diffusion. The ability of the diffusion-based
microfluidic device to handle polydisperse and heterogeneous mixtures and species, rang-
ing from small molecules to large biological polymers, often hundreds of nanometers in
diameter, makes this method ideal for high-throughput application for binding studies
with protein aggregates[203]. The variably sized molecules are characterised by a signifi-
cantly different diffusion coefficient. The interaction or non-interaction behaviour results
in a difference in the intensity profiles by using fluorescence-label. Thus, a bimodal size
distribution is expected under interacting conditions, where bound and unbound frac-
tions are quantifiable by their given coefficients.
Based on this microfluidic approach, commercial applications have evolved such as the
Fluidity One and the Fluidity One-W from Fluidic Analytics Ltd. based in Cambridge,
UK. However, both commercial machines are based on a parallel stream with sample
coming from one side and an auxiliary flow from the other (see Fig. 2.16A). At the end
of the device, both streams are split and target quantity is acquired in a diffused and
undiffused chamber. Therefore, this commercial system can only provide an average
radius of the target molecules rather than a size distribution.
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Figure 1.3: Description of the microfluidic platform used for binding measure-
ments. (A-B) Scheme of the device and relevant components: the beam of the
analyte sample is focused between two streams of the buffer in the nozzle area
of the microfluidic device. The diffusion coefficient of the molecules is mea-
sured by recording the diffusion profiles at different positions along the channel
length. (C) Representative scheme of the diffusion behaviour of a protein in the
presence and absence of interacting antibodies; proteins interacting with anti-
bodies (indicated in green colour) remain localised in the middle of the channel;
in contrast, proteins, which do not interact with antibodies (indicated in blue
colour), diffuse rapidly to the edges of the channel. This behaviour results in a
difference in the fluorescence intensity profiles of the interacting (green profiles)
and the non-interacting (blue profiles) molecules.
The investigation of protein-protein interactions is challenging as molecules can e.g. in-
terfere unspecifically with surfaces or following individual and rare binding events in
heterogeneous mixtures is hard to achieve. The clinical demand for quick and sufficient
interaction studies is increasing for, e.g. determining the risk of alloimmunisation after
transplantation[134], drug screening[169] and disease recognition[101]. Different meth-
ods have been established over the years to characterise the molecular (non-covalent)
interactions between biomolecules, which are commonly described in terms of the dis-
sociation constant (KD), the association and dissociation rate constants (kon and koff),
the standard binding enthalpy (∆H	), the standard binding entropy (∆S	) and the
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standard state free energy (∆G	). Techniques providing an experimental set-up for
simultaneous measurements of all parameters are rare and often non-applicable for a
wide variety of proteins. Such conventional approaches include calorimetry[185, 231],
capillary electrophoresis[168, 199], equilibrium dialysis[15, 109], ultrafiltration[27, 254],
affinity chromatography[246], nuclear magnetic resonance spectroscopy (NMR)[76, 141],
mass spectrometry[40, 71, 187], fluorescence-/Raman-spectroscopy[140, 256], circular
dichroism[82], biolayer interferometry[171], sedimentation assay[207] and surface plas-
mon resonance (SPR)[106]. All of these techniques have their advantages and disad-
vantages and suffer from a series of limitations. For instance, some approaches require
high sample concentration (e.g. calorimetry and mass spectrometry)[115, 167], other
techniques require special probes (e.g. isotopes, protein-tags or fluorescence labelling)
while other methods often show non-specific binding and low signal to noise ratio (e.g.
NMR, capillary electrophoresis, SPR)[18, 77, 218]. In particular, the accurate quantifi-
cation of binding parameters is severely impaired by approaches which require surface
immobilisation, such as SPR, where possible unspecific interactions with the chip surface
often result in an overestimation of the binding affinity[171]. The usage of a diffusion-
based microfluidic device (Fig. 1.3 A, B) for interaction measurements enables binding
incidences to be examined directly in the condensed phase resembling physiological con-
ditions. Compared to the conventional approaches described above, this method is tol-
erant to highly polydisperse and heterogeneous solutions, has no limitation in terms of
size of protein/complexes and offers a series of advantages including demand for limited
amount of sample and the absence of surface interactions. Furthermore, requiring small
amounts of sample is often a key consideration when analysing clinical samples from a
human source or proteins such as amyloid β and α-synuclein, which are challenging to
synthesise and therefore expensive to acquire.
One aim of my Ph.D. was to show that the diffusion-based microfluidic device is an ac-
curate and sensitive technique for binding parameter quantification and thermodynamic
measurements and represents an important step in the characterisation of chaperone
function with respect to aggregation inhibition and binding. Furthermore, I wanted to
show the practical and potential functionalities of the diffusional sizing approach for
unpurified clinical samples on the one hand and on the other hand to expand its ca-
pabilities to characterise the biophysical properties of complex solutions in an instant
multidimensional way.
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2.1 Introduction: Chaperones - natural inhibitors of pro-
tein aggregation
Molecular chaperones are crucial components of the cellular proteostasis network and
characteristically overexpressed during cell stress[69, 70, 92, 94]. Their roles involve
the suppression of aberrant processes, including misfolding and aggregation of proteins,
within the context of the complex flux of protein production and degradation. In addi-
tion to guiding nascent proteins towards their native structures following their biosyn-
thesis by ribosomes, chaperones are increasingly recognised to also inhibit key steps in
the aberrant conversion of normally soluble proteins into amyloid fibrils, protein aggre-
gates that are associated with a wide range of neurodegenerative diseases[8, 13, 63, 203].
The overall process that leads to the formation of amyloid fibrils consists of a series
of microscopic events, including primary and secondary nucleation and fibril elongation
and fragmentation[44]. Recent analysis of the aggregation kinetics of several proteins
has revealed that molecular chaperones can inhibit the process of amyloid formation
through a variety of different mechanisms[10]. In some cases, molecular chaperones
have been found to suppress a single specific microscopic step in the aggregation pro-
cess. In other cases, they have been shown to affect more than one type of aggregation
event[8, 41, 150, 203]. The modulation of the different molecular steps of protein ag-
gregation is mediated by the binding of chaperones to misfolded protein monomers and
various aggregated species[41, 207, 235]. In order to gain a comprehensive understanding
of such inhibition processes, it is therefore crucial to elucidate the thermodynamic and
kinetic determinants of chaperones binding to different species populated during amy-
loid formation. A large number of observations, including genetic and epidemiological
studies, indicate that the aberrant aggregation of normally soluble peptides and proteins
into insoluble amyloid fibrils is associated with the onset and the progression of a wide
range of neurodegenerative disorders[39, 68, 89, 90, 125, 129]. Biophysical studies are
currently revealing important molecular details underlying the formation of the fibrillar
aggregates from initially supersaturated monomer solutions[74, 130, 221]. In addition,
secondary nucleation in particular increases the rate of formation of low molecular weight
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oligomers that accompany the formation of mature fibrils and are currently thought to
represent the most toxic species produced during such processes[21, 41, 42, 90, 135].
Inhibition of such key aggregation processes therefore represents a potentially attractive
therapeutic strategy to combat amyloid associated diseases[10].
Understanding the underlying molecular determinants of these different mechanistic pro-
cesses is therefore of fundamental importance for the design of strategies that target
specifically the reactions responsible for the formation of the most highly toxic species.
Indeed, in the context of developing drugs to combat protein aggregation disorders, tar-
geted interventions rather than nonspecific suppression of the aggregation process, are
required[10]. The inhibition of different microscopic steps can lead to similar effects on
the overall formation of amyloid fibrils, yet can have dramatic differences in the genera-
tion of toxic oligomeric species[5, 10, 85]. An intervention strategy targeting the specific
microscopic steps that represent the major sources of the formation of such oligomers
is, therefore, likely to be an optimal approach to suppress the most detrimental effects
of protein aggregation.
By investigating a series of molecular chaperones that can inhibit selectively one or
more specific steps in the aggregation process of different amyloidogenic proteins, I
have shown that these molecules can influence aggregation processes through a variety
of different microscopic events and have revealed the complex mechanism evolved by
nature in order to maintain protein homeostasis[4, 8, 150]. With such information I can
exploit molecular chaperones to perturb, in a selective way, a given aggregation network
and thereby investigate the effects of individual steps in the reaction on the formation
of key intermediate species.
2.1.1 The small heat shock protein αB-crystallin
A prevalent group of molecular chaperones that inhibit amyloid formation are the small
heat-shock proteins (sHsps), including the vertebrate αB-crystallin (αB-c). The struc-
ture of αB-c is a conserved α-crystallin domain with a β-sheet structure, flanked by a
hydrophobic N-terminal region and a polar C-terminal tail, both structurally flexible
and heterogeneous[102]. Similar to other sHsps in solution, αB-c exists in a polydis-
perse oligomeric state characterised by dynamic subunit exchange leading to the for-
mation of oligomers with 10-50 subunits and molecular weights from 300 to 1000 kDa









Figure 2.1: Oligomeric assembly of αB-crystallin (αB-c). a) αB-c units inter-
act via intra-dimer interfaces and assemble through inter-dimer interactions to
higher order oligomers as commonly seen for sHsps. Dimeric subunits are shown
here as ellipsoids. b) and c) Most dominant even-numbered oligomeric species
are shown with different binding modes of polyhedral architecture as schematic
(b) and at pseudo-atomic level (c). Reproduced with permission from ref. 104
and 14.
(Fig. 2.1)[104, 112]. αB-c has been shown to inhibit the overall amyloid formation
process of α-synuclein (α-syn), a protein whose aggregation is closely associated with
the onset and progression of Parkinson’s disease[48]. The mechanism of inhibition
has been shown to originate from interactions of the chaperone with aggregated forms
of α-syn, ranging from oligomers to mature amyloid fibrils, rather than with α-syn
monomers[192, 193]. In particular, it has been demonstrated that αB-c binds to α-syn
fibrils and inhibits their elongation, thus suppressing the toxicity associated with α-syn
aggregation in cells[175, 235].
The mechanistic importance of the interactions of αB-c with protein aggregates raises
the key question of how such chaperones recognise misfolded and aggregated proteins
amongst the diverse ensemble of native states. Elucidating the binding interactions be-
tween these protein species poses fundamental challenges that originate from the hetero-
geneity and dynamic nature of the system explored. Both the chaperone and aggregate
populations are heterogeneous, and the large difference in size between relatively small
chaperones and high molecular weight client protein aggregates make interactions be-
tween them difficult to access with conventional biophysical techniques designed to probe
interactions between individual biomolecules under bulk conditions[105, 251]. I have ad-
dressed these limitations using a microfluidic platform to characterise the binding[9]. By
exploiting the different diffusion coefficients of bound and unbound chaperones, I have
shown that it is possible to quantify the thermodynamics and the kinetics of binding on
the time scale of seconds, where the spatial variation in concentration along the device
Chapter 2 The binding of chaperones and therapeutic antibodies to amyloid fibrils 17
has a negligible effect on the kinetics due to the short measurement times[9, 257]. In
this thesis, I apply this approach to identify the intermolecular interactions underlying
the recognition of α-syn amyloid fibrils by αB-c and characterise the energetic tradeoff
during this binding process in a quantitative manner.
2.1.2 The Brichos chaperone domain
The Brichos domain was identified by Stefan D. Knight in 2013 as the first exam-
ple of a chaperone-like domain with specificity for beta prone regions, amino acid se-
quences which are likely to form beta-sheet structures found in amyloids. The ∼100aa-
Brichos domain has been found in more than 300 proteins and more than 30 human
genes[97, 128, 202]. Some of these proteins are associated with degenerative and pro-
liferative diseases. Mutation in the Brichos domain triggers protein aggregation (e.g.
in familial dementia and interstitial lung diseases) or cancer suppression (e.g. chon-
drosarcoma) [202]. The ability of the Brichos domain to interact with peptides which
have a high beta-sheet propensity, its role as a trigger for protein aggregation of Bri23
(formerly proBri2) and lung surfactant protein C (formerly proSP-C), their expression
together with APP and its further secretion into the extracellular space together with
Aβ[153] makes it an ideal candidate in the context of Alzheimer’s research, especially in
combination with Aβ aggregation. It has been observed that the introduction of the Bri-
chos domain blocks the aggregation of Aβ40[127, 180, 242] and delays the aggregation of
Aβ(M1-42)[99, 242] in a concentration dependent manner both in vivo and in vitro.
An overexpression of Bri2, the secreted Brichos domain part of proBri2, in AD
mice[126, 127, 156] and Drosophila melanogaster [99] models showed reduced AD pathol-
ogy. This effect was suggested to be correlated to higher levels of unprocessed Bri2 in
the hippocampus[56] and cerebrospinal fluid of AD patient which led to an introduction
of Bri2 as a new AD-biomarker[162]. According to biophysical and chemical kinetic
analysis, in the case of the Aβ(M1-42) peptide, the Brichos domain of proSP-C (Fig.
2.2 a) inhibits its aggregation by suppressing specifically the secondary nucleation reac-
tion (Fig. 2.2 b-d) and by that the seeding effect is almost completely killed[41]. The
specific inhibition of secondary nucleation suppresses effectively the amount of toxic
oligomers, whose generation is mainly catalysed on the fibril surface. Brichos binding
to the monomeric form of Aβ is not supported by the data, as there is no indication
for inhibition of primary nucleation and inhibition of secondary nucleation is present far
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a)
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Figure 2.2: (a)The Brichos domain of SP-C shows a five stranded beta-sheet
with alpha-helices on each side in the x-ray structure. The β-sheet faces are
a likely binding site surface with many conserved hydrophobic residues[241].
(B-D) Previous studies by Cohen et al. could show that the Brichos domain
specifically inhibits the secondary nucleation processes involved in Aβ(M1-42)
aggregation. The data of ref. 41 were reproduced with permission and show
the aggregation of Aβ(M1-42) (monomers shown as orange spheres, fibrils as
green sticks) from left to right in the absence of Brichos and with 10%, 15%,
22%, 35%, 50% and 75% Aβ(M1-42) monomer equivalents of unlabelled Brichos
(shown as green spheres). Three different scenarios of inhibition mechanisms
were simulated and compared to the plotted data. The simulated inhibition
of primary nucleation (b) and fibril elongation (c) showed no match with the
data, whereas the model for inhibition of secondary nucleation indicates the
best fit (d).
below of equimolar amounts with the chaperone. A binding of the Brichos domain along
the fibril surface can be expected.
2.1.3 The extracellular chaperone clusterin
Clusterin (also known as apolipoprotein J (ApoJ), sulfated glycoprotein 2 and SP-40)
was the first identified secreted protein and is an abundant extracellular chaperone[110].
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The chaperone consists of an α- and a β-subunit connected by two disulfide bonds and
contains highly sulfated carbohydrates (23-30%). Structural information are still miss-
ing, but prediction of structural elements by sequence analysis show three amphipathic
α-helices[59] and two coiled-coil helices[145]. It has been suggested that the α-helices
form a molten globule-like binding pocket for a variety of ligands[12]. Due to its inter-
action with structurally diverse molecules, the exact biological role of clusterin is still
controversial. Clusterin is classified as an ATP-independent holdase-type chaperone
with similarities to sHsps and has the tendency to form oligomers[114]. Alternative hy-
pothesised biological functions are a role in lipid transport[59], sperm maturation[100],
complement regulation[117], membrane recycling[121] and apoptosis[35]. However, the
fact that clusterin was found to be upregulated in AD tissues supports its regulatory role
in protein aggregation as molecular chaperone. In general, clusterin is active in the pres-
ence of amorphous aggregates and inhibits the formation of amyloid fibrils from a large
variety of proteins including PrP106-126, apolipoprotein C-II, disease-associated vari-
ants of lysozyme, α-synuclein, calcitonin, κ-casein, SH3 and CCβW in vivo and in vitro.
Furthermore, the uptake of clusterin-complexes with Aβ by neural epithelical cells by
megalin (LRP2)-mediated endocytosis and subsequent degradation could be observed in
vivo[86]. It is suggested that the megalin-receptor binds specifically to the clusterin-Aβ
complex and initiates an internalisation where Aβ is targeted for lysosomal degradation.
Thus, not only targeting of aggregates, but also the aggregation process of Aβ itself is
influenced by clusterin.
Clusterin is an important member of a family of largely extracellular chaperones, which
have been observed to interact with different aggregation states of amyloidogenic pro-
teins, including oligomers, pre-fibrillar species and mature fibrils, and hence affect a wide
range of events leading to the formation of amyloid fibrils[19, 133, 166, 253, 258, 259].
As part of my PhD, I examined the combined ability of clusterin and another type of
molecular chaperone, a Brichos domain, to influence specific microscopic events in the
aggregation process, and analyse the cooperative nature of the inhibition process, thus
extracting information about the location of specific sites on the fibrils that are involved
with secondary nucleation and with fibril elongation.
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2.1.4 Antibody and small molecule strategies as potential therapeutics
targeting Aβ(42) aggregation
The significance of Aβ(42) aggregation as major driving force for AD is seen critically,
yet the formation of Aβ(42) plaques remains the main target for various therapeutics
in clinical trials or prior studies. However, evidence suggest that aggregation inhibitors
derived without determining their underlying mechanism of action may not decrease
the neurotoxicity of Aβ aggregates. Even though the small Aβ peptide aggregates to
form macromolecular amyloid fibrils, the oligomers produced during the process of fib-
ril formation have been uncovered as the dominant toxic species and have been shown
to play a key role in the death of neurons[232]. The demand for Alzheimer’s diagnos-
tics and treatment is increasing with a rising trend of medical cases, going together
with enormous suffering of affected individuals and resulting in expensive supervisions.
Current treatment approaches focus on immunotherapy or the use of small molecules,
which has been tested with varying success rates[28, 176, 201, 206]. The main focus of
most therapies is the general delay of Aβ assembly by inhibiting specific aggregation
processes[87]. More specifically, along with the recruitment of microglia and subsequent
cellular phagocytosis[28, 206], the prevention of plaque formation and/or the clearance of
oligomers is the main goal. However, recent setbacks increased the reservation from the
amyloid cascade hypothesis as clinical trials did not achieve much success. Reasons for
these drugs to fail might be manifold, yet the current evolution of Alzheimer’s therapies
does not take into account the critical connections of Aβ aggregation mechanisms and
how the generation of toxic species is affected by individual microscopic steps and their
dependence to each other[8, 41]. The inhibition of specific microscopic steps may limit
the toxicity of Aβ, whereas others might even amplify the damage. As such, specific
inhibition of fibril elongation can shift the reaction flux towards an increase of secondary
nucleation and therefore increase the content of toxic Aβ species.
During my PhD, I had the opportunity to study the murine versions of the thera-
peutic antibodies gantenerumab (chgantenerumab), bapineuzumab (3D6), aducanumab
(chaducanumab) and solanezumab (m266), as potential inhibitors for AD. The human-
derived monoclonal antibody aducanumab has shown promising results in a previous
phase 1b trial, with dose- and time-dependent reduction of brain amyloid burden, as
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measured by PET imaging, accompanied by a slowing of cognitive deterioration in sub-
jects with early AD[206]. However, Biogen Inc. halted the phase 3 trial in 2019 as
the delay of cognitive and functional degradation compared to the placebo was not sig-
nificant enough and preliminary data suggested the drug would not meet the primary
endpoint[25]. Kinetic studies on chaducanumab could show that the antibody specif-
ically suppresses secondary nucleation with no observable effect on Aβ(42) elongation
(unpublished work by Sara Linse). The murine precursor of bapineuzumab, 3D6, on the
other hand, has been shown to suppress secondary nucleation of Aβ(42) at low concen-
trations and even elongation at higher inhibitor concentrations (unpublished work by
Sara Linse), yet failed to produce significant cognitive improvements in patients in two
major trials[184]. The other two antibody types tested, gantenerumab and solanezumab
are still in phase 3 trials with solanezumab expected to fail as the antibody already
shows no significant changes in the disease phenotype compared to placebos[143, 196].
Experiments show that gantenerumab specifically binds to fibril ends and blocks elon-
gation whereas m266 specifically suppresses primary nucleation (unpublished work by
Sara Linse). Together with Sara Linse from Lund University, I have analysed the bind-
ing behaviour of the antibodies to Aβ monomers and fibrils mentioned above. The goal
was to correlate the characteristic inhibition behaviour of those antibodies, previously
studied by Sara Linse, to their individual binding parameters.
2.2 How the interaction of the small heat-shock protein
αB-crystallin to α-synuclein fibrils is driven by en-
tropic forces and what that means for the binding
mechanism
2.2.1 Microfluidic measurements of protein interactions in the con-
densed phase
The microfluidic diffusional sizing relies on fluorescent labelled molecule in order to track
their diffusional behaviour in complex solutions. Therefore, our protein of interest, αB-
c, was tagged with GFP label. First, the diffusion profiles of GFP-labelled αB-c were
acquired by epifluorescence microscopy in the absence and presence of unlabelled α-syn
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fibrils. By exploiting the difference in diffusion coefficient between amyloid fibrils and
free molecular chaperones in solution, I have detected changes in size distributions upon
the formation of the complex between the chaperone αB-c and amyloid fibrils (Fig. 2.3 a
and c). When a labelled chaperone binds to a fibril, the complex formed exhibits a dif-
fusion coefficient about one order of magnitude smaller than the diffusion coefficient of
the free chaperone. This difference has allowed me to deconvolve the diffusion profiles
into the relative contribution of the two components: the rapidly diffusing free chaper-
ones and the slowly diffusing chaperone-fibril complexes, thus determining the absolute
concentrations of both binding partners in the condensed phase.
Prior to measuring the binding parameters, I verified by means of kinetic analysis that
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Figure 2.3: Experimental diffusion profiles and analysis a) Diffusion profiles of
three chaperone-fibril samples exhibit different extent of binding: 0% (purple),
about 50% (blue), and 100% (black) of total chaperones bound to fibrils. Nor-
malised profiles are shown for three channel positions. The sample with 0%
bound chaperone diffuses the most, while the sample with 100% bound chaper-
one stays localised in the centre of the channel. Partially bound samples exhibit
superposition of two peak shapes - diffuse (corresponding to free chaperone)
and localised (corresponding to bound chaperone). (b) Experimental profiles of
αB-c (1 µM) binding to α-syn fibrils (10 µM) at 25◦C at 12 diffusion positions
along the channel together with the simulated profiles for the 50% bound sample
showing the best fit for this data set. (c) The fitting of the model simulations
to the experimental data provides a direct measure of the fraction of particles
in each size bin. Inserts in (c) show error distribution of the individual radii
determined by first order Taylor expansion of the least square equation.
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amyloid formation. To this effect, I followed the aggregation kinetics of a solution of
70 µM α-syn to which 5% w/w pre-formed seeds had been added in the presence and
absence of different concentrations of GFP by itself, and both unlabelled and labelled
αB-c (see Supplementary Fig. B.1). I observed very similar aggregation profiles for the
labelled and unlabelled chaperone, indicating that the GFP-tag does not significantly
modify the binding properties of αB-c to α-syn fibrils and its ability to inhibit their
aggregation. Furthermore, no effect on α-syn aggregation by the presence of GFP by
itself was detected. This indicates there are no interactions between GFP and the
aggregation-relevant binding sites of α-syn.
By using the described microfluidic approach, I measured the average hydrodynamic
radius, RH, of the polydisperse αB-c oligomer distribution to be 7.45±0.01 nm at 21◦C
(see Supplementary Fig. B.2). This value is in good agreement with previously re-
ported values measured by size exclusion chromatography and dynamic light scattering
(RH=7.25 nm), with the attached GFP moiety being responsible for the increased mea-
sured size relative to the wild-type[182]. The measured RH indicates that αB-crystallin
is present as an ensemble of oligomers, which is in agreement with mass spectrometric
analysis (see Supplementary Fig. B.3). When α-syn fibrils were introduced into the
system and the distribution of hydrodynamic radii was measured using the microfluidic
platform, a second species in the RH distribution emerged with size in the range of
220.5-222.5 nm (Fig. 2.3 c). This second population, with a larger radius, corresponds
to the complex formed by αB-c and α-syn fibrils, and thus reports on the interactions
between these two species.
2.2.2 Experiments under native conditions reveal a nanomolar affinity
for αB-crystallin binding to α-syn fibrils
I next exploited the quantitative power of the MDS to evaluate the affinity of the
chaperone-fibril interactions in the condensed phase under native conditions. To this
effect, I characterised the kinetics of the binding reaction by incubating a solution of 1
µM αB-c with a suspension of 10 µM α-syn fibrils and measuring the size distribution of
aliquots taken at discrete time points over the course of 50-150 hours. In a wide range
of αB-c concentrations, the distribution of the oligomer distribution has been shown to
be rather narrow and defined[182]. I carried out the measurements at seven different
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temperatures (7◦C, 10◦C, 17◦C, 20◦C, 25◦C, 30◦C, and 37◦C) (Fig. 2.4) to obtain both
the thermodynamic parameters and the activation free energy involved in this binding
process. In order to analyse quantitatively the binding kinetics at individual temper-
atures, I fitted the binding site concentration globally as its value should be identical
under all seven conditions tested.
My data reveal that the reaction exhibits kinetic characteristics of a first order re-
action (Fig. 2.4 a) in both the chaperone and the fibril concentration, and hence
second order overall. I obtained values for the association rate constants (e.g.,
kon,25◦C = 7.1± 2.6 M−1 s−1) and dissociation rate constants (e.g., koff,25◦C = 2.7·10−6±
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Figure 2.4: Kinetic data of αB-c (1 µM) binding to α-syn fibrils (10 µM)
reveal the kinetic parameters of binding. Kinetic traces at different temperatures
were fit to a second order rate equation to obtain the association (kon) and
dissociation (koff) rate constants, from which an apparent dissociation constant
KD,app was calculated. Different binding ratios of αB-c equivalents (eq) to α-syn
fibril mass eq with (a) 1:5.4±1.1 (R2 = 0.922)
, (b) 1:10 (R2 = 0.921), (c) 1:20 (R2 = 0.766) and (d) 1:50 (R2 = 0.336) were fitted.
The optimal fit (a) is given with a stoichiometry of 1:5.4 with a lower boundary for the
stoichiometry at 1:8 given by the standard deviation. The resulting R2 values are
plotted against the corresponding binding ratios as an insert in (d). List of estimated
values for kon, koff and KD,app including standard deviation at individual temperatures
can be found in Supplementary Table B.1.
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by following the dissociation of bound αB-c in a saturated α-syn fibril solution at 7◦C
(see Supplementary Fig. B.5). The dissociation rate constant measured in this experi-
ment is consistent with the koff,7◦C = 5.6 ·10−5±1.2 ·10−5 s−1, similar to the dissociation
rate calculated from the association kinetics koff,7◦C = 2.6 ·10−5±1.6 ·10−5 s−1. The dis-
sociation equilibrium constants are computed from the ratio of the rate constants (e.g.,
KD,app,25◦C = 373 ± 238 nM and KD,app,20◦C = 4.1 ± 1.7 µM). Similar affinities at low
micromolar range have been reported for αB-c binding to other amyloid fibrils, including
Aβ42 fibrils (KD = 2.1 µM), Aβ42arc mutant fibrils (KD = 0.34 µM)[207], and apoC-II
fibrils (KD = 5.4 µM)[24]. Moreover, using the MDS platform, I further obtained infor-
mation on the number of binding sites present on the fibrils; to this effect, I examined
the global influence of the binding stoichiometry on the binding kinetics by comparing
the model predictions for different binding ratios of αB-c to α-syn between 1:5.4 and
1:50 (Fig. 2.4 a-d). The modelled data do not match the measured data points if the
binding ratio of α-syn equivalents to αB-c equivalents increases beyond 8 (Fig. 2.4 b-c).
This observation yields a lower limit with a binding-site concentration of 1.2 µM under
the conditions used and given by the standard deviation of the optimal fit. This best fit
gives a concentration of binding-sites of 1.86 µM, corresponding to one αB-c equivalent
binding to, on average, every 5.4 α-syn equivalents. At the highest temperature (37◦C)
the fraction bound was within error of 100%, hence yielding only an upper bound on
KD. For this reason the KD measured at 37
◦C was not used for any further analysis.
In order to probe whether the binding reaction could be described as a two state process,
I next sought to measure the value of the apparent equilibrium dissociation constant
directly from equilibrium titration measurements, and compared the value obtained to
that of the estimated affinities given by the kinetic analysis. Concentrations of α-syn
fibrils between 1 and 100 µM were incubated with 1 µM αB-c at 25◦C for three days to
ensure that the binding reaction had reached equilibrium (see Supplementary Fig. B.4).
A non-cooperative, single-site binding model (see Materials and Methods) was found to
describe the titration data, using the previously calculated α-syn binding site ratio of
0.186 binding sites per α-syn monomer (inverse value of 5.4 binding ratio derived from
Fig. 2.4 a) as a fixed input parameter. The apparent dissociation constant given by the
titration experiment is KD,app,25◦C = 261± 76 nM (see Supplementary Fig. B.4), which
is in agreement with the KD = 373 ± 238 nM obtained from the kinetic experiments
at the same temperature in Fig. 2.4 a, showing that both experiments probe the same
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thermodynamic landscape.
2.2.3 The binding of αB-crystallin to α-syn fibrils exhibits strong en-
tropy/enthalpy compensation
The apparent dissociation constants estimated at different temperatures allowed me to
deconvolve the enthalpic and entropic components of the free energy of binding using a
non-linear van’t Hoff analysis (Fig. 2.5 b). The values obtained indicate that the binding
between αB-c and α-syn fibrils is endothermic at 37◦C (∆H37◦C = 443± 107 kJ mol−1),
and that the enthalpic loss upon binding is compensated by a gain in entropy
(∆S37◦C = 1.6± 0.4 kJ mol−1 K−1), resulting in an overall spontaneous process at a
physiological temperature (∆G37◦C = −52± 154 kJ mol−1) (Fig. 2.5 c). The gain in
entropic energy that drives the binding of the chaperone to the surface can originate
from two processes, illustrated in Fig. 2.6. A first possibility involves the reduction of
the translation and rotational degrees of freedom of the proteins upon binding to the
fibrils. In this case, the increase in entropy originates from the release of constraints on
hydrogen bonding of water molecules resulting from the burial of hydrophobic protein
patches upon binding or other solvent-mediated interactions (Fig. 2.6 a). The release of
water molecules and therefore an overall increase in entropy is typically the signature of
binding driven by hydrophobic interactions. A second explanation for the entropically
driven binding reaction is the increase of degrees of freedom induced by conformational
changes of the interacting molecules. In this case, the entropic gain would be mainly
given by the disassembly of the oligomeric chaperones (Fig. 2.6 b), while the inter-
actions between fibrils and chaperones would be specific and mediated by the surface
chemistry of the two binding partners. I measured a positive change in heat capacity
(∆Cp = 13.3± 5.5 kJ mol−1 K−1), indicating that the entropic-driven binding is due
to the disassembly of the chaperone oligomers into smaller subunits, rather than to a
hydrophobic effect. The assumption can be deduced from the fact that more water
molecules become coordinated by unveiling hydrophobic patches and/or and increase of
electrostatic interactions which finally lead to an overal negative change in heat capacity.
Furthermore, the idea of dissociating oligomers prior to binding to α-syn binding is in
good agreement with previous studies on αB-c subunit exchange kinetics. The exchange
of αB-c subunits occurs on a similar timescale of the binding between αB-c and α-syn
fibrils[112]. The described system can therefore be described by a chaperone activation


































ΔH‡37˚C = 294±42 kJ mol
-1
ΔS‡37˚C = 0.9±0.1 kJ mol
-1 K-1
ΔCp























ΔH37˚C = 443±107 kJ mol
-1
ΔS37˚C = 1.6±0.4 kJ mol
-1 K-1
ΔCp = 13.3±5.5 kJ mol
-1 K-1
Figure 2.5: Thermodynamic parameters of αB-c (1 µM) binding to
α-syn fibrils (10 µM) derived from the kinetic parameters of bind-
ing. (a) The enthalpic (∆H‡37◦C = 294± 42 kJ mol−1) and entropic
(∆S‡37◦C = 0.9± 0.1 kJ mol−1 K−1) contribution together with the change in
heat capacity (∆C‡p = 9± 1.1 kJ mol−1 K−1) involved in the formation of the
activated state of the binding partners were estimated using a model which com-
bines polymer theory and Kramer’s problem of escape from a metastable state.
Therefore, the free energy barrier of binding is ∆G‡37◦C = 24± 61 kJ mol−1.
The large barrier suggests the binding is a highly activated process. (b)
Values of KD,app were plotted according to the van’t Hoff equation to
obtain the binding enthalpy (∆H37◦C = 443± 107 kJ mol−1) and entropy
(∆S37◦C = 1.6± 0.4 kJ mol−1 K−1) together with the change in heat capacity
(∆Cp = 13.3± 5.5 kJ mol−1 K−1). The binding is enthalpically unfavourable
and entropically favourable. Value at 37◦C was not included in the analysis
and is only given as an upper bound. The dashed red lines in (a) and (b) show
similar fits with ∆C‡pand∆Cp = 0 indicating that the change in heat capacity
is positive The resulting R2 values are for a) R2 = 0.91 (red dashed curve) and
R2 = 0.98 (black curve), for b) R2 = 0.92 (red dashed curve) and R2 = 0.97
(black curve).
(c) The reaction diagram shows the fraction of the individual thermodynamic
parameters and shows that the overall chaperone-fibril binding is spontaneous with a
free energy of ∆G37◦ = −55± 216 kJ mol−1.
through substrate/temperature dependent disassembly of chaperone complexes which
e.g. is known from Hsp27 and adds up to the findings of substrate activated and ther-
mosensitive disassembly of other sHsps in order to prevent protein aggregation[78, 224].
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2.2.4 Analysis of thermodynamic contributions to the activated state
The association rate constants (kon) for chaperone-fibril binding increases with elevated
temperature. Together with the koff , these measurements indicate that the binding affin-
ity is higher at elevated temperatures. These findings provide a thermodynamic explana-
tion for the reported greater efficiency of αB-c in inhibiting α-syn aggregation at higher
temperatures[193]. From the association rate of αB-c to the fibrils as a function of tem-
perature, I estimated a free energy barrier of ∆G‡37◦C = 24± 61 kJ mol−1 (Fig. 2.5 c).
Moreover, I measured the individual enthalpic (∆H‡37◦C = 294± 42 kJ mol−1) and en-
tropic (∆S‡37◦C = 0.9± 0.1 kJ mol−1 K−1) contributions at 37◦C as well as the change
in heat capacity (∆C‡p = 9± 2.6 kJ mol−1 K−1) necessary to reach this activated state
(Fig. 2.5 a) (see Materials and Methods)[31, 32]. The observed high free energy barrier
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Figure 2.6: Potential binding mechanisms of αB-c to α-syn fibrils. The gain of
entropy during the binding reaction of αB-c to α-syn fibrils can be explained
either by (a) a solvent-mediated interaction through release of water molecules
or (b) a conformational change of the binding partners. The observed positive
change in heat capacity (∆Cp) supports the latter explanation.
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state upon binding to the surface of the fibrils. Crucially, these results show that inter-
actions between chaperones and amyloid fibrils are highly regulated and specific, which
is reflected in the high free energy barriers.
2.2.5 Discussion
The quantification of the thermodynamic and the kinetic parameters associated with
the binding of αB-c to α-syn fibrils provides important insights into the mechanisms
through which molecular chaperones are able to recognise misfolded protein aggregates
and interfere with their proliferation. The client-binding region of αB-c is still uncon-
firmed, yet it has been hypothesised to involve the N-terminal domain and the conserved
αB-c domain[23, 80, 105, 116, 228]. In fact, different residues of the chaperone may be
relevant for its binding to different clients. Recent studies have shown that αB-c is a
potent aggregation inhibitor in cells and that the αB-c core domain inhibits the aggrega-
tion of α-syn with similar efficacy to the wild-type (full-length) protein in vitro[49, 50].
Furthermore, it has been shown that αB-c binds to an amorphously aggregating client
protein (reduced lysozyme) via its unstructured N-terminal domain, but interactions
with an amyloid aggregating client (amyloid-β1−40) were mediated by the structured α-
crystallin domain[105, 149]. Both areas are predicted to be hydrophobic and are buried
in the oligomeric state of the protein. My findings provide direct thermodynamic evi-
dence that the recognition of amyloid fibrillar structures by αB-c is driven by entropic
forces, which include disassembly of the chaperone and its local structural ordering and
disordering upon binding. The latter can be described as an “entropy transfer” model,
where entropic costs of binding are paid for by entropy-increasing conformational changes
within the protein[191, 226]. Moreover, the high activation barrier associated with the
binding process for αB-c supports the hypothesis that some structural or conformational
rearrangements are necessary for binding to occur.
An intriguing possible consequence of the interactions between chaperones and amyloid
fibrils in living systems is the sequestration of chaperones by amyloid fibrils, with subse-
quent loss of function and the development of toxicity. Sequestration and reduced activ-
ity of chaperones is particularly dangerous since it can have a sequential effect, due to the
reduced ability of the cell to cope with any subsequent misfolding and aggregation[172].
By contrast, a favourable effect of the binding of αB-c to α-syn fibrils is that the surface
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coverage by the chaperone may hinder α-syn secondary nucleation, although no studies
have investigated this effect specifically to date.
2.3 Brichos and clusterin - a model system that shows how
secondary nucleation and elongation occurs at distinct
sites along amyloid fibrils
2.3.1 Clusterin suppresses specifically the elongation step of Aβ(M1-
42) aggregation
In order to investigate the capability of clusterin to inhibit the aggregation process
of Aβ(M1-42), I first incubated the peptide in the absence and presence of different
concentrations of the molecular chaperone, and monitored the time evolution of fibril
formation by recording the fluorescence signal of the dye thioflavin T (ThT), which is
strongly enhanced by its interaction with beta-sheet structures (Fig. 2.7). I observed a
delay in the fibril formation process that is proportional to the concentration of clusterin
present in the system, even at a very low substoichiometric molar ratios (including 1:500)
of clusterin. I then carried out a series of kinetic experiments at different concentrations
of Aβ(M1-42), see Supplementary Fig. B.7, in order to explore the dependence of the
various microscopic steps in the aggregation cascade and the presence of the molecular
chaperone by means of kinetic analysis[10]. According to this strategy, the experimental
kinetic profiles determined at a range of Aβ(M1-42) concentrations are compared to
simulations in which individual events are specifically suppressed (Fig. 2.7 a-c). The
least-squared error function, defined in the Materials and Methods section, at a clusterin
concentration of 135 nM is 1.5, 0.2 and 1.5 for the specific inhibition of kn, k+, and k2,
respectively. This comparison suggests that clusterin inhibits the overall aggregation
process by suppressing specifically the rate of elongation of the Aβ(M1-42) fibrils, while
having no detectable effect on primary and secondary nucleation events.
In order to test this concept experimentally, Paolo Arosio performed kinetic experi-
ments where a solution of 5% (w/w) of pre-formed seed fibrils were added to solutions
of monomeric Aβ(M1-42) (Fig. 2.7 d); under these conditions, primary and secondary
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Figure 2.7: Analysis of the effects of clusterin on the aggregation kinetics of
Aβ(M1-42). (a-c) Kinetic reaction profiles for the aggregation of 4 µM Aβ(M1-
42) solutions are shown in each panel from left (blue) to right (green) in the
absence and presence of 7.5 nM, 37 nM, 75 nM and 135 nM of clusterin with
each colour representing repetitions at the same concentration. The integrated
rate law for Aβ(M1-42) aggregation in the absence of clusterin using the rate
constants, previously determined by a least-square error function, is shown as
a dark blue line for each case[42]. Predicted profiles of the specific inhibition
processes of (a) primary nucleation, (b) fibril elongation, and (c) secondary
nucleation generated by clusterin are shown as continuous lines. Note the char-
acteristic differences in the changes in the shape of the reaction profiles in each
case. The prediction for the case where the molecular chaperone suppresses
only elongation events matches closely the experimental data in the presence of
different concentrations of clusterin. (d) Kinetic reaction profiles for the aggre-
gation reaction of a 2 µM Aβ(M1-42) solution seeded with 100 nM pre-formed
fibrils in the absence and presence of 7.5 nM, 37 nM, 75 nM and 135 nM clus-
terin. The lines represent the integrated rate laws for Aβ(M1-42) aggregation
where the elongation rate has been selectively reduced. The apparent elongation
reaction rates as a function of the molecular chaperone concentration evaluated
from the fitting in (b) and (d) are reported in (e) for both unseeded and seeded
reactions. The continuous line in (e) represents a simplified correlation between
the elongation rate and the binding affinity constant (see Materials and Meth-
ods), from which a KD,37◦C = 8 nM is determined. (f) Comparison between the
experimental data reported in (b) and theoretical predictions of the reaction
profiles calculated from a kinetic model which considers the association and dis-
sociation rate constants in the reaction scheme with a KD,37◦C = 2.5 nM. (g,
h) Schematic diagrams showing the molecular pathways involved in Aβ(M1-42)
aggregation (g) and the mechanism by which clusterin perturbs the aggregation
process (h).
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nucleation events are negligible, and fibril elongation is the major contributor to the
increase in fibril mass[7]. By increasing the concentration of clusterin, he observed a
progressive reduction in the rate of aggregation, supporting the conclusion that the
molecular chaperone inhibits this specific microscopic process. In addition, the elonga-
tion rate constants calculated from simulations of the experimental data under seeded
conditions are in excellent agreement with the values determined under unseeded con-
ditions, confirming the robustness of the analysis (Fig. 2.7 e).
Previous kinetic analysis of Aβ(M1-42) profiles indicates that monomeric species par-
ticipate directly in elongation and primary/secondary nucleation rates[42]. In par-
ticular, the elongation reaction involves the addition of monomers to fibril ends and
smaller propagons, such as oligomers and other pre-fibrillar species and therefore the
inhibition effect of clusterin could result from its interactions with either of the three
species[45, 130]. Significant binding of the molecular chaperone to monomeric Aβ(M1-
42) would, however, also affect primary and secondary nucleation reactions, since these
processes also depend on the concentration of monomers. As the kinetic analysis re-
veals that clusterin inhibits only the elongation rate, I can conclude that it interacts
preferentially with the fibril ends and all species capable of elongation. The fact that
inhibition is observed at very low substoichiometric ratios is completely associated with
the interaction of clusterin with the ends of fibrils or pre-fibrillar species, as interactions
with monomeric Aβ(M1-42) would require a much higher stoichiometric concentration
of clusterin to affect the rates to such a significant extent.
In order to interpret the kinetic effects in a more quantitative manner, he compared the
experimental data with the prediction of a kinetic model that considers explicitly bi-
nary interactions between clusterin and the ends of Aβ(M1-42) fibrils (see Materials and
Methods). The theoretical predictions account well for the concentration-dependence of
the inhibition at 37◦C by using the fitting parameters kon,37◦C = 4 · 105 M−1s−1 and
koff,37◦C = 1 · 10−3 s−1 (Fig. 2.7 f), corresponding to KD,37◦C = 2.5 nM. From an anal-
ysis of the dependence of the apparent elongation rate constant on the molecular chap-
erone concentration (Fig. 2.7 f) using a simplified kinetic model, in which the binding
reaction process is assumed to be under equilibrium conditions (see Materials and Meth-
ods), he obtains a similar value of KD,37◦C = 8 nM. I further extended this approach at a
temperature of 21◦C, and obtained a value of KD,21◦C = 1 nM (Supplementary Fig. B.8),
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indicating that the binding is exothermic. The exergonic binding and the high interac-
tion affinity are consistent with the fact that clusterin interacts with Aβ(M1-42) fibrils
in an ATP-independent manner[186].
The interactions between clusterin and fibrils of Aβ(M1-42) were probed in additional
kinetic experiments. To this effect, Aβ(M1-42) fibrils were generated in the presence
or absence of clusterin and then added to freshly prepared monomer solutions in the
presence or absence of clusterin (Supplementary Fig. B.9). Even in the absence of
clusterin in the monomer solution (Supplementary Fig. B.9 b), the pre-formed fibrils that
had been produced in the presence of clusterin accelerated aggregation to a smaller extent
than did fibrils produced in the absence of the chaperone (Supplementary Fig. B.9 a).
Application of the kinetic analysis reveals a reduction of ca. 40% in the elongation
rate in this latter case (Supplementary Fig. B.9 b), indicating that a significant fraction
of the molecular chaperone must have remained bound to the aggregates during the
time course of the reaction, and indeed immunogold transmission electron microscopy
(TEM) analysis performed by Janet Kumita (Fig. 2.8 b, d and e) indicates that clusterin
is bound to these Aβ(M1-42) fibrils. Furthermore, the ability of fibril ends to grow
was also observed to be substantially reduced when pre-formed aggregates generated
in the absence of the chaperone were added to a mixture of clusterin and monomeric
Aβ(M1-42) (Supplementary Fig. B.9 c), demonstrating the ability of clusterin to inhibit
ongoing reactions. By contrast, in this set of experiments the fibrils that had not been
exposed to the molecular chaperone at any stage maintained their full ability to elongate
(Supplementary Fig. B.9 a).
2.3.2 Quantification of interactions between clusterin and Aβ(M1-42)
fibrils by microfluidic diffusional sizing
Taken together, the kinetic data described in the previous sections suggest that clusterin
is highly effective at inhibiting the aggregation of Aβ(M1-42) at low substoichiometric
ratios by specifically reducing the rate of elongation, and provide strong evidence that
this process is mediated by the non-covalent association of clusterin with Aβ(M1-42)
fibril ends and pre-fibrillar species. The interactions between the molecular chaperone
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and the fibrils, therefore, represent the key molecular process underlying the inhibition
of fibril elongation.
Evidence of these interactions between clusterin and the fibril ends is provided by im-
munogold (TEM) (Fig. 2.8 a-d) when the presence of clusterin on the Aβ(M1-42) fibrils
have been specifically probed under a variety of conditions which implement stringent
washing steps and the use of bovine serum albumin (BSA) incubation to reduce non-
specific binding, it is apparent that clusterin binds to the Aβ(M1-42) fibrils. This
becomes particularly clear by looking at the absolute quantification of immunogold par-
ticles per quantified area occupied by aggregates (Fig. 2.8 e). A significant increase of
particles can be observed in the presence of clusterin. Although it appears that the gold
labelling is occurring mainly at the fibril ends, it is not possible to conclude that there
 







































































































































Figure 2.8: Analysis of clusterin interactions with Aβ(M1-42) fibrils using im-
munogold TEM. Aβ(M1-42) fibrils formed under quiescent condition imaged
as is (a,b) and after sonication (c,d), were incubated with BSA and clusterin
and stringently washed. Incubation with an anti-mouse secondary antibody
conjugated to a gold particle showed no non-specific labelling (a,c) whereas in-
cubation with an anti-clusterin monoclonal antibody followed by an anti-mouse
secondary antibody conjugated to a gold particle shows the presence of clus-
terin interacting with the Aβ(M1-42) fibrils (black dots). Scale bars represent
100 nm. (d) Quantification of TEM images given as bar plots showing the in-
dividual ratio of immunogold particles per area occupied by aggregates. Area
quantity was determined using ImageJ. Reported mean and standard deviation
are of at least five independent frames.
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are no interactions of clusterin with the surfaces of the fibrils (Fig. 2.8 e). Interestingly,
the quantity of bound clusterin can be seen to be slightly increased when the molecular
chaperone was incubated with fibrils that were exposed to mechanical breakage by son-
ication. These shorter fibrils possess a larger number of ends at constant surface area
compared to the unsonicated fibrils (Fig. 2.8 e). Although imaging analysis is highly
limited by the quality and uniformity of the TEM images, this result suggests that the
molecular chaperone interacts preferentially with fibril ends, in agreement with the con-
clusion from the specific inhibition of the elongation rate observed in this study by the
kinetic analysis and discussed earlier.
In order to characterise the interactions between clusterin and Aβ(M1-42) fibrils in a
more quantitative manner, I made use of microfluidic diffusional sizing that has recently
been developed to measure the interactions between biomolecules directly in solution
under native conditions[9, 257]. Briefly, the principle of this technique consists of ac-
quiring, in both space and time, the longitudinal diffusion profiles of molecules in a
solution flowing in a microfluidic channel (Fig. 1.3). The diffusion profiles acquired in
such experiments can then be analysed by considering advection-diffusion processes to
extract the distribution of diffusion coefficients, and therefore the distributions of the
hydrodynamic radii of the individual species present in solution[9]. With this technique,
interactions between macromolecules can be detected by monitoring the increase in size
associated with such events.
I therefore monitored the binding of clusterin to Aβ(M1-42) fibrils by measuring the
diffusion of clusterin labelled with the fluorescent dye Alexa-488 in the absence and
presence of Aβ(M1-42) fibrils (Fig. 2.9 b and Supplementary Fig. B.11). Clusterin
bound to a fibril will diffuse significantly slower than the unbound species because of the
much greater size of the fibrils related to the molecular chaperones, and hence exhibit a
distinct diffusion profile (Fig. 2.9 b). The size distributions extracted from the diffusion
profiles are shown in Fig. 2.9 c; in the absence of Aβ(M1-42) fibrils, clusterin exhibits a
monomodal distribution centred at a hydrodynamic radius of about 8 nm. In the pres-
ence of the fibrils, however, a bimodal distribution is observed, with a population similar
to the hydrodynamic radius of the monomodal distribution corresponding to unbound
molecular chaperone, and a peak in the larger size range, corresponding to complexes
formed by clusterin and amyloid fibrils. The integral of the area under the two sub-
populations is proportional to the concentration of free and bound clusterin. From the
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Figure 2.9: Microfluidic analysis of clusterin binding to Aβ(M1-42) fibrils. (a)
The bar charts show the average size and fraction of the species in the large-
size range in the absence and presence of Aβ(M1-42) fibrils. The average sizes
and the fraction of species in the large-size range reported have the means and
the standard deviations of at least three independent repetitions. (b) Diffusion
profiles acquired at 12 different positions along the microfluidic channel for a
0.8 µM clusterin solution in the absence (red curves) and presence of 17.5 µM
pre-formed Aβ(M1-42) fibrils (black dashed curves) in 20 mM sodium phosphate
buffer at pH 8.0; (c) The size distributions in the absence (blue) and presence
(green) of 2 µM Aβ(M1-42) fibrils were evaluated by fitting model simulations
based on advection-diffusion equations to the experimental diffusion profiles
reported in (b) (more profiles see Supplementary Fig. B.11).
titration curve, obtained by performing experiments at different clusterin concentrations
between 0 and 4.5 µM with a fibril concentration of 17.5 µM, (Fig. 2.10), I obtained
a value KD,21◦C of 670 nM. This value is two orders of magnitude larger than the KD
estimated from the kinetic analysis at the same temperature (KD,21◦C = 1 nM); the dif-
ference may arise from the specific types of information provided by the two approaches.
As can be seen by TEM images, clusterin binds both to the surfaces and the ends of
the fibrils, and the microfluidic diffusion technique detects the total quantity of bound
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Figure 2.10: Binding curve of clusterin to 17.5µM Aβ(M1-42) fibrils in 20 mM
sodium phosphate at pH 8.0 and 21◦C measured by the microfluidic diffu-
sion technique. In a first set of experiments (squares), different concentrations
of clusterin were incubated with previously generated Aβ(M1-42) fibrils and
size distributions were acquired after 48 h of incubation to ensure equilibrium
conditions. In a second set of experiments (circles), different concentrations
of clusterin were incubated with 17.5µM Aβ(M1-42) fibrils and BSA at an
equimolar concentrations to clusterin. Each point represents the mean, and
the standard deviation of at least two independent repetitions. The regression
line represents the best fit to the non-linear Langmuir binding isotherm with
KD = 0.67± 0.19 µM and M = 0.80± 0.08µM (corresponding to one clusterin
molecule per 21.9± 2.2 Aβ(M1-42) monomers
), with R2 = 0.97.
clusterin resulting from these two interactions. By contrast, the kinetic analysis is sen-
sitive only to interactions with the growing fibril ends and the smaller propagons which
determine the modulation of the elongation rate, and therefore reports a higher affinity.
These findings indicate that clusterin is capable of suppressing Aβ(M1-42) aggregation
under physiological concentration but higher concentrations of molecular chaperone are
needed to reduce substantially the effect of toxic species, in agreement with previously
reported results[67, 261]. As a control experiment, I studied the interaction and the in-
hibition effects of clusterin when a non-chaperone protein, BSA is added into the system
(Fig. 2.10 and Supplementary Fig. B.12), and detected no effect on binding.



















































Figure 2.11: Brichos and clusterin exhibit modular and additive behaviour of
their specific inhibition processes. (a) Kinetic profiles of 3 µM Aβ(M1-42) solu-
tions in 20 mM sodium phosphate buffer at pH 8.0 in the absence and presence
of 18 nM clusterin and 2 µM proSP-C Brichos, added either individually or to-
gether as indicated, at 37◦C. (b) The additivity of the inhibition effects reveals
that the sites associated with the two different microscopic steps of elongation
and secondary nucleation are distinct. Continuous lines represent model simula-
tions where either the elongation rate constant (green line), secondary nucleation
rate constant (red line) or both (blue line) have been selectively inhibited.
2.3.3 Modulation of Aβ(M1-42) aggregation by Brichos reveals that
the reactive sites of secondary nucleation and elongation are dis-
tinct
Although there is evidence deduced from the immunogold labelling and the diffusion
experiments that clusterin may be able to bind along the surface of the fibrils, as well
as to their ends, the kinetic experiments show that clusterin does not inhibit detectable
surface-catalysed secondary nucleation. By contrast, a molecular chaperone belonging
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to the Brichos family (proSP-C Brichos), has been found to inhibit the secondary nu-
cleation rate associated with Aβ(M1-42) aggregation but not the rate of elongation[41].
This observation suggests that inhibition of secondary nucleation processes requires spe-
cific interactions with defined reactive sites on the fibrils rather than non-specific binding
along their surfaces. It also suggests that the sites involved in the nucleation and elon-
gation processes are likely to be distinct. To address this question, as well as to conclude
whether or not the effect of the two molecular chaperones is additive, I added 18 nM
clusterin and 2 µM proSP-C Brichos, both individually and together, to a solution of
2.5 µM Aβ(M1-42) and monitored the aggregation over time. I observed a larger inhibi-
tion of the aggregation kinetics when the two molecular chaperones are present together
in the solution (Fig. 2.11). Moreover, the kinetic profiles can be described very closely
by simulation using the rate constants determined from the experiments where the two
molecular chaperones were added individually. In particular, the results show that in-
hibition by proSP-C Brichos on the secondary nucleation rate is essentially the same
in the presence or absence of clusterin, and reduction of the elongation rate constant is
not detectably affected by the presence of proSP-C Brichos (corresponding to the values
reported in Fig. 2.7 e).
The inhibition effects of the two molecular chaperones studied here have been found
to be additive and present a number of important implications: it indicates that the
sites on the amyloid fibrils involved with the two different microscopic processes of
elongation and secondary nucleation pathways are distinct, a result consistent with a
recent study showing the development of antibodies able to target specifically distinct
steps[5, 165]. Moreover, biologically relevant molecular chaperones can interact with
these different sites in an additive non-cooperative way. Experimental repetitions (Sup-
plementary Fig. B.14) at different inhibitor concentrations confirm the additive and
non-cooperative inhibition effect of the two individual chaperones.
2.3.4 Discussion
Increasing evidence indicates that the aggregation networks leading to the formation of
amyloid fibrils are composed of a series of distinct microscopic reactions[43, 43, 130].
For Aβ(M1-42), secondary nucleation under the in vitro conditions studied has emerged
as the most important source of toxic oligomeric species[42, 227]. Understanding the
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molecular details of this process, which is now feasible through the development of
chemical kinetic analysis, is therefore of vital importance for understanding the funda-
mental processes that are likely to be involved in AD. In this work, I have built on the
ability of this kinetic platform to identify the different microscopic mechanisms of the
inhibitory effects of two molecular chaperones on amyloid formation by Aβ(M1-42). I
have observed that clusterin induces a similar reduction of the parameters k+k2 and
k+kn, in agreement with previous findings[19]. Moreover, my analysis of seeded ag-
gregation profiles demonstrates that, for my recombinant peptide, this observation can
be explained at the microscopic level by a reduction of the elongation rate constant,
and not by an equal reduction of primary and secondary nucleation rates. In particu-
lar, I have shown that the additive nature of the inhibition by the different molecular
chaperones implies a selective inhibition of two different microscopic reactions, namely
elongation and surface-induced secondary nucleation. This result suggests that the nat-
ural protective mechanisms that have evolved to maintain protein homeostasis network
are highly sophisticated, and work together to suppress different steps in the series of
events that give rise to protein aggregation and amyloid formation. Specific inhibition
of elongation reactions alone would inhibit the formation of surface available for sec-
ondary nucleation, but could lead to an accumulation of soluble intermediates and an
increase in toxicity. For a complete inhibition of the aggregation process, therefore, ad-
ditional interactions with the surfaces of the fibrils are required to suppress secondary
nucleation events, a finding in good agreement with previous reports[67]. Future devel-
opments of the analysis described in this work may also clarify the behaviour observed
in the more complex environment of in vivo systems, for example where overexpression
of clusterin has been shown to accelerate amyloid deposition in mice but to decrease the
risk of AD in humans[57, 220, 247]. More generally, understanding how the aggregation
process is altered by specific molecules is crucial to evaluate the consequences for the
generation of potential toxic oligomeric species. These molecular details are particularly
relevant in the context of the rational design of drug molecules that could, potentially
in combination, target multiple specific aggregation steps in a selective manner.
Interestingly, these findings correlate well with another study, where it has been shown
that at a very low clusterin:Aβ42-ratio the toxicity of the aggregates is enhanced, sug-
gesting that clusterin stabilises pre-fibrillar oligomers[259]. This result supports the
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inhibition of fibril elongation events in favour of primary and secondary nucleation pro-
cesses.
In particular, experiments with synthetic Aβ40 and Aβ42 have shown that clusterin
can bind to oligomers and pre-fibrillar species, while my experiments on recombinant
Aβ(M1-42) demonstrate that clusterin is highly effective in retarding the aggregation
process of Aβ(M1-42) at low substoichiometric ratios and physiological concentrations
by inhibiting specifically the elongation process[19, 166, 243, 259].
2.4 Thermodynamic evaluation of the enthalpic Brichos
binding reveals very limited catalytic sites along
amyloid-beta fibrils
Molecular chaperones and amyloid fibrils are characterised by significantly different dif-
fusion coefficients; indeed, at the end of the channel, corresponding to a diffusion time
on the order of seconds, I observed that the amyloid fibrils remain concentrated in the
central region of the channel, while the molecular chaperones have diffused all the way
to the sides of the channel. However, any molecular chaperones interacting with the fib-
rils remain localised in the centre of the channel together with the slow-diffusing fibrils;
by contrast, unbound molecular chaperones are free to diffuse along the width of the
channel (Fig. 1.3 C). This behaviour results in a large difference in the characteristic
diffusion profiles of the interacting and the non-interacting molecular chaperones, which
can be quantified using this approach.
In order to track the mass transport of the molecular chaperones, I labelled the chaper-
one, the Brichos domain, with an Alexa-488 dye (see Materials and Methods), required
for the detection of the diffusion profiles by epifluorescence microscopy. Before initiating
the measurements, I verified by means of kinetic analysis that the labelling does not af-
fect its capability to inhibit Aβ(M1-42) amyloid formation. To this effect, I followed the
aggregation kinetics of a 3 µM Aβ(M1-42) solution in the absence and presence of dif-
ferent concentrations of both unlabelled and labelled Brichos domains. I observed very
similar aggregation profiles for the two cases (Fig. B.15), indicating that the presence of
the fluorescent label does not detectably modify the binding properties of Brichos and
its capability of inhibiting the secondary nucleation reactions.
























































































































































Figure 2.12: (a) The size distributions in the absence (blue) and presence
(green) of Aβ(M1-42) fibrils were evaluated by fitting model simulations based
on advection-diffusion equations to the experimental diffusion profiles. (b)
Corresponding diffusion profiles acquired at 12 different positions along the
microfluidic channel for a 2 µM proSP-C Brichos solution (red curve) and a
0.25 µM proSP-C Brichos solution in the presence of 24 µM Aβ(M1-42) fibrils
(black dashed curve) in 20 mM sodium phosphate buffer at pH 8.0. (c-d) The
average size and fraction of the species in the large-size range in the absence
and presence of Aβ(M1-42) fibrils at 21◦C. In the presence of the fibrils, com-
plexes of the molecular chaperone with amyloid aggregates are observed. The
specificity of the binding between Brichos and Aβ(M1-42) fibrils was confirmed
by measurements of the size distribution of 6 µM calbindin in the absence and
presence of 24 µM Aβ(M1-42) fibrils. The reported average sizes and the frac-
tion of species in the large-size range are the mean and the standard deviation
of at least three independent repetitions.
A mixture of 0.25 µM proSP-C Brichos in 20 mM sodium phosphate buffer at pH 8.0
in the absence and presence of 24 µM Aβ(M1-42) fibrils were investigated using a mi-
crofluidic diffusion device described above and diffusion profiles were acquired at 12
different positions along the channel length (Fig. 2.12 b). From the diffusion profiles
shown in Fig. 2.12 b, it can clearly be seen that in the presence of Aβ(M1-42) fibrils
the average translational diffusion coefficient of the molecular chaperone decreases dra-
matically, thereby indicating an increase in its apparent hydrodynamic radius (defined
as the Stokes radius, RH) upon binding to the fibrils. To provide a quantitative descrip-
tion of this behaviour, the measured diffusion profiles were fitted by model simulations
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based on advection-diffusion equations where a bimodal Gaussian distribution of sizes
has been assumed to account for the possible presence of both bound and unbound
chaperones[164] (see Materials and Methods and Supplementary Fig. B.17); represen-
tative size distributions measured in the absence and presence of fibrils are shown in
Fig. 2.12 a. In the absence of fibrils, proSP-C Brichos exhibits a monodisperse size
distribution of hydrodynamic radii centred at ca. 1.5 nm. In the presence of 24 µM
Aβ(M1-42) fibrils, a bimodal size distribution is observed, with one peak in the range of
hydrodynamic radii corresponding to the free molecular chaperone, and a second peak
centred at ca. 200 nm, corresponding to Brichos bound to the fibrils. The average sizes
of the complete distributions, as well as the fraction of the sub-population characterised
by the second peak, are reported in Fig. 2.12 c and 2.12 d, respectively.
I investigated the specificity of the interactions between Brichos and the Aβ(M1-42)
fibrils by measuring the size distribution of the protein calbindin in the absence and
presence of Aβ(M1-42) fibrils. The consistent hydrodynamic radius of calbindin under
changing conditions indicates (Fig. 2.12 c) the lack of interactions between calbindin
and the fibrils, and the specificity of the microfluidic binding assay.
The quantitative nature of the diffusion measurements enables readily the evaluation
of binding affinity from the experimental data, and therefore the measurement of the
dissociation constants (KD) of the binding process by determining the fraction of bound
protein at different total initial concentrations of chaperone. To this effort, I measured
the fraction of Brichos molecules at constant Aβ(M1-42) fibril concentration of 24 µM
and at Brichos concentrations ranging between 0 and 1.5 µM (Fig. 2.13). Two different
incubation procedures followed: in a first approach, I measured the binding of Brichos to
mature Aβ(M1-42) fibrils generated previously in the absence of the molecular chaperone
(Fig. 2.13, black open squares). In a second set of experiments, the chaperone was
incubated together with monomeric Aβ(M1-42) at 37◦C until essentially all monomers
had converted into fibrils, and the binding was later evaluated after 48 h incubation at
21◦C (Fig. 2.13, red circles); in this latter approach, the molecular chaperone binds to
the peptide fibrils during the aggregation reaction. In Fig. 2.13 it can be seen that the
data obtained through the two procedures are similar.
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Figure 2.13: Binding of proSP-C Brichos to 24 µM Aβ(M1-42) fibrils in 20 mM
sodium phosphate at pH 8.0 and 21◦C measured by the microfluidic diffusion
technique. In a first set of experiments (squares), different concentrations of Bri-
chos were incubated with pre-generated Aβ(M1-42) fibrils and size distributions
were measured after at least 48 h of incubation to ensure that equilibrium was
established prior to measurement. In a second set of experiments (circles), differ-
ent concentrations of Brichos were mixed with monomeric Aβ(M1-42) and incu-
bated at 37◦C until all monomers converted into fibrils. Samples were analysed
after 48 h incubation at 21◦C by the microfluidic diffusion method. In this sec-
ond approach, Brichos molecules bind to Aβ(M1-42) fibrils during their forma-
tion. Each point represents the mean and the standard deviation of at least two
independent repetitions. The regression line represents the best fit to the non-
linear Scatchard equation with KD,21◦C = 310± 80 nM and M = 168± 17 nM
(corresponding to one Brichos molecule per 143± 14.5 Aβ(M1-42) monomers
), with R2 = 0.93.
2.4.1 Binding affinity determination
By fitting the experimental data to a non-cooperative, single binding-site model (us-
ing the Scatchard equation, see Materials and Methods), I obtained a KD,21◦C of
310± 80 nM, and a maximum surface coverage of one Brichos domain per ∼143 Aβ(M1-
42) monomers. I note that the measured KD,21◦C is of the same order of magnitude but
about seven fold larger than the value defined by previous SPR experiments with a KD
of about 40 nM,[41] a result that can be attributed to the well-established non-specific
binding to the surface of the chip in the SPR technique, which is likely to lead to an
overestimation of the quantity of bound Brichos[171]. By contrast, the microfluidic plat-
form enables the interactions between the species to be measured in a solution that is
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closer to physiological conditions.
The measured KD,21◦C value indicates a very high affinity of Brichos to the Aβ(M1-42)
amyloid fibrils, yet the very low value of surface coverage demonstrates the remarkable
efficiency of this molecular chaperone in suppressing the secondary nucleation events
catalysed by the fibril surface. This high level of efficiency is likely to be due to the
ability of the Brichos domain to interact highly selectively with the more active catalytic
sites on the surfaces of the fibrils.
2.4.2 Thermodynamic parameters of Brichos binding to Aβ(M1-42)
fibrils
A further possibility opened up by the microfluidic diffusion technique proposed in this
work is the measurement of the thermodynamic parameters of the binding reaction in
solution by evaluating the temperature dependence of the dissociation constants. To this
effect, I measured the binding curve at different temperatures in the range of 21-37◦C
using the procedure described in the previous paragraphs (Fig. 2.14 a). I verified by
SDS-PAGE analysis that the attachment of the fluorescent label to Brichos is stable at
a higher incubation temperature for several hours (see Supplementary Fig. B.18). As
the image acquisition on the microscope for diffusional sizing is in the range of seconds
there is still a risk of molecules dissociating caused by the dilution through co-flow buffer.
However, this only affects very transient or weak or unspecific interactions with disso-
ciation constants conventionally above millimolar range and dissociation rate constants
above koff = 10
−3sec−1[118]. The fitting, based on the non-linear Scatchard equation,
where the amount of maximum fibril binding sites [M]= 168± 17 nM, was assumed
to be temperature-independent and indicates a progressive increase of the dissociation
constant. Therefore a decrease in the binding affinity, with increasing temperature
(KD,21◦C = 0.3 µM, KD,27◦C = 1.4 µM, KD,30◦C = 5.3 µM, and KD,37◦C = 15.1 µM) can
be observed. From the corresponding van’t Hoff plot (Fig. 2.14 b, see also Materials and
Methods), values of a standard molar-binding enthalpy ∆H	 = −141.31± 22.16 kJ/mol
and of a -binding entropy ∆S	 = −0.36± 0.07 kJ/(mol·K) were obtained. These pa-
rameters can be combined through the Gibbs-Helmholtz equation to yield a value of the
standard molar binding free energy ∆ G	37◦C = −30.38± 35.01kJ/mol, indicating that
under native conditions the binding of Brichos to Aβ(M1-42) fibrils is a spontaneous
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Figure 2.14: Thermodynamic evaluation of Brichos binding to Aβ(M1-42) fib-
rils. (a) Binding curves of proSP-C Brichos to Aβ(M1-42) fibrils in 20 mM
sodium phosphate at pH 8.0 measured by the microfluidic diffusion method at
21◦C (blue circles), 27◦C (green triangles), 30◦C (yellow diamonds) and 37◦C
(red squares). Each point represents the mean and the standard deviation of
at least two independent repetitions. The regression lines represent the best fit
based on a non-linear Scatchard equation. For the regression lines for the data
points at 27◦C, 30◦C and 37◦C an [Brichosboundmax]= 0.1680 ± 0.0167µM
were assumed which was adopted of the more high graded regression line of
21◦C. (b) van’t Hoff plot corresponding to the dissociation constants measured
at different temperatures in (a) (see Materials and Methods), providing a stan-
dard binding enthalpy of ∆ H	 = −189.2± 24.7 kJ/mol, a standard binding
entropy of ∆ S	 = −0.5± 0.08 kJ/(mol ·K) (B) and a free energy of binding
∆ G	37◦C = −34.125± 35.01 kJ/mol with R2 = 0.97.
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exothermic process where the binding enthalpy more than compensates for the loss in
entropy. As of the result of the error propagation of combining the free enthalpy and
entropy to obtain the free energy, the standard deviation of the free energy is in range
where also an endergonic reaction could theoretically occur. However, as no other pro-
teins are present and an enzymatic reaction can be excluded, the binding has to occur
spontaneous. Nevertheless, in order to validate the findings, further investigation would
be recommended. Measuring the enthalpy directly with ITC would help to minimise the
error on th free energy. Also varying the fibril concentration using microfluidic sizing
would be a potential solution.
Figure 2.15: Fraction of Brichos bound to a mixture of 24 Aβ(M1-42) fibrils
and 0.25 µM Alexa-488 labelled Brichos, measured at different incubation times
over a time period of 114 h by the space-time diffusion microfluidic approach.
The binding reaction reaches equilibrium after about 48 hours. The continuous
line represents the mean of the last four data points, while the dotted lines
represent the standard deviation.
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2.4.3 Brichos binding kinetics indicate a limitation of secondary nu-
cleation sites
The exothermic binding behaviour of Brichos to Aβ(M1-42) fibrils results in all smaller
fraction of Brichos bound at higher temperatures. Furthermore, kinetic binding analy-
sis of Brichos to Aβ(M1-42) fibrils at 21◦C exhibits a two state binding behaviour (see
Fig. 2.15, indicating a fast binding to high affine binding sites, potentially responsible for
inhibitory activity, within several minutes and a rather slow, more unspecific binding oc-
curring over several hours up to days. Previous studies on Brichos binding to Aβ(M1-42)
fibrils with SPR only focussed on the initial binding, not including the system reaching
an equilibrated state[41]. Taken both information together indicates that the actual
amount of secondary nucleation sites is even lower than the measured stoichiometry of
1 Brichos molecule per 143 Aβ(M1-42). Preliminary kinetic experiments at physiological
temperature exhibited at a very low stoichiometry of one Brichos molecule per about
70 000 Aβ(M1-42) monomers (see Supplementary Fig. B.16). These results have to be
validated with varying Brichos or Aβ(M1-42) fibril concentration. However, the kinetic
analysis and equilibrium binding experiments of Brichos binding to Aβ(M1-42) fibrils
suggest that secondary nucleation sites along fibrils a rather rare event or artefact which
might not even presented on every fibril rather than a repetitive structure universal for
all Aβ(M1-42) fibrils.
2.4.4 Discussion
I have described microfluidic diffusion measurements to probe directly in solution in
a non-invasive manner the thermodynamic parameters of a binding reaction between
biomolecules. I have demonstrated the value of this approach by characterising the
binding reaction between the proSP-C Brichos domain and Aβ(M1-42) amyloid fibrils,
a process which underlies the inhibition of the secondary nucleation events catalysed by
the surfaces of Aβ(M1-42) fibrils. The results reveal that under physiological conditions
the binding of Brichos to Aβ(M1-42) fibrils is a spontaneous exothermic process char-
acterised by the conjunction of entropic and enthalpic factors. Remarkably, the results
also reveal this molecular chaperone is able to inhibit the aggregation process of Aβ(M1-
42) even at very low fibril surface coverage, indicating preferential binding to sites that
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are active in secondary nucleation process generating new aggregates on the surfaces of
existing fibrils.
2.5 How the binding characteristics of therapeutic anti-
bodies control their inhibitory capabilities
2.5.1 Kinetic and mechanistic analysis of potential Alzheimer’s thera-
peutics
The investigation of protein binding can give insights into the inhibition behaviour of
aggregation suppressors and vice versa. Through combining binding and kinetic infor-
mation together, broader mechanistic understanding of the aggregation homeostasis can
be achieved, leading to new insights of how to approach toxicity and disease phenotypes
for future therapies. One key step in achieving this goal should be to minimise the
amount of toxic oligomeric Aβ(1-42) species. The main contributing microscopic step
for the formation of toxic Aβ(1-42) oligomers has been found to be secondary nucle-
ation. Inhibiting this particular process and destabilising Aβ(1-42) oligomers should be
the main target for therapeutic applications.
Whereas Sara Linse focused on the analysis of the inhibitory effects of a selection of
therapeutic antibodies in a collaborative project, I characterised the general binding
behaviour of those antibodies to Aβ(42) monomers and fibrils. We used the murin
counterparts of aducanumab, bapineuzumab, gantenerumab and solanezumab, all have
been or still are in clinical trial as potential Alzheimer’s therapeutics.
2.5.1.1 Aducanumab
In the beginning of 2019, the clinical trial of aducanumab was halted after promising
early 1b trials due to no significant improvement compared to given placebos for the
recent phase 3 stage[25, 206]. Accordingly, the kinetic analysis of Aβ(M1-42) aggrega-
tion in the presence of aducanumab in vitro performed by Sara Linse reveals a specific
and dramatic retardation of secondary nucleation, lowering the effective rate constant
for this process by ca. 40% even at the lowest concentrations of antibody tested with
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Non-diffused half         Diffused half
Figure 2.16: Investigation of the interactions between therapeutic antibodies to Aβ(1-42)
monomers and fibrils using diffusional sizing. (A) Microfluidic architecture and experimental
strategy used to study labelled molecules (red) interacting with ligand (orange). (B) Size
of a full-length IgG (1igy.pdb) compared with Aβ(1-42) fibril (5kk3.pdb): 9 planes of one
filament are viewed from the side (top) and fibril end (bottom). Each plane contains two
monomers in darker and paler colour, with buried epitope residues indicated in one monomer.
Each double-headed arrow corresponds to 2.5 nm. Structural models were prepared using
MOLMOL[132]. (C-F) Diffused fraction of Alexa647-antibodies in the absence and presence
of increasing concentrations of unlabeled Aβ(1-42) fibrils, concentration given in monomer
units. (G-J) Diffused fraction of Alexa647-Aβ(M1-42) monomers in the absence and presence
of increasing concentrations of each antibody. Examples of data for chaducanumab are in
panels C,G; m266 D,H; 3D6 E,I; chgantenerumab F,J. (K) Antibody saturation versus free
fibril site concentration, calculated from the fits in panels C-F and an isotype control. (L)
Monomer saturation versus free antibody concentration, calculated from the fits in panels G-J
and an isotype control. (M) Fraction of fibrils with at least one antibody bound calculated
using the fitted values of KD and n. (N) Summary of obtained affinities of each antibody
for fibrils (pKDfibril) versus monomers (pKD monomer). All data were analysed by fitting
directly to the observed diffused fraction of fluorescent species at the end of the microfluidic
channel. For detailed description of the applied binding equation, see Material and Methods.
The illustration was used with permission of Sara Linse.
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500 pM (Supplementary Fig. B.19 A and B.20 A). In addition, I could detect by dif-
fusional sizing, using the commercial Fluidity One-W system of Fluidic Analytics Ltd.
(Fig. 2.16 A), that chaducanumab preferentially binds to Aβ(M1-42) fibrils with a rela-
tively high apparent affinity of 1± 0.2 nM (Fig. 2.16 C). On the other hand, the affinity
to Aβ(M1-42) monomers is with 9± 2 µM about 4-5 magnitudes lower (Fig. 2.16 G).
This is in agreement with previous estimates by surface assays[6]. Furthermore, my mea-
surements provided a binding stoichiometry of 1 chaducanumab per about 5 Aβ(M1-42)
monomer units in the fibril, indicating that the fibril is completely coated with antibod-
ies at saturation. Indeed, the width of an IgG antigen-binding region is approximately
the summed pitch of 5 planes of a fibril (Fig. 2.16 B). Therefore, in good agreement
with our findings, Biogen Idec Inc. announced in October 2019 to file an application for
aducanumab for approval by the Food and Drug Administration (FDA). New analysis
of a larger dataset from phase 3 studies could show reduced clinical decline in patients
with early Alzheimer’s disease as measured by the pre-specified primary and secondary
endpoints[26].
2.5.1.2 Bapineuzumab
In contrast to aducanumab, bapineuzumab failed two major clinical trials and was dis-
continued in 2012[184]. Following an initial indication of plaque burden reduction in AD
patients, no further indication of significant cognitive improvements could be observed.
The corresponding mouse antibody, 3D6, shows high affinity to both the monomeric as
well as the fibrillar form of Aβ(1-42) with 38± 8 nM and 0.27± 0.2 nM, respectively
(Fig. 2.16 E and I). It should be highlighted here, that a free Asp1 at the N-terminus
of Aβ(1-42) had to be used as the recognised epitope covers residues 1-5[73, 176]. The
binding stoichiometry of antibodies to monomer units in the fibrils was 1 to 47± 10.
The kinetic analysis of the inhibitory effects of 3D6 of the individual microscopic aggre-
gation steps showed specific reduction of fibril elongation (Supplementary Fig. B.19 C
and B.20 E).
2.5.1.3 Gantenerumab
Even though gantenerumab failed to show efficacy against AD in clinical phase 3 trial,
another phase 3 trial was initiated in 2018 for an additional 4 years[16, 173]. The
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kinetic analysis of Aβ(M1-42) aggregation together with the murine counterpart of gan-
tenerumab, chgantenerumab, showed a selective inhibitory effect on fibril elongation
(Supplementary Fig. B.19 D and B.20 D). The microfluidic binding experiment de-
picted in Fig. 2.16 F showed, with a KD = 30± 15 nM, a high affinity of the antibody
to Aβ(M1-42) fibrils with a stoichiometry of one antibody per 43± 4 monomers in the
fibrils and is reflecting the limited amount of binding sites at fibril ends. The finding
that chgantenerumab inhibits elongation conforms with the fact that the epitope side-
chains of Aβ(M1-42) are buried within the fibril core and are only accessible at the
fibrillar ends, according to two high-resolution solid state NMR structures of Aβ(1-42)
fibrils[46, 234]. The affinity of chgantenerumab to Aβ(M1-42) monomers is significantly
lower with 485± 100 nM.
2.5.1.4 Solanezumab
Solanezumab is still on clinical phase 3 trail but is expected to fail, as it shows no signif-
icant difference to placebos thus far. However, it exhibited improvements for early AD
patients in early trials[107]. In contrast to all previous antibodies described, its murine
analogue, m266, specifically inhibits primary nucleation (Supplementary Fig. B.19 B
and B.20 B). Similar to gantenerumab, the side-chains of Aβ(1-42) forming the epitope
are in the central part of the sequence (residues 16-26)[6]. This again means that the
epitope is in the fibrillar core and not accessible for the antibodies, as it has been shown
by solid state NMR[46, 234]. Therefore, the binding experiments show a high affinity of
3± 2 nM to Aβ(M1-42) monomers but no binding to the fibrillar form (Fig. 2.16 D and
H).
2.5.2 Discussion
My work demonstrates the power of detailed analyses of molecular interactions in es-
tablishing the mechanism of action for amyloid inhibitors. Understanding the specific
effects and relevant interactions of inhibitors allows to identify which individual micro-
scopic steps of the aggregation process are targeted. This can pave the way for predicting
how toxicity is affected. All antibodies studied here show a distinct mechanism for in-
hibiting Aβ(1-42) aggregation (Fig. 2.17). This specific behaviour is reflected in the
measured binding properties, such as affinity, specificity and stoichiometry, and allow
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Figure 2.17: Summary of kinetic and binding analysis of selected therapeu-
tic antibodies and their effects on the aggregation mechanism. Effect of pro-
SPC-Brichos as an example for a selective secondary nucleation inhibitor (A),
chaducanumab (B), m266 (C), 3D6 (D) and chgantenerumab (E) on the micro-
scopic rate constants (pkn, pk+ and pk2) pictured in a pentagon together with
the affinity for monomer (pKDm) and fibril (pKDf). The centre of each pen-
tagon corresponds to unperturbed rate constants and a high pk value signifies a
large reduction in rate constant, e.g. the molecular chaperone proSP-C Brichos
dramatically inhibits specifically secondary nucleation by binding fibrils with a
relative high affinity
[41]. The illustration was used with permission of Sara Linse.
mechanistic evaluation of their function. However, not being able to fully quantify their
binding to oligomers is a major drawback. A general technical problem of measuring
Aβ(1-42) oligomer interactions is that they only make up a minor fraction of the en-
tire Aβ(1-42) content, are highly heterogeneous, transient and converge quickly either
to fibrils or other forms of oligomers. Therefore, a stabilisation of oligomers by anti-
bodies can not be excluded, factors which may counteract its beneficial effect. Further
microfluidic technique developments or other biophysical tools need to be applied to
investigate Aβ(1-42) oligomer antibody binding and their toxicity. One potential ap-
plication could use the advantage of chromatographic separation prior to microfluidic
analysis, as described in the following chapter. However, none of the antibodies shown
interferes strongly with the generation of oligomers. The presented strategy of uncov-
ering specific secondary nucleation inhibitors by kinetic and mechanistic analysis is a
powerful tool for the identification and assessment of potential therapeutics at early
stages to streamline drug development.
2.6 Conclusion
The results discussed in this chapter demonstrate the inherent potential of microfluidic
binding measurements in solution and that they can prove beneficial as a further bio-
physical techniques extending current technical limitations. This chapter has focused
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on natural evolved and synthetically produced aggregation inhibitors and their interac-
tions with protein aggregates or their monomeric subunits. The binding of these natural
evolved chaperones are highly regulated. Recent results have indicated on the emergence
of secondary nucleation during aggregation as the key process in the formation of the
toxicity of those aggregation events. Therefore, inhibiting other microscopic events, such
as elongation, can have contrary effects e.g. by providing more monomers for secondary
nucleation and increasing the overall oligomer content. The result show that chaperones
are part of a highly balanced system and that their activity can be dependent on the
heterogeneous dynamic of chaperone assembly and disassembly. Clusterin is a specific
elongation inhibitor and, as such, is shown to accelerate amyloid deposition in mice
when overexpressed[57]. Similar effects have to be considered for drug development. I
have shown that therapeutic antibodies, which were or still are under clinical trial, lack
sufficient capability of suppressing secondary nucleation due to their binding properties.
A general biophysical characterisation of potential drugs can accelerate and identify new





GFP (green fluorescent protein) labelled αB-crystallin (αB-c) was prepared by puri-
fying a construct with the following arrangement: αB-c-TEV site-GFP-His tag. This
construct was expressed recombinantly in E. coli BL 21 (DE3). Cells were lysed using
a microfluidiser, centrifuged to remove insoluble material and the fusion protein was
isolated using Ni affinity chromatography, HisTrap column (GE Healthcare, Chicago,
US), using standard procedures. The protein was further purified by size exclusion
chromatography on a Superdex 200 16/60 column (GE Healthcare, Chicago, US). The
resultant protein was in a solution of 300 mM NaCl, 50 mM Tris (pH 8) made up in
20% glycerol (aq).
A.1.2 α-Synuclein
α-syn was expressed and purified in PBS, pH 7.2 as described previously[4, 108]. To
prepare fibrils, a solution of 70 µM monomeric α-syn and 0.1% NaN3 in PBS, pH 7.2 was
incubated in an Eppendorf tube at 37◦C under constant shaking at 200 rpm for 5 days.
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The visibly cloudy sample was centrifuged at 15,000 rpm for 5 min and the pellet was
washed once with PBS, pH 7.2 with 0.1% NaN3 to remove residual monomer. The
fibrils were resuspended at 100 µM and sonicated with the probe sonicator SONOPULS
HD 2070 (BANDELIN electronic, Berlin, DE) at 10% power, 30% cycles for 1 min.
Fibril concentration (measured in constituent monomer concentration) was measured by
denaturing a fibril aliquot in 5.5 M GuHCl and measuring the resultant α-syn monomer
absorbance. All chemicals were of analytical grade and purchased from Sigma Aldrich
unless otherwise stated.
A.1.3 Amyloid-β(M1-42)
The expression and purification procedure for the peptide Aβ(M1-42) (MDAEFRHDS-
GYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA), the molecular chaperones clus-
terin and proSP-C Brichos were carried out as described in previous papers[54, 119, 233,
242]. In short, Aβ(M1-42) inclusion bodies were extracted from E. coli cells by sonica-
tion and dissolved in 8 M urea. Further purification was performed by ion exchange in
batch mode on DEAE cellulose resin with additional lyophilisation and gel filtration on
a 3.4 cm x 200 cm gel-filtration column at 4◦C[233].
A.1.4 Amyloid-β(1-42)
The expression and purification was performed by Sara Linse. The peptide version with-
out the N-terminal methionine had to be used for the experiments with the therapeutic
antibody bapineuzumab. The expression of Aβ(1-42) thus requires a fusion tag, the self-
cleavable tag nPro in the form of its EDDIE mutant[123]. The peptide was expressed
and purified similar to the M1-42 version. However, the EDDIE-β(1-42) was diluted
15 times with 1 M Tris, 1 mM EDTA, 5 mM DTT, pH 7.9 and allowed to stand at 4◦
for 48 h. During this time EDDIE slowly folds leading to auto-cleavage and release of
β(1-42). The solutions were then transferred to dialysis bags with 3.5 kDa MW cutoff
and dialysed in 5 mM Tris/HCl, 0.5 mM EDTA, pH 8.5, with three shifts. Further
purification was applied similar to the procedure for the M1-42 version.
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A.1.5 proSP-C Brichos
In order to obtain the proSP-C Brichos domain, E. coli cells were lysed by lysozyme
(1 mg/ml) for 30 min and incubated with DNase and 2 mM MgCl2 for another 30 min
on ice. The centrifuged cell pellet was dissolved in 2 M urea in 20 mM Tris, 0.1 M NaCl,
pH 8, and sonicated for another 5 min. After another centrifugation step, the su-
pernatant was filtered through a 5-µm filter and purified with a 2.5 ml nickel-agarose
column. The thioredoxin and His6 tag were removed by adding thrombin for 16 h at
4◦C followed by another run through a nickel column. The protein was further purified
using ion exchange chromatography[119, 242].
A.1.6 Clusterin
Clusterin was extracted from human blood plasma obtained from Wollongong Hospital
(Wollongong, NSW, Australia). Complete protease inhibitor was added and the mixture
was filtered through (i) a GFC glass fibre filter and then (ii) a 0.45 mm cellulose nitrate
filter. The filtrate was further purified on a 5 ml G7 anti-CLU monoclonal antibody
column. After severe washing steps the specifically bound material was eluted using
2 M GdnHCl in PBS. The fraction was dyalised against 20 mM MES, pH 6.0 and
loaded on a 1 ml HiTrap SP XL cation exchange column, collecting the flow through.
Finally, the pure protein was obtained by SEC on a Superose 6 10/300 column[54].
For the microfluidic experiments clusterin was covalently labelled with Alexa Fluor 488
NHS ester (Thermo Fisher, Waltham, US). To achieve this, the protein (2 mg/ml) was
incubated with a 10-fold molar excess of the fluorophore (added from a 10 mM stock
in DMSO) (1 h, RT). Unconjugated dye was removed by buffer exchange into PBS
using a PD-10 column (GE Healthcare, Chicago, US). The final protein concentration
and labelling efficiency was measured according to the manufacturer’s instructions. I
carried out kinetic experiments to show that the labelling with the Alexa dye, required
for the fluorescence detection does not modify the inhibition and the binding properties
of clusterin (Supplementary Fig. B.13). Bovine serum albumin, obtained from Sigma
Aldrich (St. Louis, US), was used. All aggregation assays and binding reactions were
carried out in 20 mM sodium phosphate buffer at pH 8.0. All chemicals were of analytical
grade and purchased from Sigma Aldrich unless otherwise stated.
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A.1.7 Generation ad purification of anti-Aβ antibodies
The expression and purification was performed by Sara Linse. chAducanumab,
chgantenerumab, 3D6 and m266 were generated as described before[6]. All antibodies
were expressed in CHO cells and purified by protein-A-affinity followed by ion-exchange
chromatography.
A.1.8 Alexa-647 labelling of Aβ peptides and antibodies
The expression and purification was performed by Sara Linse. Aβ(MC1-42), a mutant
with an extra Cys residue placed between the starting Met and Asp1 was used for
fluorophore labelling. An aliquot of purified peptide monomer was dissolved in 6 M
GuHCl, 10 mM DTT, pH 8.5, incubated for 1 h and the monomer was isolated by gel
filtration in 20 mM sodium phosphate buffer, pH 8.0. Two molar equivalents of Alexa-
647 C2 maleimide (Thermo Fisher A20347) were added from a concentrated stock in
DMSO. The solution was incubated overnight in darkness on ice. Labelled monomer was
isolated from free dye by two rounds of gel filtration in 20 mM sodium phosphate buffer,
pH 8.0. Antibodies were labelled by mixing with Alexa-647 N-hydroxy succinimidyl
ester (Thermo Fisher A20006) after gel filtration of each antibody in PBS. Two molar
equivalents of Alexa-647 were added to each antibody, and the solutions were incubated
for 2 h at 4◦C, followed by gel filtration twice to remove free dye. The absence of free
dye was confirmed using microfluidic diffusional sizing with fluorescence detection using
a Fluidity One-W instrument (Fluidic Analytics Ltd, Cambridge, UK).
A.2 Fabrication and use of microfluidic diffusion devices
The fabrication and the operation of the microfluidic diffusion device used in the present
studies have been described in previous papers[9, 164]. Briefly, the microfluidic chips
were fabricated by using standard soft lithography. The sample to be analysed and the
buffer were introduced into the system through reservoirs connected to the inlets, and the
flow rate in the channel was controlled by applying a negative pressure at the outlet by a
syringe pump (Cetoni neMESYS, Korbussen, DE); at typical flow rates in the range from
90 µl/h to 150 µl/h. Lateral diffusion profiles were recorded at twelve different positions
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(3.5 mm, 5.3 mm, 8.6 mm, 10.3 mm, 18.6 mm, 20.3 mm, 28.6 mm, 30.4 mm, 58.7 mm,
60.4 mm, 88.7 mm and 90.5 mm) by standard epifluorescence microscopy using a cooled
CCD camera (Photometrics Evolve 512, Tucson, US). The diffusion profiles were fitted to
model simulations based on advection-diffusion equations assuming a bimodal Gaussian
distribution[164]. From the area under the curves of the two Gaussian populations, the
concentrations of the bound and the free molecular chaperones were evaluated.
A.3 Aggregation kinetics
A.3.1 α-synuclein
The aggregation of 70 µM α-syn in the absence and presence of 0.5 µM, 1 µM and 2 µM
GFP and unlabelled/labelled αB-c in PBS, pH 7.2 with 0.1% NaN3 were followed by
recording the increase in ThT fluorescence at 480 nm upon excitation at 440 nm. 100 µL
samples were incubated in a 96 well plate in a plate reader Fluostar Optima (BMG
Labtech, Ortenberg, Germany) at 37◦C. ThT concentration was 20 µM. All aggregation
experiments were operated in the presence of 5% pre-formed second generation fibrils[4].
A.3.2 Clusterin and proSP-C Brichos
Aggregation reactions in the presence and absence of clusterin and proSP-C Brichos were
followed by recording thioflavin T (ThT) fluorescence emission at 480 nm after excitation
at 440 nm. 100 µL samples were incubated in a Corning R© (Corning, US) 96-Well
(COSTAR) Half Area Black with Clear Flat Bottom Polystyrene NBSTM Microplate and
measurements were recorded in a FLUOstar OPTIMA (BMG LABTECH, Ortenberg,
DE) plate reader at 21◦C or 37◦C under quiescent conditions[42]. For seeded reactions,
fibrils were freshly prepared before each experiment and mixed with freshly purified
monomeric Aβ(M1-42) at the desired concentrations. The concentrations of clusterin,
monomeric and fibrillar Aβ(M1-42) for the different experiments are reported in the main
and supplementary text as well as in the captions of the figures. The concentration of
ThT was 20 µM in all experiments that I carried out at 37◦C unless otherwise stated.
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A.3.3 Anti-Amyloid-β antibodies
Monomers of Aβ(1-42) or Aβ(M1-42) as well as all antibodies were freshly isolated by
size exclusion chromatography in experimental buffer on each day, and mixed on ice just
prior to starting the kinetics experiment. The samples were loaded as multiple (3-6)
replicates in a 96-well plate (Corning 3881) and the experiments were initiated by a
temperature jump from zero to 37◦C, thus creating supersaturated Aβ1-42 solutions.
The ThT fluorescence intensity was monitored as a function of time in a plate reader
(BMG Omega, Optima and Fluostar were used) with excitation at 44 nm and emission
at 480 nm.
Reactions were started from 3 or 4 µM Aβ42 monomer with 10 µM ThT in the ab-
sence and presence of 0.00025–2 µM chaducanumab (a murine analog of aducanumab),
0.03–2 µM 3D6 (the murine precursor of bapineuzumab), 0.03–2 µM chgantenerumab
(a murine analog of gantenerumab), 0.03–2 µM chsolaneumab (a murine analog of
solanezumab) or 0.03–2 µM isotype control, all of which were blinded. I performed
at least three separate experiments as a function of antibody concentration and in each
experiment there were 2-5 replicates of each condition.
A.3.4 Kinetic analysis and simulations
The inhibition kinetic analysis of the Aβ aggregation was performed by Paolo Arosio.
The inhibition kinetic analysis of Aβ aggregation by therapeutic antibodies was performed
by Sara Linse. The aggregation profiles in the absence and presence of different concen-














where the kinetic parameters B±, C±, κ, κ∞, and κ̃∞ are functions of the mass and
number concentrations of seeds as well as of the two combinations of the microscopic
rate constants k+k2 and knk2, where kn, k+, and k2 are the rate constants of primary
nucleation, elongation, and secondary nucleation, respectively[43, 43].
The microscopic rate constants in the absence of the molecular chaperones were con-
sidered equal to the values estimated in previous work[42]. The rate constants in
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the presence of different concentrations of clusterin were determined by fitting the




(Msim(ti)−Mexp(ti))2, where Msim(ti) and Mexp(ti) are the simulated and the
experimental total fibril mass fractions at time ti, respectively. In the simulations shown
in Fig. 2.7, kn, k+, and k2 were varied individually, but in the simulations shown in the
other figures, only k+ has been modified.
The experimental data in the absence and presence of clusterin were described by a
second kinetic model which considers binary interactions between clusterin and fibril
ends. The detailed description of the corresponding equations can be found in ref. 8.
In this model, the rate constants kn, k+, and k2 were assumed to be equal to the val-
ues estimated in the absence of the chaperone and considered to be independent of the
concentration of clusterin, the effect of which is included in the association and dissocia-
tion rates. The association and dissociation rate constants were estimated by the global
analysis of the reaction profiles at different concentrations of clusterin by minimising a
least-squared error function similar to that described above[8]. The simulation reported
in Fig. 2.7 e is based on a simplified expression which can be derived from this second ki-
netic model and relates the apparent elongation rate constant to the total concentration













In the thesis I report the dissociation constant Kd = 1/KeqEnd.
For the kinetic analysis of Aβ aggregation in chapter 2.5, the idea was to determine the
microscopic process which was most inhibited in the presence of therapeutic antibodies.
Therefore, experimental values were fitted assuming either specific secondary nucleation
or primary nucleation. If the fitting showed a smaller root-mean-square deviation for
primary nucleation, the process was determined to be most inhibited. In case of a
more favourable fit for secondary nucleation, further experiments with low and high
concentration of Aβ seeds needed to be conducted as similar kinetics can be compensated
by elongation processes. Higher seeding conditions are dominated by elongation and
therefore make it easier to distinguish between both processes.
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A.4 Sample preparation for binding experiments
A.4.1 α-Synuclein
The kinetic binding experiments of α-synuclein were performed together with Jacqueline
Carozza. Fibrils were diluted to the indicated concentrations in PBS, pH 7.2 with 0.1%
NaN3 and incubated with 1 µM αB-c. For equilibrium experiments at 25
◦C, endpoint
measurements were taken after 3 days. Aliquots of the chaperone-fibril system were
measured on the microfluidic diffusion device at the same temperature at which they
were incubated to avoid disturbing equilibrium. To minimise protein sticking to the
sides of the PDMS devices, 0.1% Tween-20 was added to the flanking buffer streams
(this is not expected to interfere with the sample, since contact between the sample and
the buffer streams is minimal and short-lived).
A.4.2 Clusterin and proSP-C Brichos
Aβ(M1-42) fibrils were generated by incubating 17 µM monomeric Aβ(M1-42) in 20 mM
sodium phosphate buffer at pH 8.0 in a 96 well plate in a plate reader FLUOstar OP-
TIMA (BMG LABTECH) at 37◦C with double orbital rotation (400 rpm). Aggregation
was monitored by following the increase in the fluorescence emission of a similar sample
implemented with 20 µM ThT dye initiated upon its binding to amyloid fibrils. After
completion of the aggregation reaction, the fibrils were collected, supplemented with
Alexa-488-labelled clusterin in the concentration range between 0 and 4.5 µM, and in-
cubated for at least 2 d at 21◦C to ensure equilibrium was obtained. Diffusion sizing
measurements were then performed at 21◦C as described below. In a second set of
experiments, three more points were evaluated with the addition of BSA (at the same
concentration as used in the clusterin experiments, i.e. 0.8 µM, 2 µM and 4.5 µM)
added to a mixture of clusterin and fibrils as described above to examine the specificity
of the binding with 17.5 µM Aβ(M1-42) fibrils. The samples were analysed again by
microfluidic diffusion methods.
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A.4.3 proSP-C Brichos only
Aβ(M1-42) fibrils were formed by incubating a solution of 25 µM Aβ(M1-42) peptide
and 20 µM Thioflavin-T (ThT) in a non-binding 96 well plate in a plate reader Fluostar
Optima (BMG Labtech, Ortenberg, Germany) at 37◦C with double orbital rotation
(400 rpm). The aggregation process was monitored by following the increase in the
fluorescence of the ThT dye upon binding to amyloid fibrils. Aliquots of Alexa-488
labelled Brichos in the concentration range between 0 and 1.5 µM were added to mature
Aβ(M1-42) fibrils and incubated for at least 2 days (see Fig. 2.15) at 21◦C to ensure
equilibrium conditions; for measurements in the range 27-37◦C the incubation time could
be decreased to 5 hours. Diffusional sizing measurements were performed at the same
temperature as that of which the incubation was carried out in order not to perturb the
equilibrium distribution. In order to evaluate the binding between Brichos and Aβ(M1-
42) fibrils during the aggregation process, samples with Alexa-488 labelled Brichos at
concentrations of 0.25, 0.35 or 0.50 µM were mixed with 24 µM Aβ(M1-42) monomers
and 20 µM ThT and incubated in a 96 well plate in a Fluostar Optima plate reader (BMG
Labtech, Ortenberg, Germany) at 37◦C under quiescent conditions. The aggregation
kinetics were monitored by following the associated increase in ThT fluorescence. After
completion of the reaction, samples were further incubated for 48 hours at 21◦C and
analysed by microfluidic diffusion sizing.
A.4.4 Anti-Amyloid-β antibodies
Antibody binding Binding interactions were assessed by a Fluidity One-W instrument
(Fluidic Analytics Ltd, Cambridge, UK) which measures the hydrodynamic radius of
fluorescently labelled species in their native state in solution by microfluidic diffusional
sizing, the principles of which have been described previously. Binding interactions
were monitored between Alexa-647-Aβ(MC1-42) and unlabelled antibodies, or Alexa-
647-antibodies and unlabelled Aβ1-42 fibrils. All binding measurements were performed
at 27-28◦C in PBS, pH 7.8. Aβ1-42 fibrils were sonicated (20/20 s on/off cycles) for 6
min on ice and shaken for 30 min at 1800 rpm before use in the binding experiments.
64 Chapter 2 The binding of chaperones and therapeutic antibodies to amyloid fibrils
A.5 Diffusion image analysis and fitting
The derivation of the code was done by Thomas Müller and Quentin Peter. The actual
analysis was done by me. Through out the thesis two different approaches were used for
analysis of diffusion images. This is caused by the evolution of the coding the analysis
is based on. The procedure used for the data found in chapter 2.2-2.4 and Fig. 3.2-3.4
were processed as follows, the three-dimensional information of the 12 images taken
along the diffusion channel were converted into two-dimensional profiles with intensities
normalised to the intensity of the first frame. Afterwards a least square fitting to a
series of simulated basis functions was applied[9, 164]. A basin hopping algorithm with
a Broyden-Fletcher-Goldfarb-Shannon (BFGS) minimisation is used to find the linear
combination of radii that gives the lowest residuals. Minimisations were run with an
accuracy value (criteria for accepting a minimum) of 10−8 and epsilon value (step width
of optimisation) of 10−8. The fit is also penalised by a term multiplied by an empirically
determined regularisation coefficient α, which serves to reduce overfitting.
Each fit was run 10-13 times increasing α from 10−6 to 10−2 taking three steps per order
of magnitude, which causes the number of radii with non-zero coefficients to decrease
and the residuals to increase as the fits become more constrained (see Supplementary
Fig. B.6 a). While α is low, the residuals remain almost constant since decreasing the
number of radii fit to the experimental profiles does not dramatically impact the quality
of the fit.
At some α (the value varies for each fit), there is a relatively large increase in the
residuals. The magnitude of this jump reports on whether the sample is monodisperse
or polydisperse[9]. Empirically, if the residuals jump is smaller than 10−7, the sample
is described best as monodisperse. If it is larger than 10−7, the sample is described
best as polydisperse (see Supplementary Fig. B.6 b). The fit immediately before the
jump in residuals was taken as the best fit and used for further analysis. The tunable
regularisation coefficient allows me to find the simplest fit that also fully describes the
data for various sets of data profiles, since the best fit differs for each.
The fitting program always includes a peak at the smallest possible radii in the range
of simulated basis functions, attributing 0-10% of diffusion to this small radius. This
artefact is due to a mismatch between the simulated diffusion profiles and the channel
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geometry. The artefact peak was removed by summing the two remaining populations
and re-calculating the percentages of free and bound chaperone.
For diffusion data in chapter 3, 4, Fig. 2.3 and Fig B.2 the analysis procedure started
with the creation of two masks from the known channel and inter-channel width. These
masks were shaped as the top of a Gaussian function to decrease interfaces effects.
Thus, the fluorescence from the channels could be maximised while the fluorescence
from the walls were minimised. The same procedure was repeated for a range of pixel
sizes around the expected value with the final pixel size selected with the best channel
to wall fluorescence ratio selected as being the most probable value. Afterwards, the
diffusion profiles can be extracted and converted into two-dimensional profiles. Basis
functions (theoretical diffusion profiles) are simulated from the first measured profile.
A global fitting was used to find the best solution over all positions. The least square
error between the recordings and the simulations was calculated. The best solution can
be extracted from the two lowest least square errors.
The diffusion profile depends on the channel cross section, the flow rate (Q), the detection
position along the diffusion channel (x), and the sample diffusion coefficient (D). All
these quantities can be combined to a dimensionless variable that is introduced as the





This variable, together with the channel height over width ratio (β) uniquely describes
the diffusion system. The error on the diffusion profiles can be estimated with first
order Taylor expansion of the least square equation for single measurements[195]. The






















The fitting algorithm cannot account for other errors and will therefore only take the
error on φ into account, but these others error can and will have an effect on the radius
estimation. In the end, the total error on the overall radius and the individual amount
of each species in a bimodal distribution was determined via repeats.
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A.6 Native mass spectrometry
The experiments were performed by Justin Benesch and Olga Tkachenko. Spectra were
acquired on a modified quadrupole-time-of-flight instrument (Waters Limited, Elstree,
UK) following a previously described protocol[131]. Samples at 20 µM were electro-
sprayed from gold-coated glass capillaries made in house. The instrument parameters
were as followed. αB-c WT: source pressure 6.0 mbar, cone 50 V, extractor 3 V, collision
gas Ar, collision energy 50 V, ToF pressure 3.1 · 10−6 mbar. αB-c-GFP: as above except
cone 200 V, extractor 9 V, collision gas SF6, collision energy 200 V. Spectra are shown
with linear background subtraction and Gaussian smoothing with a window of 50 points.
The spectra were fit with the UniDec software using an oligomer mass list of between
5-50 subunits and a peak width of 20 m/z units[154].
A.7 Equilibrium and kinetic curve fitting
The derivation of the kinetic equation was done by Matthias Bellaiche and the analysis
of the kinetic data is my work. I fit the data with a non-cooperative, single-site binding
model, where free chaperones C bind to free fibril binding sites F, forming a complex CF.
The equilibrium between free and bound states is governed by the forward and reverse





The rate of the reaction can be expressed
d[CF]
dt
= kon[C][F]− koff [CF] (A.5)
I substitute the expressions obtained from the conservation of mass [C] = [Ct]− [CF]




2 − (kon([Ct] + [Ft]) + koff) [CF] + kon[Ct][Ft] (A.6)
Chapter 2 The binding of chaperones and therapeutic antibodies to amyloid fibrils 67
where [Ct] and [Ft] are the total chaperone and fibril mass concentration, respectively.








, and solving for the fractional occupancy [CF][Ct] , I arrive at the expres-




([Ft] + KD + [Ct])−
√
(−[Ft]−KD − [Ct])2 − 4[Ft][Ct]
2[Ct]
(A.8)









1− exp (kon(x+ − x−)t)




kon([Ct] + [Ft]) + koff ±
√
k2on([Ct]− [Ft])2 + k2off + 2konkoff([Ct] + [Ft])
2kon
(A.10)
In this expression, I constrain the value of [Ct] and take the following terms as fitting
parameters: kon, koff , and [Ft], as I do not know the actual number of fibril binding
sites.
In the limit where time recovers infinity, Eq. A.9 goes to the equilibrium solution (Eq.
A.8).
The binding stoichiometry, describing the amount of α-synuclein molecules per single







where [α-synucleintotal] is the total concentration of monomeric α-synuclein equivalents
used.
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A.8 Determination of Binding parameters
A.8.1 Curve fitting to obtain thermodynamic and kinetic parameters
of α-synuclein
The van’t Hoff equation gives the relationship between the equilibrium constant Keq






where ∆H is the enthalpy, and R is the gas constant. I arrive at the linear form of
the van’t Hoff equation, using KD instead of Keq by combining Eq. A.12 with the
relationship between Gibbs free energy and the equilibrium constant ∆G = −RT ln Keq,







By adding the contribution of the change in heat capacity ∆Cp to the enthalpy and
entropy (Eq. A.14 and A.15)
∆H = ∆HTref + ∆Cp (T− Tref) (A.14)






















where ∆HTref and ∆STref are the enthalpy and entropy changes at a reference temper-
ature. The reference temperature Tref is chosen to be 310 K.
I also estimate the free energy barrier of the binding reaction from this data set by
constructing a model, which combines polymer theory and Kramer’s problem of escape
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from a metastable state considering the change in association rate constant kon of αB-c
binding to the fibrils (Φ) as a function of temperature[32].
kon = 1000 ·D ·NA · reff · e−β∆G
‡





In order to respect the contribution of the heat capacity change to the activated state
∆C‡p I combined Eq. A.14, A.15 and A.17 to:








p(ln T−ln Tref) (A.18)
D is the diffusion constant of a segment of the protein (comprising 3 amino acids,
the Kuhn length of a polypeptide chain) and has a numerical value of approx.
5 · 10−10m2s−1, NA is the Avogadro constant and reff is the characteristic distance that







with b0 being around 1 nm, the Kuhn length of a polypeptide chain, and n the number
of protein residues.
A.8.2 Thermodynamic equilibrium analysis of proSP-C Brichos
The dissociation constant KD was calculated by direct non-linear regression based on
the Scatchard equation[240]
[Brichosbound] =
[Brichosfree] · [M ]
KD + [Brichosfree]
(A.20)
where M is the total concentration of binding sites available on an Aβ(M1-42) fib-
ril surface, representing the maximum concentration of bound molecular chaperone,
Brichosbound and Brichosfree are the concentrations of the bound and free chaperone,
respectively, evaluated by the size distributions measured by the microfluidic diffusion
technique. The binding stoichiometry, describing the amount of Aβ(M1-42) molecules
within the fibril bound per single proSP-C Brichos molecule, is derived from







where [Aβ(M1-42)total] is the total concentration of monomeric Aβ(M1-42) equivalents
used. The standard binding free energy, enthalpy and entropy (∆G	, ∆H	 and ∆S	,








where KD is the dissociation constant, R is the gas constant and T is the temperature,
in combination with the Gibbs-Helmholtz equation:
∆G	 = ∆H	 − T∆S	 (A.23)
assuming ∆H	 and ∆S	 to be temperature independent.
A.8.3 Binding constant determination for anti-Amyloid-β antibodies
Equilibrium binding parameters (affinity and stoichiometry) were obtained by fitting
directly to the raw data. Because relatively dilute solutions used, activities were re-
placed with concentrations and the apparent dissociation constant KD was estimated
by global non-linear regression to the measured quantities, ID and IN, using the following
equations:
ID = ID1 + (ID2 − ID1) ·
0.5 (nLtot −KD − CP ) +
√
0.25 (nLtot −KD − CP )2 + nLtotKD
KD + 0.5 (nLtot −KD − CP ) +
√
0.25 (nLtot −KD − CP )2 + nLtotKD
(A.24)
IN = IN1 + (IN2 − IN1) ·
0.5 (nLtot −KD − CP ) +
√
0.25 (nLtot −KD − CP )2 + nLtotKD
KD + 0.5 (nLtot −KD − CP ) +
√
0.25 (nLtot −KD − CP )2 + nLtotKD
(A.25)
where CP is the total concentration of labelled protein (monomer or antibody), ID1 and
IN1 are the intensities of labelled protein in the respective half of the channel. ID2 and
IN2 is the intensity of labelled protein-ligand complex (monomer-antibody or antibody-
fibril) in the respective half of the channel, and n is the stoichiometry of the interaction.
For data with Alexa-647-labelled Aβ(1-42) monomer, n was fixed to 2, while ID1, ID2
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and KD were fitted parameters. For data with Alexa-647 labelled antibodies, n, IN1,
IN2 and KD were fitted parameters.
After fitting, the fractional saturation of the labelled species, Q, was calculated from










The average of these two values was plotted versus free ligand concentration, which was
calculated at each total concentration of added ligand, CL, as follows:
[L] = 0.5 (nLtot −KD − CP ) +
√
0.25 (nLtot −KD − CP )2 + nLtotKD (A.28)
using in the case of Alexa-647-Aβ(1-42) interacting with antibody the fitted value of
KD and the fixed value of n and CP , and in the case of Alexa-antibody interaction with
fibrils the fitted values of n and KD and the fixed value of CP . Based on the ratio of the
IN and ID, the instrument reports an apparent hydrodynamic radius of the fluorescent
labelled species.
A.9 Immunogold-labelling Transmission Electron Mi-
croscopy (TEM)
The experiments were performed by Janet Kumita. The actual quantification was per-
formed by me. Aβ(M1-42) fibrils (1.5 µM Aβ(M1-42) monomer equivalents) were in-
cubated with BSA (1 µM; NEB) in 20 mM phosphate buffer, pH 8.0 (10 min, RT).
Clusterin (0.15 µM) was added to the solution and this was further incubated (10 min,
RT). The fibril sample was centrifuged (15,000 rpm, 20 min, 4◦C) and the supernatant
was removed. The pellet was resuspended in PBS containing 0.01% (v/v) Triton and
0.01% (v/v) Tween-20 (15 µL) then the sample was centrifuged (15,000 rpm, 20 min,
4◦C). The pellet was resuspended in PBS (10 µL). For the sonicated samples, Aβ(M1-42)
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fibrils (1.5 µM) were sonicated using a probe sonicator (Bandelin, Sonopuls HD 2070)
for 1 min with 10% maximum power and 30% cycles prior to incubation with BSA and
clusterin. The prepared fibril samples (5 µL) were applied to a carbon support film,
400 mesh, 3 mm nickel grid (EM Resolutions Ltd., Saffron Walden, UK) and incubated
(5 min, RT). The grid was blocked with 1 mg/ml BSA in PBS for 15 min and incubated
with 1:100 G7 mouse anti-human-clusterin monoclonal antibody (2 mg/ml stock solu-
tion) in PBS for 30 min. For the secondary antibody only negative controls, samples
were incubated with PBS only at this step. The grid was washed (3 X 5 min); first in
PBS/0.01%Triton/0.01%Tween-20 and then twice with PBS only, followed by incuba-
tion with 1:500 gold labelled, anti-mouse secondary antibody (BBI Solutions, Cardiff,
UK) in PBS for 30 min. Finally, the grid was washed three times as described above,
twice with water and then incubated for 2 min with 2% uranyl acetate (w/v). In order to
remove excess uranyl acetate, the grid was washed twice with water and dried completely
before imaging. The fibrils were imaged on a FEI Tecnai G2 transmission electron mi-
croscope (Cambridge Advanced Imaging Centre, University of Cambridge, UK). Images
were analysed using the SIS Megaview II Image Capture system (Olympus, Tokyo, JP).
In order to quantify the amount of immunogold labels per fibril mass, a ratio of counted
particles in a frame and the area occupied by aggregates were formed. Therefore, using
ImageJ, the TEM image threshold was set to ”Shanbhag” auto threshold and further
applying the ”analyze particles” function. The particle analysis settings were pixel size
1000-infinity and circularity 0-2. The sum of all quantified particles per frame was used
for quantification[208].
A.10 SDS-PAGE analysis
SDS-PAGE electrophoresis was run with Novex NuPAGE SDS-PAGE Gel System (Life
Technologies). Brichos samples were incubated for 17 h at 30◦C and loaded in the gel
together with a Brichos sample at the same concentration which was freshly defrozen
as a control. Samples were analysed under both reducing and non-reducing conditions.
Samples under reducing conditions were analysed by Coomassie blue staining, while
samples under non-reducing conditions were analysed by fluorescence detection by using
a Typhoon Trio variable-mode imager (GE Healthcare, Little Chalfont, UK).
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Supplementary information
Table B.1: Summary of the kinetic parameters kon and koff and the dissociation
constants Kd for the binding of αB-c to α-syn fibrils at different temperatures.
Values were obtained by fitting the kinetic data to Eq.
A.9 (Materials and Methods). Note that at 37◦C where the binding curve reaches
saturation, the value for koff and therefore also the value of Kd obtained from the fit is
subjected to be more error prone than the other dissociation constants at lower
temperatures. The fit still gives us an estimate of the binding affinity, and still reports
well on kon.
αB-c
T (◦C) kon (M
−1s−1) koff (s
−1) Kd (nM)
7 0.6 ± 0.4 2.6×10−5 ± 1.6×10−5 45310 ± 15890
10 0.3 ± 0.1 4.2×10−6 ± 6.3×10−7 12330 ± 4465
17 0.7 ± 0.3 4.1×10−6 ± 1.9×10−6 6118 ± 2722
20 2.4 ± 0.9 9.8×10−6 ± 2.8×10−6 4075 ± 1701
25 7.1 ± 2.6 2.7×10−6 ± 8.6×10−7 373 ± 238
30 31.4 ± 12.9 1.8×10−6 ± 1.1× 10−6 58 ± 53
37 199.5 ± 86.8 1.2×10−16 +1.9×10−6−1.2×10−16 ≤ 10
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α-synuclein + αB-c WT
(a) (b)
Figure B.1: Kinetic reaction profiles of 70 µM α-syn solutions are shown (a)
in the absence (black curve) or in the presence of either 0.5 µM (solid curve),
1 µM (dashed curve) and 2 µM (dotted curve) of GFP (green curves) or (b)
unlabelled/labelled αB-c including 5% seeds in PBS, pH 7.2 with 0.1% NaN3
(red and blue, respectively). Each curve is an average of three independent mea-
surements with individual measured points shown in each plot (faded colors).
(a)
(b) (c)




























































Figure B.2: (a) Complete set of 12 diffusion profiles for αB-c alone and αB-c
incubated with α-syn fibrils and exhibiting 100% binding. Histograms of the
sample size distribution for (b) αB-c alone and (c) αB-c with α-syn fibrils.
Inserts in b) and c) show error distribution of the individual radii determined
by first order Taylor expansion of the least square equation.






































mean 619 kDa (31 subunits)
mean 1059 kDa (22 subunits)
Figure B.3: Native mass spectrometry of (a) wild-type αB-c and (b) αB-c-GFP
fusion. The mass spectra are shown in black with a Bayesian deconvolution
fit in red[154]. Charge-deconvolved mass distributions underlying the fit are
shown as insets. The mean and standard deviation for the fit mass distributions
was 619 ± 187 kDa (31.0 ± 9.3 subunits) for αB-c WT and 1059 ± 417 kDa
(21.6 ± 8.5 subunits) for αB-c-GFP. Please note that, at this mass spectral
resolution, the fit enables only an estimate of the average mass distribution and
detailed interpretation of relative intensities of the different oligomers is not
appropriate.














Figure B.4: The chaperone αB-c binds to α-syn fibrils in the high nanomolar
affinity range KD,25◦C = 261 ± 76 nM. The concentration of αB-c was kept
at 1 µM and the concentration of α-syn fibrils was varied over two orders of
magnitude to obtain a titration curve, and the data were fit according to a
single-site binding model, with an α-syn binding site ratio of 0.186 binding sites
per α-syn monomer. The fit gives a R2 = 0.903.
Error bars represent standard deviations from at least two independent measurements.
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Figure B.5: Dissociation kinetic of αB-c (1 µM) in a saturated α-syn fibril
solution at 7◦C. The data was fitted to a one phase exponential decay equation
and the rate constant is koff,7◦C = 5.6× 10−5 ± 1.2× 10−5 s−1 with R2 = 0.95.













Figure B.6: Representative fits for (a) homogeneous (αB-c alone) and (b)
heterogeneous compositions (αB-c incubated with fibrils), exhibiting binding.
Higher regularisation coefficients penalise the number of individual components
considered in the fitting. The change in the residuals relative to the sum of the
residuals of the first fit (α = 10−5) for the homogeneous (c) and heterogeneous
(d) samples plotted against α demonstrate that there is some critical value of
α, at which point there is a jump and the experimental profiles are no longer
well described by the fit. The magnitude of that jump reports on whether the
samples are homogeneous or heterogeneous (the cutoff value is α ≈ 10−7). The
fit immediately before the jump in residuals (marked with a star) is taken as
the best fit for that set of profiles.
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Figure B.7: Analysis of the effects of clusterin on the aggregation kinetics of
Aβ(M1-42) at 37◦C. (a) Kinetic reaction profiles at 37◦C for the aggregation
of 3 µM Aβ(M1-42) solutions are shown from left (blue) to right (green) in the
absence and presence of 7.5 nM, 37 nM, 75 nM and 150 nM of clusterin. Con-
tinuous lines represent integrated rate laws where the elongation rate constant
has been specifically inhibited. b) Same as in a) in the absence and presence
of 37 nM and 75 nM of clusterin. The average least-squares error function of
these simulations, defined in the Materials and Methods section, is 0.1.
























Figure B.8: Analysis of the effects of clusterin on the aggregation kinetics of
Aβ(M1-42) at 21◦C. Aβ(M1-42) aggregation kinetics are shown from left (blue)
to right (green) in the absence and presence of 40 nM, 60 nM, 80 nM, 120 nM
and 140 nM of clusterin (symbols) with an Aβ(M1-42) monomer concentra-
tion of 4 µM. The data was globally fitted similar to the procedure at 37◦C
in Fig. S2 (continuous lines) in order to determine the dissociation constant
KD,21◦C = 1 nM at this temperature.
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Figure B.9: Seeding experiments of Aβ(M1-42) in the presence and absence of
clusterin. Aggregation profiles of reactions where pre-formed Aβ(M1-42) fibrils,
grown in the presence or absence of clusterin, were added to monomeric solutions
of Aβ(M1-42) in the presence or absence of the chaperone. (a) Pristine fibrils
that had never been exposed to the chaperone (blue ◦) were able to accelerate
the aggregation reaction of Aβ(M1-42) monomers compared to the kinetics in
the absence of added pre-formed fibrils (black symbols). (b) Fibrils grown in
the presence of 37 nM clusterin (blue ◦) did not accelerate the reaction to the
same extent as pristine fibrils when added to monomer without the chaperone
in solution (black ◦), showing that clusterin binds to fibrils. (c, d) Clusterin
added in solution is able to arrest the reaction and prevent the acceleration
due to added fibrils (blue ◦) even when the latter were grown in the absence of
chaperone. The solution concentrations of Aβ(M1-42) and clusterin were 2µM
and 37 nM, respectively. The amount of added seeds has been 5% w/w for all
seeded experiments. The dashed lines show predictions for the reaction profiles
of seeded and unseeded reactions assuming (a) the value of the elongation rate
constant measured previously in the absence of the chaperone, (10) (b) the value
in (a) reduced to 60% of its value, and (c,d) the elongation rate reduced to 48%
with additional chaperones in the Aβ(M1-42) monomer solution.
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a b2o antibody only 1o + 2o antibodies
Figure B.10: Aβ(M1-42) fibrils formed in the presence of BSA and clusterin
and probed for clusterin interaction using immunogold TEM. (a) sample probed
with only the secondary antibody conjugated to a gold particle showing no non-
specific labelling; (b) fibrils probed with an anti-clusterin monoclonal antibody
followed by an anti-mouse secondary antibody conjugated to a gold particle.
Black dots indicate the presence of clusterin interacting with the fibrils. Scale
bar is 100 nm.
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c                                              d
AβM1-42 fibrils + 0.15 µM clusterin AβM1-42 fibrils + 0.25 µM clusterin
I II III IV V VI VII VIII IX X XI XII
Measurement point
AβM1-42 fibrils + 0.35 µM clusterin AβM1-42 fibrils + 0.50 µM clusterin
I II III IV V VI VII VIII IX X XI XII
Measurement point











































































Figure B.11: Diffusion profiles of specific samples at twelve different positions
in a microfluidic device. (a-d) Representative fluorescence diffusion profiles cor-
responding to solutions of 17 µM Aβ(M1-42) fibrils in the presence of different
clusterin concentrations acquired at twelve different positions along the chan-
nel. The simulated diffusion profiles (red lines) were fitted to the measured data
(black dashed lines) by a least square fit.
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Figure B.12: Analysis of interfering effects of transient proteins on clusterins
inhibition activity. (a) Kinetic reaction profiles for the aggregation of 2 µM
Aβ(M1-42) in the absence (blue symbols) and presence (red symbols) of 7.5 nM,
37 nM and 75 nM of bovine serum albumin (BSA). (b) Same as in (a) but in the
presence of 75 nM of BSA and 75 nM of clusterin, showing that the presence of
BSA does not affect the inhibition activity of clusterin.
a b





































Figure B.13: Effects of the fluorescent label of clusterin on the inhibition process
on Aβ(M1-42) aggregation. (a) Kinetic reaction profiles for the aggregation
of 2 µM Aβ(M1-42) solutions are shown from left (blue) to right (green) in
the absence and presence of 7.5 nM, 37 nM and 75 nM of labelled clusterin.
Continuous lines represent model simulations where the elongation rate constant
has been specifically inhibited; (b) The decrease in the apparent elongation
rate constant as a function of molecular chaperone concentration is similar for
labelled and unlabelled clusterin.



























Figure B.14: Kinetic analysis on the aggregation kinetics of Aβ(M1-42) in the
presence of Brichos and clusterin separately and combined. Kinetic reaction
profiles for the aggregation of 2.5 µM Aβ(M1-42) solutions in 20 mM sodium
phosphate buffer at pH 8.0 in the absence and presence of 37 nM clusterin and
3 µM proSP-C Brichos, added either individually or together as indicated at
37◦C. Continuous lines represent model simulations where either the elongation
rate constant (green line), secondary nucleation constant (red line) or both (blue
line) have been selectively inhibited.










































a                                      b
Figure B.15: (a) Kinetic reaction profiles of 3 µM Aβ42 solutions are shown from
left to right for reactions in the absence of Brichos and with 10%, 22%, 35%,
50%, 75% and 100% Aβ(M1-42) monomer equivalents of unlabelled Brichos.
(b) A similar Aβ(M1-42) aggregation behaviour was observed in the presence
of Alexa-488 labelled Brichos. Shown from left to right are kinetic profiles
without Brichos and with 50% and 100% Aβ42-monomer equivalents of Alexa-
488 labelled Brichos.
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Figure B.16: Kinetics of Brichos binding to Aβ(M1-42) fibrils measured with
Fluidity One-W. The kinetic was measured at 37◦C in 20 mM sodium phosphate
buffer at pH 8.0 with 9.2 nM Alexa-647 labelled Brichos and 20.5 µM Aβ(M1-42)
fibrils.
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c                                               d
Aβ42-fibrils + 0.15 µM Brichos Aβ42-fibrils + 0.25 µM Brichos
I II III IV V VI VII VIII IX X XI XII
Measurement point
Aβ42-fibrils + 0.35 µM Brichos Aβ42-fibrils + 0.50 µM Brichos
I II III IV V VI VII VIII IX X XI XII
Measurement point
I II III IV V VI VII VIII IX X XI XII
Measurement point
Figure B.17: (a-d) Representative fluorescence diffusion profiles corresponding
to a solution of 24 µM Aβ(M1-42) fibrils in the presence of different Alexa-488
labelled Brichos concentrations, acquired at twelve different channel positions.
The simulated diffusion profiles (red lines) were fitted to the measured data
(black dashed lines) by a least squared fit.
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Figure B.18: SDS-PAGE analysis of Alexa-488 labelled Brichos samples freshly
prepared or incubated at 30◦C for 17 h. The assay was performed both under
reducing with Coomassie blue staining (left box) and under non-reducing condi-
tions with fluorescence detection (right box). Taken together, the two analyses
show that both the Brichos and the Alexa-488 dye are stable upon incubation.
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Figure B.19: (A-D) Thioflavin T (ThT) fluorescence as a function of time
for reactions starting from 3-4 µM recombinant Aβ(1-42) in 20 mM HEPES/-
NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0 in the absence and presence of
chaducanumab (A), m266 (B), 3D6 (C) or chgantenerumab (D). The first column
shows data obtained for Aβ(1-42) monomer in the presence of 30% pre-formed
Aβ(1-42) fibrils. The last three columns show data obtained for monomeric
solutions in the absence of pre-formed fibrils. The colour codes for the antibody
concentrations in nM are given on each row. The data are shown in normalised
form. The solid lines are fits to the data and assume in the left two columns
global values for k2 and kn and curve-specific values for k+, in the third column
global values for k+ and k2 and curve-specific values for kn, and in the right
column global values for kn and k+ and curve-specific values for k2. The best
fit in each case is indicated by a green tick. Grey colour indicates discarded
mechanisms based on the results of heavy seeded data (first column). Note that
the x-axes cover different ranges depending on the magnitude of the effect of
each antibody.
The data was used with permission of Sara Linse.
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Figure B.20: Aggregation kinetics in the presence of pre-formed seed fibrils
at low concentration (2%). The data show normalised ThT fluorescence as a
function of time for reactions starting from 3 to 4 µM Aβ(1-42) monomer and
2% (60 to 80 nM) Aβ(1-42) fibrils in 20 mM HEPES/NaOH, 140 mM NaCl,
1 mM CaCl2, pH 8.0 in the absence (black) and presence of A)
chgantenerumab,
B) m266, C) isotype control antibody (yellow), D) chaducanumab, or E) 3D6
at five concentrations as given by the colour code in panel A. The fitted curves
in panels A-C and E allow only a variation of k2, whereas the fitted curves in
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immunological screening
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3.1 Clinical relevance of diffusional binding measurements
for alloimunisation detection
In order to understand characteristic behaviour and function of biomolecules, they have
to be analysed under relevant conditions, ideally in biofluids, cells or systems which
mainly adapt these properties. This plays a major role in medical applied science, e.g.
drug screening, cancer treatment or pre/post-transplant alloimunisation detection. In
the latter case, due to a self-recognition process in every vertebrate, the body can start an
immune response against foreign, mutated or infected cells. The recognition is therefore
facilitated by the membrane protein human leukocyte antigen (HLA), also known as
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major histocompatibility complex (MHC) in humans, which covers almost every cell
in the body. Besides alloimunisation, an association between HLA and diseases e.g.
multiples sclerosis, Type I diabetis, celiac disease and up to 500 more, with or without
a fortuitous correlation, could be identified[225]. The gene encoding the HLA-protein
is highly polymorphic, which results in differences in the amino acid sequences between
individuals and can influence the function to a major proportion.
The HLA is separated into two classes, class I and II. Class I is composed of two chains,
one glycoprotein heavy chain anchored in the membrane and a non-covalently associated
β-2 microglobulin, approximately 45 and 12 kDa, respectively[223]. In contrast, class
II is formed by two membrane anchored glycoprotein heavy chains (α and β) with
approximately 34 and 29 kDa, respectively[223]. Even if it is known that antibodies
trigger the alloimmunisation by binding to non-self HLA, almost nothing is known about

















































































Figure 3.1: Basic principle of applying MDS for clinical samples. (1) Human
serum is taken from a patient, which (2) is then incubated with labelled HLA
to allow binding. (3) The size of the complex is, subsequently, determined by
microfluidic diffusional sizing (scheme shows single side buffer co-flow but also
surrounding buffer co-flow was used for experiments below), of which (4) the
dissociation constant KD and the antibody concentration [Ab] are evaluated.
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peptide binding cleft during that process. However, nowadays semiquantitative binding
measurements have to be done as part of an intensive screening for every transplantation
patient[223]. Frequently used techniques are on the one hand cell-based assays such as
the complement-dependent cytotoxicity test (CDC) or flow cytometry and on the other
hand solid phase assays (SPA) as ELISA and Luminex, which is used in the field of
solid-organ transplantation most frequently[134]. Although techniques of both assays
can semiquantify relative amounts of binding HLAab directly in human blood serum,
specific binding information is missing (Fig. 3.1). Usually, conventional measurement
methods, together with extensive sample purification and preparation, are needed. The
microfluidic diffusion device could be introduced here with its capabilities to acquire
binding parameters directly in the condensed phase and highly heterogeneous solution
as a novel type of binding studies with intact human samples. HLA interacting proteins
will remain localised in the centre of the channel, whereas non-interacting molecules
diffuse by their own diffusion coefficient (Fig. 1.3C).
As part of my Ph.D., I wanted to introduce this technique in the field of pre/post-
transplant alloimunisation detection. Furthermore, I wanted to test the capabilities of
the microfluidic diffusion device of being able to probe specific molecular interactions in a
complex environment such as human serum (Fig. 3.1). The human serum is an ideal rep-
resentation of the extracellular space with its diverse protein composition, electrolytes,
hormones and other exogenous substances.
3.2 Binding measurements of human leukocyte antigens
and related antibodies in buffer
To fulfil a detailed binding characterisation the diffusion-based microfluidic device
was used. The acquired fluorescence profiles at twelve different positions along the
diffusion-based microfluidic device correspond to the diffusion profile of the labelled
HLA-tetramer. The comparison of the HLA diffusion profiles in the presence and ab-
sence of mABs showed a clear change in the diffusion behaviour of the HLA (Fig. 3.2).
A dramatic decrease of the translational diffusion of 100 nM HLA class I A*01:01 in
the presence of 560 nM mABs WIM8E5 became clear and was connected to a decrease
in the diffusion coefficient as well as an increase in the hydrodynamic radius (rH). The
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change in the signal distribution indicated a binding between the Alexa-488 labelled
HLA-complex and mABs. Through least-square fittings of simulated diffusion profiles
to the measured diffusion profiles (see Supplementary Fig. D.3 for examples), an average
rH of the detected molecules was evaluated.
However, the advantage of the diffusion-based microfluidic device is not constricted on
the qualitative investigation of the binding. The documentation of changing rH by
changing the mAB concentration provides the opportunity to calculate the dissociation
constant (KD) and to describe the intensity of the binding. Experiments in PBS showed,
if the Alexa-488 labelled HLA concentration is kept constant at 100 nM with a variation
of the mAB concentration between 0-545 nM, a typical binding curve reaching a plateau
with increasing ligand concentration was generated with the rH against the used mAB
concentration on the axes (Fig. 3.3). The experimental data points were fitted to a
non-cooperative, single binding-site model (equation C.11, see Methods and Analysis).
Accordingly, a KD ≤ 5.61 nM and a maximum molar binding ratio (MMBR) of 2.75±0.27
mABs per HLA-complex could be estimated. In particular, the low dissociation constant

























Figure 3.2: Diffusion profiles of 100 nM Alexa-488 labelled HLA (red curve) and
100 nM Alexa-488 labelled HLA (A*01:01) in the presence of 560 nM monoclonal
antibodies (WIM8E5) (black dashed curve) in PBS-buffer with 0.1% Tween at
pH 7.4 measured at twelve different positions along a diffusion-based microfluidic
device.
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Figure 3.3: Binding curve for the mAB WIM8E5 interacting with HLA class I
A*01:01 in PBS-buffer with 0.1% Tween at pH 7.4 and 21 ◦C measured by
microfluidic diffusion devices. In one set of experiments, different concentrations
of mABs were incubated with 100 nM Alexa-488 labelled HLA (circles) and
measured after a short incubation time of at least 30 minutes. Each point
represents the mean and the standard deviation of at least two independent
repetitions. The regression line represents the best fit to a non-linear binding
equation (see equation C.11, Methods and Analysis), with KD ≤ 5.61 nM
, [mABboundmax]= 274.8± 27.4 nM and MMBR = 2.75± 0.27 with R2 = 0.871.
indicated a very high affinity and the MMBR let suggest a stoichiometry of 2:1 or 3:1
for mABs and HLA-complex. The detected affinity of ≤ 5.61 nM is located in a low
nanomolar range and is highly affine, as you would expect for a specific antibody. When
I describe antibody affinity it takes into account the affinity of the entire antibody to
the HLA-tetramer as it is not yet feasible to distinguish between affinity and avidity
with the applied system.
3.3 Investigation of graft rejection factors in human serum
The ability of the diffusion-based microfluidic device to measure heterogeneous samples
directly in the condensed phase, seems as an optimal set up for direct interaction mea-
surements in biological samples. To resemble biological relevance binding parameters
for HLAab, I measured the interaction of purified Alexa-488 labelled HLA and secreted
antibodies directly in patient serum. The relative binding was measured beforehand by
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the Luminex system[134], usually used for alloimmunisation tests before transplantation.
The two HLA-types of interest gave a relative standard fluorescent intensity of 21108
for patient 1 blood serum in combination with HLA A*02:01 and 6478 for HLA A*01:01
(see Supplementary Fig. D.4). This is an indication for a clear binding of the beads
to HLA A*02:01 and just a weak binding to HLA A*01:01, measured by the Luminex
system. The measurements of both HLA types were repeated for patient 2. A negative
result for binding in human serum with 0 was identified for A*02:01. Nevertheless, also
a weak signal could be detected for A*01:01 with 7310 in human serum of patient 2.
However, all four conditions were measured as well with the diffusion-based microfluidic
device.
An indication for an interaction between Alexa-488 labelled HLA and HLAab was given
by the change in the detected average molecule size (Fig. 3.4A). By fitting the resulting
diffusion profiles to a convective-diffusion based model (see Supplementary Fig. D.5)
considering a bimodal gaussian distribution, an average hydrodynamic radius was cal-
culated. The significant increase in the average size of HLA A*02:01 in the presence of
human serum from patient 1 has to be related to the increased amount of formed HLA-
HLAab complexes with a higher molecular weight and size. However, the exchange of
the human serum of patient 1 against the serum of patient 2 showed no indication of
binding. This suggests that the interaction between HLA A*02:01 and HLAab is specific
and furthermore not influenced by the dye. Both systems of HLA in human serum of
patient 2 show a low average radius and indicate no binding which goes in line with
the results from the Luminex platform. However, the results of the Luminex platform
indicate an extremely low relative value for interaction of HLA A*01:01 in patient 1
serum, caused by low affinity or by low concentration of HLAab, the sensitivity of the
diffusion-based microfluidic device is not yet sufficient enough for measuring those small
quantities.
Even though it is the first time that binding parameters were measured directly in
unpurified patient samples, the binding characterisation of HLA and HLAab was studied
in the same way as it was done with the mAB in the beginning of this paragraph. The
only difference was the usage of a lower HLA concentration of 50 nM and using a human
serum as fraction between 0 and 1, as the HLAab concentration in human serum is
unknown. HLA A*02:01 and human serum of patient 1 were the sample of choice for
studying interactions in human serum as binding is indicated in previous studies (see
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Fig. 3.4A). As the stoichiometry could not be verified clearly beforehand, the interaction
was constraint to a stoichiometry of either 1:2 (dashed grey curve) or 1:3 (black curve)
for the non-linear fitting of the binding curve. Both fittings were almost similar with
minor differences in KD, with KD,1:2 ≤ 7.33 nM and KD,1:3 ≤ 9.22 nM. In addition to
the dissociation constant, the unknown HLAab concentration in the patients human
serum can be estimated in respect to the stoichiometry. The individual concentration is
[HLAab1:2]= 306.9± 83.4 nM or [HLAab1:3]= 459.6± 117.7 nM.
Although the labelling of HLA with fluorophores is well established via biotinylation[1,
188], the quality of the acquired HLA sample seems questionable. The measured hydro-
dynamic radius of the HLA species are significantly lower than expected for a tetrameric
HLA species. By consideration of tetramerisation of biotin and streptavidin, a final























with 1:2 HLA:HLAab stoichiometry constraint
with 1:3 HLA:HLAab stoichiometry constraint
Figure 3.4: Binding measurements of Alexa-488 labelled HLA directly in human
serum with a diffusion-based microfluidic approach. (A) Least-square fitting be-
tween simulated and measured diffusion profiles provided an average molecule
radius of the detected species. The human serum of two patients were enriched
with Alexa-488 labelled HLA A*01:01 or A*02:01, each. (B) Based on the func-
tionality of the diffusion-based microfluidic devices to give an average rH by
adding different amount of human serum fraction a binding curve was gener-
ated. The binding curve represents the measured interaction between Alex-488
labelled HLA A*02:01 with a constant concentration of 50 nM and various
amount of HLAab containing human serum from patient 1 (circles). The ex-
periments were done at 21 ◦C and human serum was diluted in PBS at pH 7.4.
Tween was added to a total amount of 0.1%. Both regression line represent
the best fit to a non-linear binding equation (see equation C.11 , Methods and
Analysis) with R2 = 0.69
and constrained in the stoichiometry, assuming either binding 1:2 HLA:HLAab (dashed
grey curve) or 1:3 HLA:HLAab (black curve). This results in a KD,1:2 ≤ 7.33 nM,
[HLAab1:2]= 306.9± 83.4 nM or KD,1:3 ≤ 9.22 nM, [HLAab1:3]= 459.6± 117.7 nM.
The reported average sizes in A and each point in B represents the mean and the
standard deviation of at least two independent repetitions.
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bioconjugate should be formed consisting of four biotinylated class I HLA molecules
(∼57 kDa each) and one streptavidin tetramer (∼67 kDa). The total molecular mass of
the HLA complex should be around 295 kDa and be equivalent to a hydrodynamic radius
of ∼5.9 nm. Indeed, native polyacrylamide gel electrophoresis (PAGE) (see Supplemen-
tary Fig. D.1) indicate the presence of slight impurities. In addition, a chromathographic
analysis of the HLA complex shows that the sample is not homogeneous and free dye is
present (see Supplementary Fig. D.2). Free dye should not have any interfering effect
on the binding measurements except for decreasing the average hydrodynamic radius.
However, in order to overcome this problem, further experiments have been examined
using Alexa-647 labelled monomeric HLA.




















Figure 3.5: Binding curve of Alexa-647 labelled monovalent HLA and anti-
body infused human serum. Human serum was infused with a range of different
concentrations of SN23OG6 antibody and 5 nM Alexa-647 labelled A*02:01
HLA monomer. The plotted red points give the relative size increase, averaged
over the data of at least three replicates, the black line represents the fitting
with R2 = 0.972 according to the non-linear binding equation including back-
ground subtraction and a constrained stoichiometry of one antibody to two HLA
molecules (see Methods and Analysis). From the fit, the dissociation constant
KD = 3.7± 1.8 nM could be determined. The results were obtained with the
Fluidity One-W (Fluidic Analytics Ltd., UK).
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Ltd., UK) diffusional sizing technology. The significantly higher sensitivity compared to
the microscopic setup used beforehand made a more reliable sample acquisition possible.
However, the general interest was whether such a commercial setup is capable of measur-
ing biophysical parameters in a complex solution such as human serum. Due to the high
sensitivity, the measurements were limited by the background given by the serum and
had to be corrected by subtraction (see Methods and Analysis). The autofluorescence
of human serum is attributable to the presence of porphyrin derivatives such as biliru-
bin, the metabolic product of hemoglobin. The porphyrin fluorophore was reported to
exhibit fluorescence between 520 nm and 700 nm[155]. The increase in fluorescence is
thought to be due to accumulation of porphyrin derivatives resulting from the degrada-
tion of bilirubin at the storage conditions. The labelled monomeric HLA version A*0201
was added into a serum sample with a range of previously supplemented HLA specific
antibody SN23OG6 concentrations (see Fig. 3.5). The constructed binding curve results
in a dissociation constant of KD = 3.7± 1.8 nM by applying a non-linear binding equa-
tion including background subtraction (see Methods and Analysis). The stoichiometry
was constrained to one antibody binding to two HLA molecules, which was determined
for monovalent HLA previously (see Supplementary Fig. D.6). The results exhibit that
the Fluidity One-W is able to fully quantify binding of serum solved antibodies even at
low probe concentrations. The lower limit of sufficient probe quantification is directly
connected to the limit of detectable antibody concentration in patient sera.
3.4 Discussion
Notwithstanding, it has to be considered that besides the already used microfluidic
devices which mimic the in vivo environment by perfusion cell cultures, extracellular
matrix analogues, microscaffolds, spheroid formation and co-cultures [263], the ambience
of the here presented microfluidic diffusion device is distant from realistic extracellular
environment. The extracellular molecular heterogeneity, concentration and turnover
is impossible to imitate. Hence, I have shown that measuring interactions directly in
extracellular fluid rather mimicking them is possible with the used microfluidic diffusion
device. Human serum is highly heterogeneous and represents the entire extracellular
milieu in the blood stream except blood cells and clotting factor. In this way, the serum
contains a huge variety of diverse proteins, nutrients, hormones, electrolytes and waste
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material such as urea. Nevertheless, by using human serum from two patients I could
distinguish a positive from a negative binding event by a change in the hydrodynamic
radius. Consequently, the binding between the HLA and the HLAab in human serum
is specific rather than generic or even induced by the method or label itself. Together
with the determination of the dissociation constant it makes the diffusion-based device
the first application for obtaining binding parameters from pure human samples in the
condensed phase.
Nevertheless, even if a KD in the nanomolar range could be detected and the unknown
antibody concentration could be determined in serum, a more extensive characterisation
of the system has to be done. Generating two different binding curves at different HLA
concentrations would significantly decrease the error. It has to be pointed out that the
hydrodynamic radius of unbound HLA seems too small by assuming a tetramer including
a streptavidin. Therefore, further consideration has to be taken about sample quality
and in selecting a specific probe, being monomeric, dimeric or tetrameric. Further
studies will show whether avidity effects of mulimeric probes are wanted in order to
increase the sensitivity for rare antibodies in human serum. Measuring clinical samples
or providing machines and facilities to do so are an emerging market with increasing
economical interest. Rating the risk for graft rejection or determining the affinities of
immunological factors in human serum is crucial for health care and it seems equipment
such as the Fluidity One-W machine is a further application making those parameters
accessible.
Although the system of HLA and interacting antibodies needs more characterisation, I
was able to show the potential of a powerful tool for non-invasive real-time monitoring
of protein-protein interactions in complex biological mixtures such as body fluids. The
technique might be applicable for much more disease-related proteins such as antibodies





C.1.1 Biotinylated HLA together with mAB in PBS or human serum
HLA class I was obtained from Emory Healthcare, US, and were biotinylated and as-
sembled with Alexa-488 labelled streptavidin. They were solved in PBS with 0.02%
sodium azide at pH 7.4. Used HLA forms were A*01:01 and A*02:01 with the cleft pep-
tide STDHIPILY and VLHDDLLEA, respectively. The mABs on the other hand were
provided in RPMI or IMDM medium with 10% FCS and sodium azide. The used mABs
were WIM8E5 and W6/32. Human serum from anonymised patients were blended with
EDTA to 0.3% in total, which diluted the serum by 2.5%. Labelled HLA and mAB-
s/human serum were diluted and incubated in 1xPBS at pH 7.4 in the presence of 0.1%
Tween.
C.2 Labelling of non-biotinylated HLA with Alexa Fluor
647 fluorophore
With assistance of Matthias M. Schneider. To HLA (between 50 - 80 µL in NaHCO3,
0.89 nmol, 1 equiv.), Alexa Fluor 647 N-Hydroxysuccinimide ester (in DMSO 3 equiv.)
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was added. The reaction mixture was incubated for 1 h at approx. 20◦C, protected
from light. The sample was purified by size exclusion chromatography on a Superdex
200 increase 10/300 GL column (GE healthcare, US) with a flow rate of 0.5 mL/min
and PBS (pH 7.3, supplemented with NaN3 (0.02% (w/v)) as eluting buffer, to yield
labelled HLA (1 mL, 370 nM, DOL between 0.33 to 2.25, depending on variant). The
conjugated HLA was stored at 4◦C until further use.
C.3 Fabrication and use of microfluidic diffusion devices
The fabrication and use of microfluidic diffusion devices is explained in detail in sec-
tion A.2. For the human serum experiment with the spiked antibody, chips for the
Fluidity One-W from Fluidic Analytics Ltd. (Cambridge, UK) were used.
C.4 Native-PAGE analysis
Native-PAGE electrophoresis was run with Novex NativePAGE Gel System (Life Tech-
nologies, US). The electrophoresis has been performed on ice in order to prevent to much
heating. Samples were analysed by Coomassie blue staining.
C.5 Binding analysis
C.5.1 Derivation of non-linear binding equation
KD =
[Mf ] · [Lf ]
[Lb]
(C.1)
[M ] = [Mf ] + [Lb] (C.2)
Equation C.1 in C.2 results in:
KD =
([M ]− [Lb]) · [Lf ]
[Lb]
(C.3)
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[Lb] and [Lf ] are related to each other by:
[Lf ] = [L0]− [Lb] (C.4)
Equation C.4 in C.3 results in:
KD =
([M ]− [Lb]) · ([L0]− [Lb])
[Lb]
(C.5)
which can be formed to:
[Lb] =




[L0] + [M ] +KD
2
)2
− [L0] · [M ] (C.6)
[L0] + [M ] will be defined as:
q = [L0] + [M ] (C.7)
If [L0] of undiluted ligand sample is unknown it can be extended by a fraction factor F ,
which is 1 in the undiluted form:
qF = F · [L0] + [M ] (C.8)
[Lb] is related to the hydrodynamic radius by:
[Lb] =
∆rH · [M ]
∆rH,tot
(C.9)









− [L0] · [M ]
 ∆rH,tot
[M ]
= rH,x − rH,0 (C.10)
and can be formed to:













C.5.2 Binding equation with background subtraction
Measurements with the Fluidity One-W (Fluidic Analytics Ltd., UK) with human serum
were background subtracted under the assumption of additive fluorescence intensity.
The hydrodynamic radius rH was extracted from the measured apparent hydrodynamic
radius rappH and the corresponding signal intensity I
app by using the following equation:
rH =





with rserumH and I














Figure D.1: Native-PAGE of Alexa-488 labelled HLA. Gel was stained with
Instant Blue stain. The lower band at around 260 kDa is identical with the
expected size of a tetrameric HLA complex. However, the upper band indicates
some higher complex species which could be mediated by multiple unspecific
biotinylation of some HLA molecules.
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Figure D.2: Size-exclusion chromatogram of tetrameric HLA (Emory, US) with
measured absorbance at 280 nm and eluted with PBS, pH 7.4. A Superdex
200 Increase column (GE healthcare, US) was used. As can be seen from the
chromatogram, the provided sample shows a clear heterogeneous composition,
however a pure tetrameric HLA entity was expected. Therefore peaks cannot
reliably be assigned to specific protein species.
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HLA A*01:01 + 0 nM WIM8E5 mAB HLA A*01:01 + 130 nM WIM8E5 mAB
HLA A*01:01 + 360 nM WIM8E5 mAB HLA A*01:01 + 540 nM WIM8E5 mAB
Figure D.3: Examples of normalized fluorescence profiles of 100 nM Alexa-488
labelled HLA A*01:01 in the presence of different mAB WIM8E5 concentra-
tions were acquired at twelve different channel positions at 21◦C in PBS. The
simulated diffusion profiles for one (red), two (green) or an infinite amount of
species (blue line)
were fitted to the measured data (black dashed line) by a least square fit depending on
species restriction. The best fit to the measured profiles gives the size distribution and
the referring amount of each species based on the simulated diffusion.
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Figure D.4: The human serum of two patients were measured with the
Luminex-bead system and gives a normalised standard fluorescence intensity
for interactions with bead coated HLA A*01:01 or HLA A*02:01. (Measure-
ments were done by members of the Addenbrooks hospital, Cambridge, UK)
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HLA A*02:01 + 0.6 fraction human serum



























HLA A*02:01 + 0 fraction human serum























HLA A*02:01 + 0.9 fraction human serum























HLA A*02:01 + 0.2 fraction human serum
Figure D.5: Examples of normalized fluorescence profiles of 50 nM Alexa-488
labelled HLA A*02:01 in the presence of different fractions of human serum were
acquired at twelve different channel positions at 21◦C. The simulated diffusion
profiles (blue, green, red line) were fitted to the measured data (black dashed
line) by a least square fit depending on species restriction. The best fit to the
measured profiles gives the size distribution and the referring amount of each
species based on the simulated diffusion.
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Figure D.6: Binding Curve of 25 nM HLA A*03:01 with varying concentration
of antibody W6/32. The blue points give the relative size increase, averaged
over the data of at least three replicates, the red line to the fit according to the
non-linear binding equation (see Methods and Analysis) with R2 = 0.98
. From the fit, the dissociation constant KD = 487.9± 298.3 pM and the binding site
concentration B = 12.98± 1.00 nM could be determined. This results in an overall
stoichiometry of one antibody and two HLA molecules. The experiment was performed
by Matthias M. Schneider and Mengsha Hu.
Chapter 4
Multidimensional characterisation of
complex mixtures by microfluidic
coupled size-exclusion chromatography
List of publications
• T Scheidt, T Kartanas, Q Peter, MM Schneider, KL Saar, T Müller, PK Challa,
A Levin, S Devenish, TPJ Knowles, Multidimensional Protein Characterisation
Using Microfluidic Post-Column Analysis, Lab Chip, (2020).
4.1 Introduction
The formation of discrete structures by proteins is dictated by their ability to correctly
fold, interact and assemble into hierarchically ordered complexes. Thus, the ability of
proteins to serve as the basic machinery in cells is governed by their range of static and
dynamic interactions enabling their flexible and specific functionality. Therefore, it is
not surprising that over 80% of proteins do not appear on their own, but as part of
complexes[22]. The nature of these interactions is defined by the specific amino acid se-
quences of the proteins and their post-translational modifications[146], thus modulating
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their interactions[209, 229, 255, 262]. In particular, the direct electrostatic interactions
are enabled by charged and polar groups at the protein surface that allow the formation
of ion pairs, hydrogen bonds and other electrostatic interactions. The overall protein
charge and formation of complexes in solution are dependent on the number and nature
of the charged groups presented and is related to the isoelectric point (pI), known as
the pH value at which the net charge is zero[161]. While electrostatic interactions can
be highly specific and possess strong geometric constraints, hydrophobic interactions
minimise water-exposed hydrophobic residues, and these are usually buried inside pro-
teins or protein complexes[142]. Malfunctioning proteins that misfold and interact in
an unregulated manner can lead to protein aggregation, a key feature in many neurode-
generative diseases. Thus, this wide range of interactions is a key feature of protein
self-assembly and function, both in vivo and in vitro.
Techniques capable of characterising complex mixtures are limited and commonly only
allow to determine unidimensional information. As protein complexes are highly dy-
namic and their composition is dependent on exogenous factors including temperature,

























Figure 4.1: Scheme of an integrated (in-line) liquid chromatography with ana-
lytical microfluidics. Starting with a complex protein mixture, the molecules are
separated by their individual properties depending on the column applied. The
eluting liquid is divided by a macro- to microfluidic flow adapter. Following this
step, the flow-through can be guided to individual microfluidic components or
collected separately. In this way, the hydrodynamic radius and electrophoretic
mobility of the eluent can be measured continuously on a microfluidic chip.
The acquired information is processed and gives multidimensional information
of individual species of a complex mixture.
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properties under physiological conditions. Simultaneous acquisition of multidimensional
characteristics is therefore essential as state and compositions of the sample can change
between sequential measurements. Conventional approaches for multidimensional char-
acterisation include e.g. size exclusion chromatography coupled to multi-angle light
scattering (SEC-MALS)[222], 2D-gel electrophoresis[170], liquid chromatography-mass




















































Figure 4.2: Microfluidic components in a single camera field of view with sub-
sequent analytical processes. b) Overlay of two images taken at 0 V (magenta)
and 60 V (green). The field of view captures the microfluidic electrophoresis
device on the left side and the diffusional sizing part on the right side. Scale bar
is given in 100 µm. a) Experimental diffusion profiles (black curve) from the dif-
fusional sizing were fitted against theoretical basis functions (red dashed curve)
resulting in a hydrodynamic radius prediction. c) The sample gets deflected
when an electric field of 60 V (green curve) is applied in the electrophoresis
device. From the distance of deflection, x, the electrophoretic mobility can be
deduced.
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spectrometry (LC-MS)[47], LC coupled to nuclear magnetic resonance spectroscopy (LC-
NMR)[210], high performance anion exchange coupled with pulsed amperometric detec-
tion (HPAEC-PAD)[197] and electrochromatography[79, 137]. In many cases, these
approaches require special probes, including isotopes, oxidisable functional groups, pro-
tein tags or fluorescence labeling[141, 197] or the use non-physiological conditions, such
as sample ionisation and high sample concentration[115]. The difficulty in conserving
protein conformation and observing non-native complexes, can in principle, be avoided
by operating under physiological conditions. Yet, methods with high separation power
that work under these conditions have been found challenging to develop and adapt.
In order to overcome current challenges in obtaining high resolution understanding
caused by the diversity of molecular species of heterogeneous samples, most of the tech-
niques described above have a chromatographic and/or electrophoretic step as part of
the workflow, which requires large sample volumes. The stationary phase used in chro-
matography can have a major influence on the purification strategy and can consist of
biomolecules such as dextran, agarose or cellulose or synthetic substrate such as poly-
acrylamide, polystyrene or silica-based polymers[213]. By contrast, the selection of the
mobile phase controls the interplay between the analyte molecules and the matrix and






























Figure 4.3: Composition of molecule mixtures used for label-free and Atto-488
labelled in-line size exclusion chromatography-electrodiffusion measurements a)
Proteins used for label-free detection were thyroglobulin (bovine), conalbu-
min (chicken) and lysozyme (chicken). b) For the labelled mixture, biotiny-
lated Atto-488, streptavidin and biotinylated bovine serum albumin (BSA) were
mixed. The three components form various labelled and unlabelled components
in different stoichiometry varying in size from 1.2 kDa to 320 kDa.
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Microfluidic systems are used to parallelise different assays while allowing small sam-
ple volumes being used. Such lab-on-a-chip devices enable manipulation and control
over small quantities of fluids, usually in the range of pico- to microliters[238]. Ex-
amples of microfluidic analytical tools are diffusional sizing[9, 29, 160, 257], capillary
electrophoresis[151], free-flow electrophoresis (FFE)[98, 120, 183, 189, 200] and mi-
croscale thermophoresis[239, 249]. Along with the wide range of existing LC methods,
e.g. size exclusion, reversed phase, ion-exchange and affinity chromatography[53, 83,
122, 160, 163, 219], microfluidic tools can be used for a resolved characterisation of
physiological protein complexes from endogenous samples[96, 237].
In this study, I combined high flow size exclusion chromatography with microfluidic
protein analysis. A small fraction of the eluting sample was continuously distributed
between two functionally separate fluidic circuits. By measuring the sample composition
in the condensed phase, I was able to analyse proteins and their complex formation un-
der native conditions. The microfluidic systems applied here allow for the simultaneous
determination of hydrodynamic radius and electrophoretic mobility of molecules in a
quantitative manner in complex mixtures[9, 38, 98, 200, 257]. Furthermore, by applying
multiple orthogonal downstream analyses approaches, I was able to increase the limited
effective resolution of the SEC column. In order to quantify multiple biophysical pa-
rameters, the individual microfluidic components were arranged to fit within a single
camera field of view (Fig 4.2b), where one part documents the deflection of molecules
in an electric field applied on an electrophoretic chamber (Fig 4.2c) and a second part
records the molecular diffusion at distinct positions along a channel. The acquired in-
tensity of the diffused molecules in converted into two-dimensional profiles and fitted
against theoretical basis functions assuming a range of hydrodynamic radii (Fig 4.2a).
Only a small fraction of the solution is used for analysis, whereas the main volume of
the sample is collected and can be used for further evaluation.
4.2 Results and Discussion
4.2.1 Label-free protein characterisation
In order to test whether this combined strategy is capable of detecting and analysing a
mixture of unlabelled proteins following SEC, I used a UV-microscope set up, capable of
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Normalised Absorbance at 280 nm
Figure 4.4: Label-free multidimensional characterisation of thyroglobulin,
conalbumin and lysozyme by in-line SEC Electrodiffusional sizing. a) The mix-
ture was separated into three major peaks and the eluting molecule size, elec-
trophoretic mobility and effective charge were measured continuously. b) Indi-
vidual measurements conducted every 20 s were analysed based on the molecular
absorption at 280 nm revealing 3 major populations in the protein mixture with
individual size and charge. c) Hydrodynamic radius and net charge of the three
major peaks assigned to the proteins originally being used.
exciting aromatic amino acids and measuring their intrinsic protein fluorescence[38]. The
mixture I used consisted of the three unlabelled proteins thyroglobulin dimer (bovine),
conalbumin (chicken) and lysozyme (chicken) (see figure 4.3). These proteins vary in
size from 14 to 670 kDa and were selected to give adequate separation by size exclu-
sion chromatography. Therefore, all three proteins were completely separated into three
major peaks eluting at volumes of 1.06 mL, 1.52 mL and 2.12 mL, respectively, with a
minor conalbumin oligomer peak at 1.34 mL (see figure 4.4). Following this, the eluting
samples were continuously input into a free-flow electrophoresis and diffusional sizing
device (see figure 4.1), devices which have previously been described individually and
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are able to measure electrophoretic mobility µe and hydrodynamic radius Rh of indi-
vidual molecules, respectively (see figure 4.4a)[9, 38, 98, 200, 257]. More specifically,
one fraction of the sample is loaded into an electrophoresis device between two liquid
electrodes with a perpendicularly applied electric field. A second fraction of the sample
is loaded into the diffusion device in a simple buffer co-flow geometry along a channel
and the diffusion monitored in a time resolved manner. Date from the two devices
can be used together to calculate the effective charge q of individual species (see fig-
ure 4.4a-c). To determine the biophysical properties of the separated molecular species
more accurately, I have aligned their corresponding elution volume by setting a 10%
maximum peak intensity threshold. The measured signals of thyroglobulin, conalbumin
and lysozyme correspond to a hydrodynamic radius of 7.86±0.30 nm, 3.96±0.14 nm and
2.20±0.14 nm, respectively (see figure 4.4c). The measurements agree with previously
established biophysical values [17, 159, 214]. Furthermore, I have been able to simulta-
neously acquire the effective charges as -19.4±1.3 e, -0.8±0.3 e and 6.3±0.4 e for each
protein (see figure 4.4c). The measured net charge at pH 7.4 for the three analysed pro-
teins correlates with reported pIs, which are 4.5 for thyroglobulin, 6.5-6.8 for conalbumin
and 10.7-11.3 for lysozyme[194, 230]. The online tools Prot pi/Protein Calculator v3.4
predict a net charge of unfolded lysozyme, conalbumin and thyroglobulin of 6.2/7.3, -
5.6/-3.2 and -54.7 -46.8 at pH 7,4, respectively. The overall trend of the predicted values
is in good agreement with the experimental results and the absolute difference can be
caused by charge screening through protein folding and oligomerisation. Additionally, I
combined the measured information in a 3-D plot showing molecular size versus effective
charge map with a 280 nm absorbtion intensity related color-map (see figure 4.4b). The
plot shows three species with individual biophysical properties. Thus, I demonstrate an
in-line label-free biophysical characterisation tool of a heterogeneous mixture following
SEC separation.
4.2.2 Heterogeneous labelled analyte separation and characterisation
The advantage of fluorescent labels is an increase in sensitivity and specificity such that
detection of particular molecules is possible even in highly diverse mixtures and at low
concentrations. Thus, fluorescent labelling enables tracking of individual interactions
of a probe in complex solutions. In my study, I used a mixture of biotinylated BSA
and biotinylated Atto-488 dye, both capable of binding to streptavidin with one of
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Normalised Absorbance at 500 nm
Absorbance 500 nm pH 6.5
Absorbance 500 nm pH 7.3
Absorbance 500 nm pH 8.2
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Normalised Absorbance at 500 nm Normalised Absorbance at 500 nm
Figure 4.5: The labelled streptavidin/BSA/Atto-488 mixture was characterised
at three different pH values. a) The five identified labelled molecule complexes
were characterised and 3-dimensional charge versus size maps were generated.
The points are binned and weighted based on the absorption intensity at 500 nm.
b) The labelled mixture was incubated and separated via LC at pH 6.5 (blue
curve and points), 7.3 (black curve and points) and 8.2 (red curve and points).
The hydrodynamic radii, electrophoretic mobilities and effective charges of all
elutions were recorded. c) Measured mobilities of the individual identified
species were plotted against the different pH conditions and analysed further
by linear regression. d) After identifying the molecular elution volume ranges,
the molecule biophysical properties as hydrodynamic radius, effective charge,
theoretical (ExPASy) and experimental isoelectric point were estimated.
Chapter 4 Multidimensional characterisation by microfluidic coupled SEC 119
the strongest affinities found in nature (KD = 10
−15 M)[236]. To illustrate the power
of this technique and estimate yet another analytical dimension, I have repeated the
experiment under three different pH conditions, 6.5, 7.3 and 8.2 and followed changes in
molecular charges to investigate individual isoelectric points. The LC separation of the
Atto-488 labelled streptavidin-biotin based system resulted in similar sample elution
peaks for all three conditions (see figure 4.5b). Simultaneously, I measured the size
and electrophoretic mobility of the eluting material via fluorescence microscopy (see
Experimental Section). Both sets of information were used to calculate the distinct net
charge of each molecule (see figure 4.5b). I plot the effective charge versus the molecular
size where the intensity of each point is the absorption intensity at 500 nm summarising
the biophysical properties of the five Atto-488 labelled molecular complexes abundant
in the mixture (see figure 4.5a). By further applying a Savitzky-Golay filter before
and after taking the second derivative of the raw absorbance spectrum, four distinct
Atto-488 labelled molecules and the free dye itself can be assigned (see Experimental
Section). The first major peak with elution volume between 1 ml and 1.5 ml has three
subpeaks which could not be separated completely due to the insufficient resolution
at the given molecular weight range of my selected column. However, using the second
derivative analysis of absorption at 500 nm I estimated the approximate elution volumes
for streptavidin with one, two and three BSA molecules to be 1.08 ml, 1.16 ml and
1.33 ml respectively (see Supplementary Fig. F.3b). The second major peak with an
elution volume between 1.5 ml and 1.9 ml could be identified to be streptavidin with
four Atto-488 dye molecules and, finally, the last well-defined peak with an elution
volume between 2 ml and 2.3 ml was the free biotinylated Atto-488 dye. Furthermore,
I have used the elution volume ranges to estimate the size and effective charge with
the corresponding confidence intervals for each of those five species (see figure 4.5d).
All molecules have a negative charge under measured conditions and, more specifically,
the charge of a biotinylated Atto-488 dye was measured to be -1.00±0.07 e at pH 7.3
which agrees with the expected charge of -1 e [11]. Streptavidin with four bound dyes
resulted in the size of 3.21 ± 0.04 nm and the effective charge of around -2.77 ± 0.12 e.
The mono-, di-, and trivalent streptavidin-BSA complexes have hydrodynamic radii of
5.43±0.07 nm, 7.39±0.38 nm, 7.55±0.92 nm and effective charges of -13.18±0.51 e,
-20.19±1.20 e and -23.19±1.43 e, respectively (see figure 4.5d). The relative charge
accumulation between each complex correlates with the relative amino acid contribution
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of the individual BSA/streptavidin components. The same characterisation for all five
molecules were performed at two further pH conditions (see figure 4.5d).
One way to find the pI of individual molecules is to screen the electrophoretic mobility
of those molecules over a range of different pH conditions[136]. Therefore, I analysed my
streptavidin/BSA/Atto-488 mixtures described above at pH 6.5, 7.3 and 8.2. By linear
regression of mobility values at different pHs of individual species, I extrapolated the
condition where the overall net charge is 0 (see figure 4.5c). I determined the theoretical
isoelectric point (pItheo) by using the ExPASy platform which predicts the pI based
on the amino acid sequence. Comparing the experimental acquired isoelectric points
(pIexp) with the ExPASy sequence predicted pItheo of all four protein species, a high
similarity can be seen, ranging from 6.1 of streptavidin with four dyes to 5.6 and 5.7,
respectively, for streptavidin with three BSA. This shows that streptavidin on its own
has a significant higher pI than the dye and the pI of BSA is even lower than both of
them.
4.3 Conclusion
Conventional liquid chromatography, especially size exclusion chromatography, is lim-
ited by the effective resolution of protein mixtures. By applying orthogonal multiplex
microfluidic downstream analyses, I was able to increase this effective resolution. I es-
tablished a direct coupling between size exclusion chromatography and multidimensional
microfluidic analysis system while diverting only a minor fraction of the sample for anal-
ysis with the majority remaining available for preparative purposes. The multidimen-
sional characterisation of distinct complexes yields their size, electrophoretic mobility
and effective charge simultaneously. First, I demonstrated the operation principle of
my approach by determining the biophysical properties of unlabelled standard proteins
within a mixture. I further show the potential of this analytical method with a hetero-
geneous labelled mixture to analyse multiple partially separated peaks after chromato-
graphic separation and predicting the effective charge and molecular size of complexes
within the mixture. By reproducing this separation at different pH conditions I was also
able to find the pI of each labelled species of this mixture individually.
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The strategy presented here can be further expanded beyond size exclusion and the two
microfluidic modules chosen here. Further analytical and separative techniques such
as affinity, ion exchange and reversed phase chromatography as well as capillary elec-
trophoresis or isoelectric focusing can be utilised to investigate more complex forms of
protein oligomerisation and protein assembly. The study of highly dynamic oligomeric
composition and formation, which can either quickly convert to other higher order ag-
gregates or dissociate again, is of vital importance. In particular, the formation of
short-lived, on-pathway oligomers represent the major toxic species formed through the
aggregation of proteins such as amyloid-β and α-synuclein, resulting in neurodegener-
ation related to Alzheimer’s and Parkinson’s diseases, respectively[232, 245]. Recently,
however, the aggregation of such amyloidogenic proteins has been found to be inhib-
ited or modulated through the interaction of formed oligomers with chaperones, such as
the small heat shock protein family[95]. Therefore, the in-line approach of separation
and biophysical characterisation before re-equilibration described here are an ideal ap-
proach for investigating protein oligomerisation and their inhibition by a diverse range
of chaperones. The proposed approach can further be extended to detect molecular
interaction in complex samples, such as serum or cell lysate. The limitations are mainly
based on the capabilities of the separation by the liquid chromatography stage. The
method can be improved upon by introducing combinations of separation techniques,
e.g. size-exclusion and ion-exchange. The use of labelled proteins enables the microflu-
idic biophysical characterisation of specific proteins even in such complex solutions.
However, if multiple molecular species are targeted simultaneously using the presented
microfluidic setup, only an average hydrodynamic radius or charge can be determined,
when no particular multimodal distribution can be identified[203, 252]. As the duration
between the separation following liquid chromatography and microfluidic detection lies
in the range of a few minutes, our technique might not be suitable for characterising very
transient oligomers and complexes formed of very weak or unspecific interactions. Those
complexes conventionally exhibit dissociation constants above hundreds of micromolar
or dissociation rate constants above koff = 10
−4sec−1[118]. In this particular case, the
dissociation rate of the streptavidin complex described above has previously found to
be 5.4 · 10−6s−1 and the duration of re-equilibration is in the order of days[58]. Further-
more, the detailed investigation of post-translational modifications of protein mixtures,
such as ubiquitination, phosphorylation or carbohydrate moiety, each showing individ-
ual changes in either size, charge and hydrophobicity, is another scope my application
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can be used for. Therefore, this unique protein analysis approach has great potential to




To demonstrate the functionality of the method I have selected a mixture of three
proteins varying in size and isoelectric point (pI): bovine thyroglobulin (Mw=670 kDa,
pI=4.5, GE Healthcare, 28-4038-42), chicken conalbumin (Mw=76 kDa, pI=6.7, GE
Healthcare, 28-4038-42,) and chicken lysozyme (Mw=14.3 kDa, pI=9.3, Sigma-Aldrich,
L6876) (figure 4.3a). The proteins were diluted in a 100 mM sodium HEPES buffer
(pH=7.3) at a ratio of 4.6 : 33 : 110 µM, respectively; total sample volume was 40 µL.
The second system that I used to generate a heterogeneous sample was based on
streptavidin-biotin complex formation. I prepared the mixture by incubating strep-
tavidin (Prospec, Israel, PRO-791), biotinylated bovine serum albumin (Generon, UK,
7097-5) and biotinylated Atto-488 (ATTO-TEC GmbH, Germany) dye at a ratio of 1:1:3
(15.7:15.7:47.1 µM, total volume was 50 µL) for 1 hour at room temperature in 10%
Phosphate buffered saline solution (0.1xPBS) at pH 6.5, 7.3 and 8.2, respectively. The
mixture is expected to form seven distinct complexes with sizes ranging from 1 kDa
to 300 kDa (figure 4.3b). Five of the complexes contain an Atto-488 fluorophore and,
therefore, the latter molecules were the focus of detection and analysis.
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E.2 LC separation
Two different buffers were used for the sample elution through the column. First, I used
a 100 mM sodium HEPES buffer (pH=7.3) for the label-free sample characterisation.
In contrast, the streptavidin-biotin mixture was eluted in a 0.1xPBS buffer with a pH
of either 6.5, 7.3 or 8.3. Both buffers also contained 0.01% Sodium azide and 0.1%
Tween to reduce sample adhesion to microfluidic channels. A Superdex 200 Increase
3.2/300 column (GE Healthcare, UK) at a flow of 10 µL/min was operated on an ÄKTA
Pure System (GE Healthcare, UK). I was monitoring the eluting sample absorption at
280 nm and 500 nm wavelengths simultaneously with a 10 mm path length absorption
monitor U9-M (GE Healthcare, UK). The absorption intensity was used for matching
the molecular elution volume with the image sequence on a fluorescence microscope.
The flow from the LC separation was connected to the microfluidic flow adapter.
E.3 Microfluidic flow adapter
A microfluidic junction (P-722, IDEX Health & Science, USA) with carefully pre-cut
polyether ether ketone (PEEK) capillaries (IDEX Health & Science, USA) and flow sen-
sors (MF2 7 µL/min, Elveflow, France) were built, directing only a fraction of the flow
coming from chromatographic separation into multiple microfluidic devices (Supplemen-
tary Fig. F.1 and F.5). The lengths of the capillaries were as follows: the fractionator
output was made of a capillary with Lf=10.2 cm and 125 µm ID and the outputs A and
B were made of two capillaries (L1=10 cm with 125 µm ID and L2=8.1 cm with 67.8 µm
ID. Outputs A and B were connected to microfluidic devices operating at flow rates close
to few 100 µL/h (∼ 1.7 µL/min). In general, the flow from the LC protein separation
can be in the range of 10 µL/min - 1 mL/min (600 µL/h - 60 ml/h) depending on the
pressure and column used and, therefore, the capillary resistances have to be fine-tuned
for the desired flow splitting ratio. The flow sensors were integrated into ÄKTA Pure
system with an I/O-box E9 for real time flow monitoring (GE Healthcare, UK). Stable
flow splitting was achieved directing about 10% of the total flow to different parts of
the microfluidic chip (Supplementary Fig. F.2). The flow rates at the diffusional sizing
and the electrophoresis device sample inlets were measured to be 40.0±0.7 µL/h and
37.4±0.7 µL/h respectively.
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E.4 Flow control
The need for purification or separation techniques of complex mixtures in biomolecular
studies is vast. However, most of these bulk techniques cannot directly be transferred
to microfluidic scales due to the high pressure flow systems commonly used. In order to
match macrofluidic flows used in chromatographic systems with microfluidic flows found
in chips with micron sized features, a flow adapter scalable to a wide range of rates had to
be designed and implemented (Supplementary Fig. F.2). The incoming flow can be split
into numerous outlets, each adjusted for specific applications. Thus, my flow adapter
interface enables a standard LC separation, followed by simultaneous multidimensional
characterisation. The LC system used was an ÄKTA Pure system which drives two high
pressure pumps maintaining a highly stable flow with a 1-5% fluctuation level depend-
ing on the buffer and the separation column used (Fig. S3†). In my experiments, the
microfluidic flow adapter with carefully adjusted resistances distributed the fluid from
the the LC absorption measurement cell between two microfluidic sample inlets and a
fractionation outlet. The flow rates at the chip inlets for the free-flow electrophoresis
and diffusional sizing were measured to be 6.7±0.1% and 6.2±0.1%, of the initial flow
rate, respectively. The rest of the post LC separation fluid not used for further char-
acterisation (∼ 90%) was collected via the fractionation outlet. The ratios used were
adapted to the microfluidic application used or separation procedure applied.
E.5 Microfluidic chip design and operation
The microfluidic device was designed to fit two distinct analytical parts in one fluo-
rescence microscope field of view. One part contains the diffusional sizing device and
consists of a long diffusion channel of a length of LD=43 mm, a width of WD=300 µm
and a height of HD=55 µm (figure 4.1). The positions for the diffusion profile acqui-
sition were chosen to allow a high dynamic range for sizing and fixed to distances of
1.4 mm, 2.0 mm, 10.7 mm, 11.3 mm, 19.9 mm, 20.5 mm and 39.2 mm from the sample
injection point. I injected a degassed co-flow buffer (same as the LC mobile phase) at a
150 µL/h flow rate with a neMESYS syringe pump (CETONI GmbH, Germany) into the
device. The outlet of the microfluidic flow adapter is connected to the sample inlet on
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the diffusional sizing device. I record the injected sample diffusion profile and perform
a fit to the numerical diffusion simulations [9, 164].
The second part of the microfluidic chip is a free-flow electrophoresis device with liquid
electrodes [200]. It was designed to create up to 60 V/cm transverse electric fields on
chip while avoiding bubble formation and electrolysis product build-up on chip. I inject
a conductive 3 M KCl electrolyte solution from the sides (figure 4.1) at flow rates of
150 µL/h. The sample buffer solution is injected as a co-flow of the sample at a flow
rate of 150 µL/h using a neMESYS syringe pump. The second output of my fluidic
adapter is connected to the sample inlet of my free-flow electrophoresis device. Hollow
stainless steel 1.5 mm ID electrodes are inserted into the liquid electrode channels on the
sides of the device and connected to a power supply (EA Elektro-Automatik 6230207,
Germany). The power supply is connected to the chip via a multimeter (Agilent 34410A,
USA) recording a current flowing through the circuit.
The two microfluidic devices were operating continuously and a measurement of the
hydrodynamic radius, electrophoretic mobility and charge were obtained for every 3.3 µL
of the eluting sample (every 20 s) from the column while still fractionating 90% of the
total volume.
E.6 Microfluidic chip fabrication
The devices were fabricated using a standard polydimethylsiloxane (PDMS) soft-
lithography approach [157]. The master for the replica molding of PDMS is fabri-
cated with an SU-8 photolithography process [37]. After mixing PDMS (Sylgard184,
Dow Corning, two components 10:1 ratio and degassed) and casting it onto the photo-
lithographically defined structure, it is cured at 65◦ C for 1 h. A carbon black nanopow-
der (Sigma-Aldrich) is added to the PDMS before curing to create black devices, thus
minimising background noise and the unwanted autofluorescence from PDMS under
280 nm-LED illumination during the measurements. The PDMS replica of each master
is then cut, and the connection holes are made with a biopsy punch. The PDMS device
is sonicated for 3 min in isopropanol, blow-dried with N2, and placed in an oven at
70◦ C for 10 min. Finally, the replica is activated using O2 plasma at a 40% power for
10 s (Diener etcher Femto, Germany) and bonded to a clean quartz slide (Alfa Aesar,
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76.2 x 25.4 x 1.0 mm) for UV measurements or a simple glass slide for fluorescence
measurements.
E.7 Fluorescence microscope setups
Two different fluorescence microscopes were used for the experiments: an intrinsic fluo-
rescence microscope for a label-free protein detection and a green label epifluorescence
measurement setup. First, the autofluorescence measurements of proteins containing
aromatic amino acids were measured on a quartz-based intrinsic fluorescence visualisa-
tion platform [38]. In short, the proteins were illuminated with a 25 mW 280 nm LED
(M280L3, Thorlabs, UK) through an excitation filter (FF01-280/20-25, Semrock, USA)
centred at a λex=280 nm and a dichroic mirror (FF310-Di01-25x36, Semrock, USA). The
fluorescence from the sample was collected through an emission filter (FF01-357/44-25,
Semrock, USA) centred at λem=357 nm, and focused onto a EMCCD camera (Rolera
EMC2, QImaging, Canada).
The green epifluorescence microscope, optimised for the Green Fluorescent protein
(GFP) / Alexa-488 detection, consisted of a 490 nm LED (M490L4, Thorlabs, UK),
an excitation filter at 482 ± 9 nm, a dichroic mirror (350 - 488 nm / 502 - 950 nm) and
the emission filter at 520± 14 nm (filter set MDF-GFP2, Thorlabs, UK). The microscope
had an xyz stage for accurate chip positioning in the field of view of a 2.5x objective,
and the pictures were taken with a CCD camera (Retiga R1, QImaging, USA). A raw
background corrected fluorescence image of a sample under test is shown in figure 4.1).
E.8 Time matching
There is a slight delay between the molecule absorption measurement after the LC sep-
aration and the detection on chip. The delay volume from the absorption measurement
cell to the flow adapter is 70 µL and the volume from the flow adapter to the chip
detection channel is around 8 µL causing 20-30 min delay time depending on the system
flow. Both were matched by comparing absorption intensity on the absorbance detector
(280 nm and 500 nm) of the LC and the fluorescence intensity of the eluting sample on
chip.
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E.9 Electrophoresis device calibration and mobility anal-
ysis
I applied a voltage V0 to the electrodes of the electrophoresis device. First, I performed
the mobility measurements while recording the current flowing through the circuit I.
Then, I filled the device electrophoresis chamber with the conductive electrolyte solu-
tion and measured the current I0 while applying the same voltage V0 (Supplementary
Fig. F.4). Then
V0 = I(Relec +Rch), (E.1)
V0 = I0Relec, (E.2)
⇒ V = IRch = Relec(I0 − I) = V0(1− I/I0). (E.3)
Distance along the direction of flow:
























The total flow to the device Q = 146 µL/h, V0 = 60 V, d = 2880 µm, h = 55 µm,
I = 0.267 ± 0.002 mA, I0 = 0.283 ± 0.001 mA.
E.10 Size and charge calculations
The diffusion profiles were extracted by processing the images and removing the back-
ground using image alignment in the Fourier plane. The curve, generated by the non-
uniform illumination intensity, was removed by multidimensional polynomial fitting.
The channel edge positions and image rotation angle were detected and corrected au-
tomatically using an FFT-based technique[190]. The noise was then reduced by spatial
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averaging along the channel before extracting the profiles at 7 predefined positions along
the diffusion channel. Then, a set of basis functions, predicting the diffusion profiles of
predefined sizes (diffusion coefficients), was generated[9, 38, 164, 215]. Finally, a fit de-
convolving the measured experimental profiles into a linear combination of the simulated
basis functions was computed using a least-squares error algorithm. The fit interpolation
yielded the average eluting analyte hydrodynamic radius with the associated error.
The measured hydrodynamic radius Rh and the electrophoretic mobility µe can be used
to estimate the complex charge using the Nernst-Einstein relation:[111]
q = Ze = 6πηRhµe, (E.6)
with Z being the charge number and e the elementary charge, using the correspond-
ing hydrodynamic radius and electrophoretic mobility. The equation is based on the
assumption that the electrical force exerted on the analyte molecules balance with the
drag force arising from analyte migration through the solution.
E.11 Isoelectric point and net charge prediction
The isoelectirc point of BSA, streptavidin and their various combinations were predicted
using the ExPASy online pI/Mw computing tool. Therefore, I used the sequence for BSA




The net charge of lysozyme, conalbumin and thyroglobulin was predicted using the Prot
pi and the Protein Calculator v3.4 online tool.
E.12 Second derivative analysis of chromatograms
An example for separation of the heterogeneous labeled streptavidin/BSA/Atto-488 mix-
ture is shown in Supplementary Fig. F.3a. Taking the second derivative of the absorption
130 Chapter 4 Multidimensional characterisation by microfluidic coupled SEC
intensity at 500 nm (Supplementary Fig. F.3b) reveals three most significant peaks at
1.08 ml, 1.16 ml and 1.3 ml, respectively. To take the second derivative I have applied
Savitzky-Golay filter two times with 251 points: on the original spectrum and on the
final second derivative of the spectrum. The three peaks can be identified as streptavidin
with one, two and three BSA molecules, respectively.
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Figure F.1: The flow adapter interface contains a 4-way fluidic channel with
calibrated PEEK capillaries acting as hydrodynamic resistors. The ratio of the
capillary hydrodynamic resistance determines the fluidic adapter flow splitting
ratio which can be monitored with flow sensors.
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Sample flows during the experiment
Diffusion device
Electrophoresis device
Figure F.2: Flow rate measurements recorded at the inlet of the individual
devices. The flow at the diffusional size and the electrophoresis devics has been
constant to few percent variation.
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Figure F.3: a) Streptavidin, BSA and Atto-488 dye complexes absorbance at
500 nm just after the LC separation at pH 8.2. We can identify three distinct
regions in the spectra representing the 5 different labelled molecular complexes.
b) second derivative of the spectrum between 1-1.4 ml reveals 3 most significant
sub-peaks.












Figure F.4: The representation of the electrophoresis device equivalent elec-
tronic circuit. During the calibration step, the chamber electric resistance can
be neglected, allowing Relec estimation. Due to a high electrode resistance of











Figure F.5: Microfluidic flow adapter matching the flow between liquid chro-
matography and microfluidic chip over two orders of magnitude. The flow is
split between the fractionation outlet and outputs A and B; the flow through
the outlets A and B is monitored with flow sensors.
Chapter 5
Concluding remarks
Microfluidic approaches offer an extension of conventional biophysical techniques for the
study of the intricate nature of biomolecule recognition. In particular, the microfluidic
above described diffusion device on its own or in combination with other techniques such
as liquid chromatography or other microfluidic platforms introduce a fundamentally
new strategy for the study of molecular interactions in the liquid phase. Thus, this
thesis presents a detailed characterisation of molecular chaperone activity in suppressing
protein aggregation and the underlying binding mechanisms leading to specific inhibitory
phenomena. In particular, I have studied in detail the entropic binding dynamics of the
sHsp αB-c to α-syn fibrils and have shown that changes in heat capacity are indicating
a necessary structural change of the chaperone prior to the binding. For clusterin and
Brichos, chaperone systems previously described in the context of Aβ(42) aggregation,
binding studies and aggregation kinetics have been conducted and revealed a complex
suppression system in which each chaperone specifically inhibits distinct microscopic
aggregations steps without overlap. These results together with further binding kinetics
of Brichos form a distinct structural picture of elongation sites on fibrillar ends and
secondary nucleation sites along the fibrillar surface. However, such secondary nucleation
sites found along the fibrils are rather rare events than ordered repetitive structures.
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Intuitively, mimicking nature’s specific inhibition of aggregation for therapeutic appli-
cations in the context of aggregation related diseases seems like an ideal solution. Es-
pecially secondary nucleation seems to be the major inhibitory target desired in order
to prevent the formation of toxic oligomeric species. However, studies presented here
show that potential therapeutic antibodies for Alzheimer’s, namely aducanumab, bap-
ineuzumab, gantenerumab and solanezumab, which were or still are under clinical phase
3 trial, are not,on their own, sufficient for inhibiting secondary nucleation. Each anti-
body shows individual binding properties either to Aβ(42) monomers, fibrils or both,
resulting in a specific inhibition pattern. A full biophysical characterisation of potential
therapeutics and all intermolecular interactions involved could thus increase the positive
outcome in drug development.
The main challenges of most biophysical techniques in quantifying molecular interac-
tions, are the lack of representation of physiological conditions or inability to deconvolute
the composition of complex mixtures. In this work I have demonstrated that the MDS
technique applied can overcome both obstacles. A full quantification of serum molecules
can be achieved using a fluorescent labelled probe. Thus, the absolute quantification of
anti-HLA antibodies and their affinity have been applied, as these have crucial impact
on studying and rating the risk for graft rejection. The commercial available MDS in-
strument, Fluidity One-W from Fluidic Analytics Ltd., have been found to be capable
of quantifying target molecules in human serum down to low nanomolar concentrations.
In order to study heterogeneous solutions and measuring multiple molecules simulta-
neously, I combined the microfluidic diffusion device with liquid chromatography ap-
proaches. By coupling a microfluidic electrophoresis device to the system, I have acquired
multidimensional biophysical properties such as hydrodynamic radius, electrophoretic
mobility, relative amount and isoelectric point of a heterogeneous solution consisting
of five different molecular species. This multidimensional characterisation seems well
suited for studying oligomerisation and their dynamics seen for sHsps, α-syn and Aβ,
but can also be extended for protein modification, such as ubiquitination, glycosylation
and phosphorylation.
This work focused on studying a range of different intermolecular interactions, obtain-
ing binding parameters and gain insights into molecular processes using microfluidic
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approaches. However, further microfluidic development has to be done in order to be-
come able to fully quantify and investigate rare transient molecular species such as
amyloid precursors. Studying toxic oligomeric species by on-chip separation or single
molecule detection is already emerging as a crucial aspect in biophysics and under-
standing neurodegenerative diseases. In addition, multiplexing binding measurements
becomes essential for further clinical application. Fast and sensitive techniques being
able to quantify individual composition of body fluids are needed in hospitals for reliable
diagnosis and risk assessment.
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